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Abstract 
 
It is estimated that 32.8 million people are living with Human Immunodeficiency 
Virus (HIV) globally with the number of people receiving antiretroviral therapy in 
low- and middle- income counties increasing to more than 5 million people in 2009. 
These successes are threatened by treatment failure and the development of resistance 
to treatment. With an estimated 3.7% patients failing first line treatment after 2 years 
and 17.9% after 4 years on treatment there is a need for a practical and cheap in-house 
drug resistance assay that can be used to provide drug resistance data to clinicians and 
to use as a research tool to investigate drug resistance. In this study we attempted to 
optimize and validate an in-house drug resistance assay, adapted from Jacobs et al, 
2008, to be used as a diagnostic tool and to study the presence of antiretroviral 
resistance in patients on the Western Cape Mother-To-Child-Transmission (MTCT) 
regimen. 
Quality control samples were received from The National Institute of Communicable 
Diseases AIDS Virus Research Unit, The Round Robin HIV-1 genotyping assessment 
system from the University of Würzburg and the QCMD assessment system were 
used for the optimization and validation of an in-house drug resistance assay. The 
ViroSeq™ HIV-1 Genotyping System was used for comparison of sample and 
mutation detection.  
It was possible to optimise and validate a genotyping assay for diagnostic testing and 
research use by comparison with the ViroSeq™ HIV-1 Genotyping System and 
evaluation with external quality assessment systems. This assay could subsequently 
be used to determine the development of genotypic-antiretroviral resistance in patients 
treated according to the provincial prevention of mother-to-child-transmission 
(PMTCT) protocol in the Western Cape (single dose nevirapine (sd-NVP), combined 
with a short course Zidovudine (AZT)). Patient samples were collected from pregnant 
women who took part in the Western Cape PMTCT program and visited the 
Tygerberg Obstetrics Clinic and Delft Community Hospital. EDTA blood was 
obtained to measure CD4-cell count, viral load, and to do genotyping for viral subtype 
and the presence of resistance mutations. Information on prior exposure to 
antiretroviral therapy was also collected. A detected resistance rate of 17.1% in this 
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predominantly HIV-1 subtype C population is lower than previously recorded when 
sd-NVP was administered to HIV-1 subtype C positive patients in PMTCT programs. 
This could indicate that a dual PMTCT regimen including AZT and NVP reduces the 
risk of resistance to NVP relative to a regimen that uses sd-NVP.  
The genotyping assay uses four primers to amplify the PR and the RT gene separately 
to obtain PCR products, of 487 and 804 base pairs respectively for sequencing. The 
two PCR products were sequenced with three and five primers respectively to 
sequence the complete PR and approximately 250 amino acids of the RT gene. The 
sequences generated, thus, are analysed and aligned with the Sequencer V4.7 software 
to obtain a consensus sequence of approximately 1200 base pairs for analysis of 
resistance mutations in the protease and reverse transcriptase genes.   
The developed assay was hence further simplified and improved, by combining the 
PR and RT assay into one, which was optimised and validated for use in the routine 
diagnostic setting. The final genotyping assay uses 8 primers for sequencing to obtain 
a 1200 bp sequence for genotyping that contains the protease and the 5’ of the reverse 
transcriptase genes in which antiretroviral resistance associated mutations are found. 
The assay was accredited by SANAS in 2008.  
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Chapter 1  
1. Introduction and literature review 
1.1 Introduction 
In 2008, an estimated 32.8 million people were living with human immunodeficiency 
virus (HIV) globally with 2.7 million new infections. In South Africa 5.7 million 
people are living with HIV, of which almost one in three are women attending public 
antenatal clinics (UNAIDS, 2010). The number of people receiving antiretroviral 
therapy in developing countries have increased to 5.2 million in 2009 and it is 
expected that treatment access have averted 14.4 million acquired immunodeficiency 
syndrome (AIDS) related deaths since 1996 (UNAIDS 2010). Unfortunately some 
patients have treatment failure and resistance to the initial treatment regimen. In a 
study done by Boulle et al, 2008 it was estimated that 3.7% fail first line treatment 
after 2 years and 17.9% after 4 years on treatment (Boulle et al, 2008). The cost of 
second line antiretroviral drugs still remains too high for use in many developing 
countries with an increasing number of patients that requires it (UNAIDS 2010). 
Since most of HIV infected people are living in low-income countries the 
affordability of anti-retroviral drugs and monitoring of patients receiving treatment, is 
an important factor. With the efforts of treatment activists the prices of anti-retroviral 
drugs have decreased but the cost of the new most tolerable combination therapy 
regimens is still very high. In resource limited settings the most affordable treatment 
regimens are often preferred. Treatment failure increases costs as more expensive 
second line regimens are then needed to suppress viral replication and because failing 
patients have an increased risk of suffering from HIV related conditions. Drug 
resistance testing can help to lower cost by enabling clinicians to choose the most 
effective treatment regimen and could avoid unnecessary switches to second-line 
therapy in patients without resistance, but the cost of drug resistance testing, with 
commercial assays, is extremely high. Licensed commercial assays that are available 
are the ViroSeq™ HIV-1 Genotyping System (Celera Diagnostics, Alameda, 
California, USA) and the TRUGENE™ HIV-1 Genotyping Kit assay (Visible 
Genetics, Toronto, Canada). These are routinely used for diagnostic HIV drug 
resistance testing in industrialised countries but the cost is prohibitive for resource-
 28 
limited settings. There is therefore a need for a practical and affordable in-house 
antiretroviral drug resistance assay for clinical and research use.  
In this study we will attempt to optimize and validate an in-house drug resistance 
assay, adapted from Plantier et al (2005) and published in Jacobs et al (2008), for 
clinical diagnostic use and for the study of antiretroviral resistance in patients on the 
Western Cape Mother-To-Child-Transmission (MTCT) regimen. 
This chapter will give a short overview of the history of AIDS and HIV, the 
epidemiology of the virus, the genomic structure, proteins, and the replication of the 
virus, viral diversity, transmission of the virus, treatment of the infection, drug 
resistant development and mutations, assays available for drug resistance testing and 
the aim of this study. 
1.2 Prevalence of HIV and availability of treatment 
Of the estimated 32.8 million people that are living with HIV, the largest HIV positive 
population, 22.5 million are living in Sub-Saharan Africa. The number of new 
infections in 2009 was estimated to be 2.6 million and AIDS related deaths were 1.8 
million of which 31% of new infections and 34% of deaths due to AIDS related 
illness occurred in Sub-Saharan Africa. It has been estimated that the global HIV 
prevalence have been level since 2001 and that most of Sub-Saharan Africa’s HIV 
prevalence have stabilised or are showing a decline. These declines could be due to 
the natural history of the pandemic or a drop in transmission due to interventions such 
as increased access to antiretroviral therapy in the region.  
The availability of anti-retroviral therapy to those who requiring treatment have 
increased 10 fold from 2002 and the number of people receiving antiretroviral therapy 
in developing countries increased to more than 5 million people in 2009. It is 
estimated that in developing countries, only 36% of those who need treatment are 
receiving it. In South Africa approximately 5.6 million people are living with HIV, of 
which 991 556 are receiving antiretroviral therapy in 2009. Almost one in three 
people in South Africa infected are women attending public antenatal clinics. South 
Africa is one of the countries that showed a marked increase in the availability of 
treatment for HIV positive pregnant women. The coverage of prevention of mother-
to-child-transmission increased from 15% to more than 80% from 2004 to 2009 
(UNAIDS 2010, Republic of South Africa, 2008). 
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1.3 A short overview of the history of HIV and AIDS 
AIDS was first recognized as a new disease in 1981, with the report of 4 cases of 
Pneumocystis carinii pneumonia in previously healthy homosexual men with a 
distinct and unusual clinical syndrome, which was linked to a severe acquired T-cell 
defect (Gottlieb et al, 1981). Other cases of opportunistic infections or tumours such 
as kaposi sarcoma, in homosexual men, provided additional evidence of acquired 
immunodeficiency, which led investigators to suspect a new pathogen that could be 
sexually transmitted (Centre for Disease Control, 1982, Masur et al, 1982). In 1983 
HIV-1, called lymphadenopathy-associated virus (LAV), was isolated from lymph 
node cells of a patient with lymphadenopathy (Barré-Sinoussi et al, 1983) and the 
pathogen was identified for the first time. It was found to be transmitted through 
sexual intercourse, via blood and blood products and from mothers to infants, either 
before, during and after birth or through breast feeding (Cohen et al, 2008). In 1985 a 
second virus that causes AIDS, HIV-2, was identified in West African patients (Barin 
et al, 1985).  
1.4 The Origin of HIV  
It is believed that HIV originated in Africa. Phylogenetic evidence was presented that 
showed that HIV-1 crossed over from the chimpanzee Pan troglodytes troglodytes 
(Gao et al, 1999) and HIV-2 from the sooty mangabey Cercocebus atys (Chen et al, 
1996; Chen et al, 1997). The first known human HIV-1 infection, based on the 
detection of antibodies from a frozen serum sample, occurred in Central Africa in 
1959 (Nahmias et al, 1986) and phylogenetic analytical methods have indicated that 
the virus originated before 1930 (Korber et al, 2000, Salemi et al, 2000, Worobey et 
al, 2008). The epidemic started in Africa and spread to the homosexual population in 
America and Europe with newer information indicating that the epidemic spread from 
Central Africa via Haiti to America and Europe (Gilbert et al, 2007).   
It was believed to be a problem of men who have sex with men and intravenous drug 
users. It soon became clear that the disease was spreading to the heterosexual 
populations as well as infants, haemophiliacs, and blood recipients (Centre for 
Disease Control, 1986 and Scott et al, 1984). Today the virus has spread worldwide 
and affects every country to different degrees, reflecting biological and social factors 
(Cohen et al, 2008).  
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1.5 HIV genome, proteins, morphology, and replication  
The HIV genome, proteins, morphology and replication are reviewed by the following 
publications: Briggs et al, 2003, Frankel and Young, 1998. Freed, 2001, Nisole and 
Saib, 2004, Sierra et al, 2005, Turner and Summers, 1999, Wang et al, 2000. 
1.5.1 HIV-1 genome and proteins 
The HIV-1 genome contains two copies genomic ribonucleic acid (RNA). The RNA 
genome is approximately 9.2-kilobases and it contains 9 open reading frames that 
encode for different viral proteins. The genome is presented schematically in Figure 
1.1 
 
Figure 1.1: Schematic diagram of the HIV-1 genome (Wikipedia. HIV genome.png 
http://en.wikipedia.org/wiki/Image:HIV genome.png 24 November 2010).  
The structural genes are the gag, env, and pol genes that are present in all retroviruses. 
The gag gene codes for the virus core proteins, the capsid that packages the viral 
RNA, the matrix that contains nuclear import signals and the nucleocapsid that binds 
RNA. The pol gene codes for the enzymes, protease (PR), reverse transcriptase (RT), 
RNase H, and integrase. The env gene codes for virus envelope glycoproteins gp120 
on the surface and transmembrane glycoproteins gp41. The tat and rev genes are 
essential for replication in vitro. Tat is responsible for the regulation of viral 
transcription and rev regulates viral RNA transport and splicing. The nef, vpu, vif, vpr 
gene are not essential for replication in vitro and are called the accessory genes. The 
nef gene down regulates the CD4 and Major histocompatibility-I (MHC-I) and binds 
cellular kinases. It plays an essential role in the induction of disease. The vpu gene 
down regulates the CD4 and MHC-I and promotes virus release. The vif gene 
facilitates the viral replication and virion maturation. The vpr gene plays a role in the 
regulation of viral and cell gene expression and blocks cell proliferation. A summary 
of the HIV-1 viral proteins and their functions are set out in Table 1.1 and ribbon 
representations of the structurally characterized viral proteins and protein fragments 
are set out in Figure 1.2. 
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Table 1.1: The HIV-1 viral proteins and their functions (Frankel and Young, 1998) 
Protein Function 
Capsid (CA) Package the viral RNA 
Matrix (MA) Contains nuclear import signals 
Nucleocapsid (NC) Helps with incorporation of Vpr during viral assembly  
gp120 surface envelope 
glygoprotein 
Binding of the viral particle to the host cell receptors  
gp41 transmembrane 
glycoprotein 
Fusion with the host cell and viral entry  
Tat The regulation of viral transcription 
Rev Regulates viral RNA transport and splicing 
Nef Down regulates the CD4 and MHC-I and binds cellular 
kinases, enhances viral particle infectivity, effects on cellular 
signal transduction and activation  
Vif  Facilitates the viral replication and virion maturation 
Vpr Plays a roll in the regulation of viral and cell gene expression 
and blocks cell proliferation 
Vpu Down regulates the CD4 and MHC-I and promotes virus 
release 
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Figure 1.2: Drawing of the mature HIV virion surrounded by ribbon representations 
of the structurally characterized viral proteins and protein fragments. The protein 
structures have been drawn to the same scale (Turner and Summers, 1999).  
1.5.2 HIV-1 morphology 
The HIV-1 virus is a Lentivirus from the subfamily of Orthoretrovirinae, Family 
Retroviridae. A diagram of the HIV-1 particle is presented in Figure 1.3. 
The HIV-1 virus contains a lipid bilayer envelope that is derived from the membrane 
of the host cell. The lipid membrane contains approximately 72 spikes of viral 
Envelope protein (Env) glycoproteins and cellular proteins. The surface glycoprotein, 
gp120 is anchored to the virus particle by interaction with the transmembrane 
glycoprotein, gp41. Other cellular membrane proteins are also present, including actin 
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and ubiquitin. The core is formed by approximately 2000 copies of the matrix protein 
directly to the inside of viral envelope. In the centre of the viral particle is a conical 
shaped capsid, capsomeres are assembled in hexametric rings that contain 
approximately 2000 copies of capsid protein. The capsid contains two copies of the 
viral RNA. The genome is stabilized by forming a complex with nucleocapsid protein. 
The capsid also contains the viral enzymes, protease, reverse transcriptase, and 
integrase. The accessory proteins Negative factor protein (Nef), viron infectivity 
factor protein (Vif) and Viral protein (Vpr) are also found enclosed in the capsid. 
 
Figure 1.3: Schematic diagram of the HIV-1 particle modified from Wikipedia. 
http://commons.wikimedia.org/wiki/Image:Niaid-hiv-virion-mod.jpg 24 November 
2010. 
1.5.3 HIV-1 replication 
The general HIV-1 replication features are set out in Figure 1.4. HIV infects a large 
amount of cells in the immune system. CD4+ T-cells, Cytotoxic T-lymphocytes, 
CD4+ monocytes, macrophages, CD4+ dendritic cells and B cells can all be infected 
by HIV and resting CD4+ T cells are the major reservoirs for latent virus (Blankson et 
al, 2002). The virus have been found in the blood plasma, peripheral blood 
mononuclear cells (PBMC’s), lymph nodes, breast milk, the central nervous system, 
the genitourinary tract and other body fluids and cells after infection (Blankson et al, 
2002, Coovadia, 2004, Pierson et al, 2000, and Stebbing et al, 2004).  
The life cycle can be divided into 2 phases. The early phase begins with the 
recognition of the host cell by the virus particle and includes all processes up to the 
point and including the integration of the viral genomic DNA into the host 
Lipid envelope 
membrane 
Matrix 
gp12 
gp4 
Capsid 
RNA 
Reverse 
transcriptase 
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chromosome. The late phase begins with the synthesis of RNA and includes all 
processes to the stage where the mature virus leaves the cell.  
During the early phase the virus attach to the surface of the host cell by the interaction 
of the gp120 protein with the CD4 receptor. This interaction triggers a change in the 
gp120 that opens a previously hidden region that acts as a co-receptor binding site. 
CXCR4 and CCR5 have been identified as the most important co-receptors necessary 
for viral entry and replication into the host cell and will bind to the opened site by 
electrostatic interactions. Other co-receptors that can be used by HIV-1 include 
CCR3, CCR2b, CCR8, CCR9, Bonzo/STRL33, BOB/GPR15 (Berger et al, 1999). 
The binding to a cellular co-receptor triggers another change of the Env protein and 
the HR1 and HR2 domains of the gp41 will interact with one another and form a six-
helix bundle structure that contains the “fusion peptide”, a highly hydrophobic N 
terminus, that will initiate the membrane fusion. The viral capsid will enter the host 
cytoplasm after fusion between the viral and the host membrane. 
The uncoating of the core is not well understood. It has been found that cellular 
proteins and capsid phosphorylation play a role in uncoating (Wacharaporini et al, 
2007 and Auewarakul et al, 2005). After the uncoating of the core, the reverse 
transcriptase complexes (RTC) are formed, followed by the pre-integration complexes 
(PIC). The uncoating of the core initiates the reverse transcription process by which 
RNA is transcribed into complementary deoxyribonucleic acid (DNA) by the enzyme 
Reverse Transcriptase (RT). The viral DNA is transported to the nucleus as part of the 
PIC that includes the integrase, matrix, RT and Vpr proteins. The PIC enters the 
nucleus via the nuclear pore complexes, large supramolecular protein structures, with 
the help of the Vpr protein.  
Integration of linear double stranded DNA into the host DNA is mediated by the 
integrase enzyme. The sites for integration in host DNA are random and integrase 
creates staggered ends in the linear double stranded DNA by removing several 
nucleotides from the 3’ termini of both strands of DNA. This molecule is inserted into 
the host DNA that has been cleaved asymmetrically.  
 
 35 
 
Figure 1.4: General features of the HIV-1 replication cycle (Turner and Summers, 
1999). 
The late phase of the virus replication begins with the transcription of the viral RNAs, 
which will encode the structural, regulatory, and accessory proteins for viral 
replication from the integrated proviral DNA by cellular RNA polymerase II. The first 
RNAs synthesised encode for the regulatory proteins Tat, Rev and Nef. The Tat 
protein acts as a transcriptional activator. Unspliced mRNAs are present in the 
nucleus where they are processed. The Rev protein mediates the export of the full 
length unspliced HIV mRNAs, encoding for the Gag and Gag-Pol proteins, and single 
spliced HIV mRNAs, encoding for the Env, Vpu, Vif, Vpr proteins, to the cytoplasm 
for synthesis and packaging.  
In the cytoplasm the spliced env mRNA gene is translated to the Env precursor 
protein, gp160, which is glycosylated in the endoplasmic reticulum. The gag-pol gene 
is translated to the Gag and the Gag-Pol precursor proteins. The Gag-Pol precursor 
polyprotein is produced with the occasional ribosomal 1 frame shift during 
translation. The Gag-precursor polyprotein is cleaved by the protease enzyme to 
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produce 6 structural proteins which rearrange and produce the mature viral particle. 
After translation the Env proteins migrate and insert in the plasma membrane. The 
Gag and Gag-Pol polyproteins move to the cellular membrane and start to assemble 
directed by the Gag polyprotein. Viral enzymes, full size genomic RNA, cellular 
tRNAlys3 primer and cellular compounds are assembled within the immature viral 
particle. This viral particle buds through the plasma membrane producing immature 
viral particles. During the budding process the protease enzyme is activated and 
cleavage of the Gag and Gag-Pol polyproteins are activated that release the structural 
proteins and enzymes and the mature viral particle is formed. The infection of resting 
memory or naïve CD4+ T cells, macrophages and mononuclear cells leads to latent 
infection.  
1.6 The HIV-1 enzymes that is essential to this project  
The pol gene of the HIV-1 genome encodes for the viral enzymes, protease (PR), 
reverse transcriptase (RT), RNase H, and integrase. These enzymes are produced by 
the cleavage of the Gag-Pol polyprotein. These enzymes have been reviewed by the 
following publications: Fields et al, 1996, Frankel and Young, 1998, Meek and 
Dreyer, 1990, Prasad and Goff, 1990, Shafer, 2002 and 2004, Turner and Summers, 
1999 
1.6.1 The Protease enzyme  
The PR is a dimer that consists of two structurally identical monomers which each are 
99 amino acids long. A structural model of HIV-1 PR homodimer is presented in 
Figure 1.5. The enzyme targets the cleavage sites on the Gag and Gag-Pol 
polyproteins to produce the structural proteins and enzymes of the virus. The active 
site in each monomer is positioned in a loop at positions 25-27, and forms part of the 
catalytic site. Above the active site is a binding cleft for the substrate. There is enough 
room in the cleft to accommodate a substrate of seven amino acids in length. The 
entrance to the binding site is covered by to flaps in the dimer and these flaps move to 
permit substrate to enter. The enzyme has specificity for more than one cleavage site. 
There are four cleavage sites in the Gag and seven in the Gag-Pol polyprotein. 
Cleavage specificity is determined by four amino acids upstream and three amino 
acids downs stream in the target substrate. The amino acids upstream of the cleavage 
site are always hydrophobic and unbranched at the -carbon. The enzyme cleave 9 
 37 
different peptide sequences to produce the matrix, capsid, nucleocapsid, and p6 
protein from the Gag polyprotein and protease, reverse transcriptase, RNase H and 
integrase proteins from the Gag-Pol polyprotein.  
 
Figure 1.5: Structural Model of HIV-1 Protease Homodimer The polypeptide 
backbone of both protease subunits is shown. The active site, made up of positions 
25-27 from both subunits, is displayed in ball and stick mode. The protease inhibitor 
resistance mutations are shown for the subunit on the left but not for the mirror-image 
subunit on the right. The protease was co-crystallized with indinavir, which is 
displayed in space-fill mode. This drawing is based on a structure published by Chen 
et al, 1994. 
1.6.2 The Reverse Transcriptase (RT)  
A structural model of HIV-1 RT enzyme is presented in Figure 1.6. The RT is a RNA-
dependant DNA polymerase and can synthesize DNA from both RNA and DNA 
templates. The PR enzyme cleaves the RT enzyme from the Gag-Pol polyprotein 
during viral assembly. This cleavage happens in two steps. First the p66 is cleaved 
from the polyprotein and forms a homodimer. The p66 subunit is cleaved near the C-
terminus to yield a heterodimer that contains both the p51 and the p66. The p51 
subunit contains 440 amino acids of the RT gene and has no enzymatic activity. The 
p66 subunit contains the complete 560 amino acids of the RT gene. The N termini of 
both subunits are identical. The p51 and p66 interact in a head-to-tail configuration to 
produce the heterodimer. The structure of the RT domain has 5 subdomains that 
resemble a hand with fingers, palm and thumb. The catalytic site of the RT lies in the 
cleft of the palm of the p66 subunit. The thumb of the p66 subunit contains two -
helices that together with the palm act as a clamp to position the template-primer to 
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the active site of the enzyme. The 3-hydroxyl of the primer terminus is in position for 
polymerization of the incoming nucleotide triphosphate.  
RT is responsible for HIV-1 diversity. It has poor proofreading ability and non-
complimentary incorporation of nucleotides occurs that leads to single point 
mutations. Slippage of the two DNA strands may occur that will lead to deletions or 
insertions of one and more nucleotides. A frameshift can occur when 
misincorporation is followed by misalignment. Base substitutions can result when 
slippage occur with correct insertion and realignment. It can also cross over from one 
template to another resulting in recombination (McCutchan, 2006). All of these can 
produce variation over a large portion of the genome and contribute to diversity and 
mutations that can lead to resistance.  
 
Figure 1.6: Structural model of HIV-1 reverse transcriptase (RT). The polypeptide 
backbone of the "fingers", "palm", and "thumb" subdomains of the p66 subunit are 
shown. This drawing shows the RT that is co-crystallized with nevirapine, which is 
displayed in space-fill mode. The active site is shown in ball and stick mode. The 
positions associated with Non-nucleoside reverse trancriptase inhibitor (NNRTI) 
resistance are shown surrounding the hydrophobic pocket to which nevirapine and 
other NNRTIs bind. The drawing is based on a structure published by Kohlstaedt et 
al, 1992. 
1.6.3 RNase H 
RNAse H functions in reverse transcription by degrading the RNA of RNA:DNA 
hybrids and uncovering the template for viral DNA synthesis. RNAse H also produces 
oligoribonucleotide primers for the reverse transcriptase process. RNAse H is cleaved 
from the Gag-Pol polyprotein by PR on the p66 subunit of the RT enzyme. The viral 
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RNAse H is folded into a five-stranded mixed -sheet flanked by an asymmetric 
distribution of four -helices. Four acidic amino acid residues in the RNAse H 
enzyme of HIV-1 have been identified as necessary for the catalytic activity of the 
enzyme. The RNase H only becomes catalytically active on addition of the p51 
subunit.  
1.6.4 Integrase  
The integrase enzyme possesses both DNA cleavage and joining activities. A 
pharmacophore model for the integrase enzyme is presented in Figure 1.7. The 
enzyme is responsible for the linkage of double-stranded viral DNA into the host cell 
genome. The C-terminus of the Gag-Pol polyprotein is cleaved by the PR enzyme to 
produce the integrase enzyme. The core domain consists of a central five-stranded -
sheet and six helices. The enzyme forms a dimer – two monomers of integrase are 
bound together. Each molecule of integrase contains one catalytic site and has 
separate DNA binding sites for the ends of linear viral DNA and double-stranded host 
cell DNA. The substrate of the enzyme is short double-stranded olignocleotides 
corresponding to termini, called att sites of linear viral DNA. The activities of the 
integrase gene include the cleavage of deoxythymidylate-deoxythymidylate (TT) 
dinucleotide from the 3’ of double-stranded att site substrate, the cleavage of double-
stranded target DNA to produce a staggered 5 base overhang and the transfer of 
activity in which the recessed 3’ end in the substrate DNA is joined to the 5’ 
phosphoryl end in the target DNA.  
 
Figure 1.7: The pharmacophore model for the integrase enzyme. Jaganatharaja and 
Gowthaman, 2006. 
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1.7 HIV Diversity  
There are two genetically distinct HIV types identified, HIV-1 is associated with 
disease across the globe and HIV-2 is associated with disease mostly in western 
Africa. The two viruses are similar in the pathogenesis and both lead to AIDS related 
death, although HIV-2 is associated with a slower disease progression. (Klimas et al, 
2008). Phylogenetic analyses have shown that there are four distinct groups of HIV-1, 
HIV-1 group M (major), group O (outlier), group N (non-M/non-O) and group P. 
(Kober et al, 2000, Keele et al, 2006, Plantier et al, 2009). These groups can be 
further divided into subtypes on the bases of the phylogenetic relation. Group M is 
responsible for the majority of HIV-1 infection worldwide. It can be subdivided into 
subtypes A to K. Two of these subtypes can be divided into sub-subtypes, A1 to A4, 
F1 and F2. Recombinant forms have also been described (McCutchan, 2006, Ramirez 
et al, 2008, Taylor et al, 2008,) and can be divided into circulating recombinant forms 
(CRF) and unique recombinant forms (URF). There are 48 CRF (Los Alamos 
Sequence Database, 2010). These have emerged when genomes of different subtypes 
combined to form a genetically distinct viral lineage. Recombination occurs when a 
patient is infected with two different HIV-1 subtypes. During the replication of the 
viruses an RNA stand from the one virus is co-packaged with an RNA stand from the 
other when a new viral particle is formed. When a new replication cycle starts, the 
two RNA strands of the virus are transcribed to proviral DNA. The reverse 
transcriptase enzyme switches between the RNA templates to give rise to recombinant 
proviral DNA that is a mixture of the two RNA strands containing genes from both 
the HIV subtypes infecting the patient (Ramirez et al, 2008, Taylor et al, 2008). The 
CRF represent recombinant forms that are circulating in the population, so that it 
could be detected in epidemiologically unlinked cases. URF are recombinants with a 
unique structure and subtype composition and have only been identified in one 
individual (McCutchan, 2006). Almost all subtypes and CRFs can be detected in Sub-
Saharan Africa. The rest of the world shows a specific geographic distribution pattern 
for HIV-1 subtypes that can be attributed to the founder effect, the first HIV-1 
subtype that are successfully introduced into a population is likely to became the most 
predominant subtype (Buonaguro et al, 2007, Thomson and Najera, 2005). Figure 1.8 
shows the global distribution of HIV-1 subtypes.  
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Figure 1.8: Geographic distribution of HIV genetic forms (Ramirez et al, 2008)  
HIV-1 subtype diversity can have a major impact on antiretroviral treatment and the 
development of drug resistance. It may affect the genetic barrier, defined as the 
amount of viral mutations necessary to result in a drug resistant virus as 
polymorphisms associated with a particular HIV-1 subtype can affect the genetic 
barrier towards a particular antiretroviral drug. (Beerenwinkel et al, 2005).  
1.8 Mother-To-Child-Transmission (MTCT) 
In the absence of interventions MTCT of HIV-1 occurs at a rate of more than 15%-
30% and is one of the major causes of AIDS in children under the age of 15 years. 
Approximately 370 000 new infections occur in children under the age 15, of which 
90% are in Africa (UNAIDS, 2010). 
HIV-1 is transmitted from mother-to-infant during pregnancy, labour and delivery or 
during breastfeeding. It is estimated that 25-48% of transmission in developing 
countries occurs during labour and delivery, approximately 20% of infections occur 
during breastfeeding (De Cock et al, 2000) and 20-30% in-utero (Farquhar et al, 
2010). The risk of transmission from mother-to-infant has been shown to decrease 
with the administration of antiretroviral drugs. In 1994 it was shown that the 
administration of AZT to pregnant women reduces the risk of MTCT by 70% (Conner 
et al, 1994) and when antiretroviral therapy during pregnancy, throughout labour and 
therapy to the neonate is combined with caesarean section only 2% of infants become 
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infected (The International Perinatal HIV Group, 1999). Highly active antiretroviral 
therapy (HAART) regimens have shown similar results (Cooper et al, 2002). 
Nevertheless, the cost of these regimens has limited their availability in developing 
countries. In 1999 a study done in Uganda showed that sd-NVP decreases the risk of 
MTCT (Guay et al, 1999). NVP is a Non-Nucleoside Reverse Transcriptase Inhibitor 
(NNRTI) that inhibits viral replication. Developing countries that have implemented 
preventative MTCT programs have been able to lower MTCT to below 10% 
(UNAIDS, 2010). However a problem of using an sd-NVP regimen is the 
development of HIV-1 resistance mutations to NVP due to the low genetic barrier of 
HIV for NVP (Ren and Stammers, 2008). Resistance occur in 19-69% of mothers that 
receive a single dose of NVP. Different HIV-1 subtypes have been shown to 
developed resistance to a single dose of NVP at different rates (46-69%) with the 
highest incidence of resistance seen in HIV-1 subtype C (Eshleman et al, 2001, 
Eshleman et al, 2005 and Kurle et al, 2007). 
1.9 Antiretroviral drugs  
There are 32 antiretroviral drugs approved by the Federal and Drug Administration 
(FDA) for treatment of HIV-1 positive patients in 2010 (Federal and Drug 
Administration, http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates 
/HIVandAIDSActivities/ucm118915.htm (November 2010)). These include 
combination of drugs, but exclude generic forms. They are divided into different 
classes according to their mode of action. The classes available are Nucleoside and 
Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI), Non-nucleoside Reverse 
Trascriptase Inhibitors (NNRTI), Protease Inhibitors (PI), Integrase Inhibitors, Fusion 
Inhibitors and CCR5 receptor antagonist. 
Zidovudine (AZT), an NRTI, was the first antiretroviral drug available for treatment 
of HIV-1 positive patients that was approved for use by the FDA in 1987 after it was 
found to be effective in the treatment of AIDS patients (Fischl et al, 1987). Currently 
there are 8 NRTIs approved by the FDA and 4 combinations of NRTI drugs. NRTIs 
enter the host cell where they are triphosphorylated by the cellulular enzymes 
Tenofovir is the only NRTI licensed for HIV therapy, taken in its 
monophosphorylated form (Fung et al, 2002). The triphosphorylated synthetic 
nucleosides and then compete with natural deoxynucleoside triphosphates (dNTPs) 
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for incorporation into the newly synthesised DNA chains. This incorporation 
terminates the elongation of the chain and inhibits the viral replication (Shafer, 2004). 
Four NNRTIs have been approved by the FDA, Nevirapine (NVP), Efavirenz (EVF) 
Etravirine (ETR) and Delavirine (DLV). NVP was approved in 1996 by the FDA for 
use with AZT to obtain prolonged HIV-1 suppression. All the NNRTIs bind to the 
same area in the RT enzyme and have the same functional properties. The NNRTIs 
bind to the HIV-1 reverse transcriptase in the hydrophobic pocket located between the 
6-10- 9 and 2-13-14 sheets of the p66 subunit. Binding of the NNRTIs to this 
site displaces the catalytic aspartate residues relative to the polymerase-binding site 
and inhibits HIV-1 replication (Shafer, 2004). 
HIV therapy was limited to the NRTIs until the PIs were FDA approved during 1995. 
Studies showed that NRTIs in combination with PIs and NNRTIs were more effective 
in long term suppression of HIV-1 (Deeks et al, 1997, Markowitzet al, 1995). 
Currently there are 9 PIs approved by the FDA. PIs bind to the active site of the 
protease enzyme and prevent the cleavage of the Gag and Gag-Pol polyproteins to 
yield the structural proteins and enzymes of the HIV-1 virus (Shafer, 2004). 
The development of resistance has let the development of new antiviral drugs for 
treatment of resistant viruses. Fusion and integrase inhibitors and a co-receptor 
antagonist have been approved by the FDA. The integrase inhibitor acts against strand 
transfer by binding to the target DNA site of the integrase enzyme. The fusion 
inhibitor, enfuvirtide, corresponds to part of the heptad repeat domain HR2 which 
consists of residues 127-162 of the gp41, the transmembrane glycoprotein subunit of 
the envelope glycoproteins. The gp41 subunit promotes fusion of viral and cellular 
membrane and entry of the viral core into the cell. The heptad repeat domains HR1 
and HR2 form a helical bundle that contains trimers of each domain during fusion. 
Enfuvirtide is a synthetic peptide that inhibits the interaction between HR1 and HR2 
by mimicking HR2 (Shafer and Shapiro, 2008). Maraviroc, a CCR5 antagonist, is the 
only licensed antiretroviral drug that does not target a viral-encoded protein but 
inhibits HIV-1 replication by blocking a host cell co-receptor. This drug is used in 
patients, harbouring viruses with CCR5 receptor tropism (Fätkenheuer et al, 2005).   
The South African National Antiretroviral Treatment guidelines, in 2006 
recommended 2 regimens for treatment of adult patients. Regimen 1 consisted of two 
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NRTIs, Stavudine (d4T) and Lamivudine (3TC), and 1 NNRTI, Nevirapine (NVP) or 
Efavirenz (EFV). Therapy naïve patients started with regimen 1 and if they failed on 
the first line regimen their treatment had to be adjusted to regimen 2 that consisted of 
2 NRTIs, Zidovudine (AZT) and Didanosine (ddi), and 1 boosted PI, 
Lapinavir/ritonavir (LPV/r) (Republic of South Africa, 2004). In 2010 this policy 
chanded to Tenofovir (TDF), 3TC or Emtricitabine (FTC), and EFV, or NVP as first-
line regimen followed by zidovudine (AZT), Lamivudine (3TC) and LPV/r as second-
line regimen (Republic of South Africa, 2010). 
1.10 Drug of interest for the purpose of this study 
In the Western Cape Province, AZT and NVP are the drugs used in the prevention of 
MTCT program. In 2010 the national policy was changed to include this dual regimen 
for use in the National PMTCT program.  
1.10.1 Zidovudine (AZT) 
A structural representation is in Figure 1.9. AZT was the first drug approved by the 
FDA in 1987 after a study done by Fischl et al (1987) found that AZT was effective 
in reducing the mortality and rate of opportunistic infections of HIV-1 positive 
patients. AZT is an NRTI and inhibits the replication of HIV-1 by acting as a 
substitute for dNTPs. Chain termination follows after the incorporation of the 
inhibitor due to the fact that it does not contain a 3’-OH group (Arts et al, 1998). 
After the success of AZT, other NRTIs were developed and initially favoured over 
AZT due to the adverse side effects and the development of drug resistance mutations 
to AZT. Today, used in a lower dose, AZT, in combination with other NRTIs and 
NNRTIs has remained one of the most effective drugs available for treatment of HIV-
1 positive patients (Gulick, 1997).  
 
Figure 1.9: Structure of Zidovudine (AZT) with substitution of 3’-OH group with a 
nitrile group. (Menendez-Arais, 2008). 
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1.10.2 Nevirapne (NVP) 
NVP showed the potential in suppressing HIV-1 replication in initial studies (Davey 
et al, 1993, Merluzzi et al, 1990, Saag et al, 1993). The NNRTIs bind to the RT 
enzyme close to the active site and prevent the binding of the enzyme substrate to the 
active site of the RT, thus inhibiting HIV-1 replication (De Clerq, 2004, Shafer, 
2004). Although a potent inhibitor of HIV-1, the development of drug resistant virus 
strains was seen in all initial studies with NVP as a monotherapy (Saag et al, 1993, 
Davey et al, 1993). In studies done where NVP was used in combination therapy, it 
was found to be very effective and the drug was approved by the FDA in 1996 for use 
in combination with other antiretroviral therapies. Its use in pediatric patients was 
approved in 1997 and the effectiveness of the drug in the prevention of MTCT was 
described in 1999 in Uganda cohort of HIV-1 positive woman and their infants 
receiving a single dose of NVP (Guay et al, 1999). The structure of NVP is presented 
in Figure 1.10. 
 
Figure 1.10: Structure of Nevirapine (NVP) (De Clerq, 1999). 
1.11 HIV-1 drug resistance  
The first HIV-1 antiretroviral drug resistance was described in 1989 by Larder et al. 
when it was noted that patients become less likely to respond to AZT therapy after 
prolonged treatment.  
Drug resistance is the reduction of drug susceptibility of a virus compared to the wild-
type virus by the presence of genetic mutations. Drug resistance mutations occur in 
the protease and reverse transcriptase genes and can be attributed to the poor 
proofreading ability of the RT enzyme during the replication cycle that causes genetic 
variation in HIV-1. The average error rate of the enzyme is 1 error per 2000-5000 
nucleotides polymerized (Menéndez-Arias, 2008) and it has been estimated that single 
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point mutations occurs 10 000 to 100 000 times per day in an untreated HIV-1 
positive person. The number of HIV-1 variants is further increased by the extremely 
high rate of replication of HIV-1, up to 1010 viral particles produced per day (Coffin, 
1995). This contributes to the high degree of diversity of HIV-1 during the course of 
an infection.  
Single point mutations, deletions and insertions during the HIV-1 replication cycle 
lead to the development of drug resistance mutations. The size and variation of the 
HIV-1 population within an individual, the suppression of viral replication during 
antiretroviral therapy, the path by which a mutation is acquired, the effect that the 
mutation will have on viral fitness and the influence that the mutation will have on 
drug susceptibility, can all play a role in the rate and amount of drug resistant 
mutations that develop (Shafer, 2002).  
There is a standard numbering system for drug resistance mutations based on their 
amino acid positions within the protease and reverse transcriptase gene. The subtype 
B consensus sequence is used as the reference sequence. This consensus sequence 
was formed from the alignment of sequences available in the HIV Sequence Database 
(Kuiken et al, 1999) at the Los Alamos National Laboratory. Mutations are described 
by using the first letter of the consensus subtype B amino acid, followed by the 
position of the mutation in the sequence, followed by the letter of the amino acid that 
indicate the mutation e.g. M184V. When a mixture of more than one amino acid is 
reported at one position, the different amino acid letters are written after the position 
separated by a forward slash e.g. M184M/V indicating a mixture of the wild-type 
amino acid and the mutant amino acid (Shafer, 2004). 
Some resistance mutations, can on their own, cause resistance to one or more drugs, 
e.g. M184V, and are referred to as primary or major resistance mutations. Other 
mutations only cause resistance if present in combination with major resistance 
mutations e.g. E138A, and are refered to as secondary or minor mutations (Shafer, 
2004).  
The accumulation of mutations such as M41L, D67N, K70R, L210W, T215F or 
T215Y and K219Q or K219E can cause high level of resistance against the NRTIs. 
These mutations are known as the thymidine analogue mutations (TAMs) as they are 
found most often when the patients are on a regimen containing AZT and d4T 
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(Shafer, 2004). These mutations are frequent in low-income countries, like South 
Africa that use thymidine analogues in the first and second line regimens (Shafer and 
Schapiro, 2008). There are two patterns seen for the accumulation of TAMs. The type 
1 pattern includes mutations M41L, L210W and T215Y and the type 2 pattern 
includes mutations D67N, K70R, T215F and K219Q/E. The type 1 TAMs cause 
higher levels of resistance than type 2 TAMs (Shafer and Schapiro, 2008).  
HIV-1 diversity also plays a role in the development of resistance mutations. It was 
found that naturally occurring polymorphisms in non-B HIV-1 subtype can contribute 
to drug resistance (Cornelissen et al, 1997). Polymorphisms in non-B subtype HIV-1 
sequences also create shorter pathways for the selection of drug resistance mutations. 
The pathway for the selection of the V106M mutation, that causes resistance to 
NNRTIs, is shorter in HIV-1 subtype C than in subtype B viruses. The polymorphism 
at codon 106 of GTG, found in 94% of HIV-1 subtype C sequences, can be changed 
to ATG with a single mutation. This polymorphism is rarely seen in the HIV-1 
subtype B viruses where the codon is GTA and 2 mutations are needed for the 
V106M resistance mutation to develop (Brenner et al, 2003). The implications of the 
effect of subtype associated polymorphism on the algorithms used for drug resistance 
and the treatment options for patients with non-B subtypes HIV-1 still are not fully 
understood.  
1.11.1 Protease inhibitor (PI) resistance 
The PR targets the cleavage sites on the Gag and Gag-Pol polyproteins to produce the 
structural proteins and enzymes of the virus. More than 30 mutations are associated 
with PI resistance (Johnson et al, 2008). Resistance to PI’s develops due to structural 
changes that reduce the binding of the protease to the inhibitor.  
1.11.2 Nucleoside analogue Reverse Transciptase (NRTI) resistance  
The mechanism of NRTIs is to block the elongation of the proviral DNA during 
reverse transcription and terminate the DNA chain formation. A drug enters the host 
cell where it is phosphorylated and then competes with natural dNTPs for 
incorporation into the newly synthesised DNA chains. This incorporation terminates 
the elongation of the chain and inhibits the viral replication. Resistance to NRTI’s 
develops via two biochemical processes. One method is to decrease the incorporation 
of NRTI’s by the action of mutations that allow RT to discriminate between NRTI’s 
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and natural dNTPs during phosphorylation and thus prevent their incorporation into 
the newly formed DNA chain. Such discriminatory mutations are the M184V, 
Q151M, K65R and L74V. The second process is phosphorolytic removal of the 
incorporated NRTI’s from the newly formed chain to allow continued polymerisation 
and strand elongation. Mutations that facilitate phosphorylitic removal of 
incorporarated NRTIs are the TAMs, the T69 insertion and accessory mutations 
(Shafer, 2004, Shafer and Schapiro, 2008). 
1.11.3 Non nucleoside analogue Reverse Transciptase (NNRTI) resistance  
The NNRTIs bind to the HIV-1 reverse transcriptase in the hydrophobic pocket 
located between the 6-10- 9 and 2-13-14 sheets of the p66 subunit. Binding of 
the NNRTIs to this site displaces the catalytic aspartate residues relative to the 
polymerase-binding site and inhibits HIV-1 replication. Resistance arises with the 
development of mutations in or next to the NNRTI binding site. Only one or two 
mutations in this area are necessary for the development of high level resistance, 
therefore HIV has a low genetic barrier to the development of NNRTI resistance. 
These mutations often lead to a high level of cross resistance between the different 
NNRTI’s. Resistance occurs due to mutations causing a reduction in the binding 
potential of the NNRTI’s (Y181C and Y188C/I/H), stabilizing of the RT 
conformation (K103N) or reduction of protein inhibitor contact (L100I, V106A and 
V108I) and charge repulsion (K101E, E138K) (Ren and Stammers, 2008). 
Mutations for NNRTI resistance can be categorized into 4 groups: 1) major NNRTI 
resistance mutations that cause resistance to one or more NNRTI’s and that develop 
early, 2) minor NNRTI resistance mutations that occur in combination with major 
NNRTI resistance mutations, 3) minor non-polymorphic mutations that occur alone or 
in combination with other mutations that cause low-level NNRTI resistance and 4) 
polymorphic mutations that influence the effect of other NNRTI resistance mutations 
(Shafer and Schapiro, 2008).  
Mutations in the envelope gene and the integrase gene that confers resistance to the 
entry inhibitors and the integrase inhibitors have been identified but will not be 
discussed as the inhibitors are not feely available in South Africa and have no bearing 
on the project. 
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1.12 Drug resistance testing  
Different methods are available for detection of drug resistance mutations. The most 
commonly used method is genotypic testing which uses gene sequencing to detect 
mutations that could result in decreased susceptibility to a drug. Phenotypic testing, 
which measures the amount of resistance that the viral population shows in an in vitro 
replication system, is more expensive and time consuming, although one advantage is 
that it can be used to study complex interactions of mutations (Shafer, 2004, and 
Hanna and D’Aquila, 2001). 
Genotypic testing relies on population based sequencing and reports consensus 
sequence at each nucleotide. It can detect mutations in mixed populations that are too 
low to cause drug resistance on its own. This could provide insight in the potential for 
resistance to emerge and it can also detect transitional mutations that do not cause 
drug resistance by themselves but indicate the presence of selective drug pressure. 
Another advantage of genotypic assays is that they have a more rapid turn-around 
than phenotypic tests and are less costly.  
The presence of some resistance mutations can lead to the phenotypic sensitivity to 
other drugs for example, the lamivudine-selected M184V mutation can lead to the 
reversal of AZT resistance in the presence of several nucleoside analog-resistance 
mutations (NAM’s) (Tisdale et al, 1993).  
Detection of significant minority species also remains a problem with sequence-based 
methods. Most genotypic resistance assays can detect minority resistance mutations at 
approximately 20%. In patients heavily treated and have since change a level of 
therapy due to resistance, strains containing the resistance mutations will become 
undetectable within weeks as the viral population revert back to a predominant ‘wild 
type’ strain without resistance mutations. The resistant virus will however reappear as 
soon as the drug is reintroduced (Devereux et al, 1999).  
Studies have shown that genotypic testing is more useful clinically than phenotypic 
testing (Baxter et al, 2000, Clingolani et al, 2002, Cohen et al, 2002, Durant et al, 
1999, Haubrich et al, 2001, Tural et al, 2002).  
Commercial assays for genotyping, like the ViroSeq™ HIV-1 genotyping assay and 
the Trugene™ HIV-1 genotyping assay, are FDA approved and available. The high 
costs prohibit the use in recourse-limited settings such as the South African public 
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programme. Also, the sequencing primers, developed for industrialised countries, 
where HIV-1 Subtype B is the prevalent subtype, do not detect non-subtype B viruses 
as effectively. (Beddows 2003, Jagodzinski 2003) 
New sensitive assays are available for resistance testing, including single-genome 
sequencing (Palmer et al, 2005), allele-specific Polymerase Chain Reaction (PCR) 
(Bergroth et al, 2005, Menzner et al, 2003, and 2005), hybridisation assays (Flys et al, 
2005) phenotypic analysis using S. cerevisiae (Nissey et al, 2005), massively parallel 
sequencing in microfrabricated PicoTiterPlates (Leamon et al, 2003), pyrosequencing 
(O’Meara et al, 2000) and parallel allele-specific PCR (Cai and Gochin, 2007). These 
assays are very specialised, generally costly, and not adapted for use in diagnostic 
monitoring of patients on antiretroviral treatment.  
1.13 Optimisation of the Polymerase Chain Reaction (PCR) 
The aim of this study is to optimize and validate a genotyping assay. In this section 
the PCR method will be discussed in relation to optimisation.  
1.13.1 Polymerase Chain Reaction (PCR) 
The PCR method was developed in 1985 by Kary B. Mullis (Mullis and Faloona, 
1987). The basic PCR method involves DNA heat denaturing, primer annealing and 
DNA extension in repeated cycle steps (Saiki et al, 1988). The standard conditions 
will amplify most target sequences but new PCR protocols require optimisation to 
perform efficiently in repetitive conditions. The following factors must be considered 
in optimisation of a PCR, the enzyme, dNTP and magnesium concentrations, template 
quality and input, and additives or enhancers for PCR. Primer design, annealing 
temperature and extension times also is important in PCR optimisation (Innis et al, 
1990, Promega, Protocol and Applications guide 
http://www.promega.com/paguide/chap1.htm, November 2010). 
1.13.2 Enzyme concentration 
If the enzyme concentration is too high, non-specific background products may be 
seen and if the concentration is too low and insufficient amount of product is 
amplified (Innis et al, 1990, Promega, Protocol and Applications guide 
http://www.promega.com/paguide/chap1.htm, November 2010). 
 
 51 
1.13.3 Deoxynucleotide triphosphates (dNTP) concentration 
The four dNTP’s should be used at equivalent concentration to minimize 
misincorporation errors. The specificity and the fidelity of PCR are increased by using 
lower dNTP concentration. Low dNTP concentrations minimize the mispriming at 
non-specific sites and reduce the likelihood of extending misincorporated nucleotides. 
The recommended concentration for dNTP’s is 200µM of each dNTP. If the 
concentration is increased, the magnesium concentration must also be increased as an 
increase in dNTP’s reduces the free Mg2+ and interfers with polymerase activity and 
primer annealing (Innis et al, 1990). 
1.13.4 Magnesium concentration 
The magnesium concentration can affect the primer annealing, denaturing 
temperatures of the template and PCR product, product specificity, formation of 
primer-dimers, and enzyme activity and fidelity. The magnesium concentration must 
be 0.5-2.5mM for a PCR. Lower magnesium concentrations increase the specificity of 
priming and amplification and higher concentrations lead to non-specific 
amplification. DNA template concentrations, chelating agents like EDTA, dNTP 
concentration and the presence of proteins can affect the amount of magnesium in a 
reaction (Innis et al, 1990, Promega, Protocol and Applications guide 
http://www.promega.com/paguide/chap1.htm, November 2010). 
1.13.5 Template quality and amount of input 
The quality and purity of the template are crucial for it success. The amount of 
template influences the performance of the PCR. Low amount of template will require 
specific modifications to the PCR, such as an increase in cycle number, redesign of 
primers, use of specific enzymes to accommodate input volume. Large amounts of 
template can lead to inhibition of the PCR. (Ausubel et al, 2006, Promega, Protocol 
and Applications guide http://www.promega.com/paguide/chap1.htm, November 
2010). 
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1.13.6 Additives and enhancers for PCR  
Some components enhance the efficiency, specificity or yield of a PCR. These 
components can sometimes also cause inhibition, therefore they should be used with 
caution so care should be taken when using them. Nonionic detergents (Triton X-100) 
neutralizes charges of ionic detergents used in the extraction methods. Enzyme-
stabilising proteins (bovine serum albumin), enzyme-stabilising solutes (Betadine) 
and enzyme-stabilising solvents (glycerol) and solubility-enhancing solvents 
(Dimethyl sulfoxide) will achieve higher yields of PCR product by stabilizing or 
enhancing the polymerase enzyme (Ausubel et al, 2006, Promega, Protocol and 
Applications guide http://www.promega.com/ paguide/chap1.htm , November 2010). 
Reducing agents e.g. dithiotheritol (DTT), reduce disulfide bonds and provide free 
Mg++ for the reverse transcriptase reaction (Nagai  et al, 1998, Ralser et al, 2006).  
1.13.7 Primer design, annealing temperature and extension times  
An optimal primer must hybridize effectively to the target template with no or little 
hybridization to other DNA templates present. The primers must be designed to be 
specific for the target template. Primers are usually designed to be exactly 
complementary to the template. Some primers have mismatches and the closer the 
mismatches are to the 3’ end of the primer, the higher the chance that it will not 
amplify. A primer should be 20- 30 bases in length. Sufficient primer length could 
help with specific amplification of the target sequence. The primer sequence must be 
designed to have the same GC content than the template and it should be between 40-
60%. There should not be three G or C bases near the 3’ end of the primer to 
minimize non-specific annealing. Avoid primers with unusual sequence distributions 
such as long areas of polypuridines, since this can form secondary structures. To 
avoid primer-dimer formation, primers that are not complementary to one another 
must be designed. Primer-dimers are observed when the 3’ end of the one primer bind 
to the 3’ end of the other and DNA polymerase extend each of the primer ends. The 
melting temperature (Tm), the temperature at which 50% of the primer molecules are 
annealed to the template, of the primers used in the PCR must be within 5°C of one 
another so that the efficiency of the primers is at the same temperature. There are 
several computer programs e.g. Primerplex, Primer 3, OligoPerfect™ Designer, that 
can help in primer design. The MyBio webpage contain links to many primer design 
tools (http://mybio.wikia.com/wiki/Primer_design_tools) (Ausubel et al, 2006, Innis 
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et al, 1990, Promega, Protocol and Applications guide http://www.promega.com/ 
paguide/chap1.htm, November 2010). 
1.13.8 Primer selection for sequencing 
Fluorescence-based cycle sequencing reactions are used to sequence DNA templates 
from PCR products. A single primer is used for each PCR reaction and primer 
extension is terminated at different sequence lengths with the size of the primer 
corresponding to the sequence length and the particular fluorescent label 
corresponding to the terminal base. The quality of sequencing results will depend on 
the quality of the sequencing primer. The following criteria must be met for sequence 
primer design: the primer sequence must be unique to the region of interest; the 
primers must not contain hairpin loops; the melting temperature of the primer must be 
appropriate for cycle sequencing and the primer must be pure (Li et al, 2008). 
The size of the sequence obtained with one primer reaction is approximately 500 bp. 
If a larger DNA region must be sequenced the region must be broken down into 
smaller fragment for sequencing. This is done by obtaining sequence data for the 
DNA fragment that must be sequenced. Primers are designed to correspond to shorter 
sequences of the region of DNA of interest (Strauss et al, 1986). These shorter 
fragments can be assembled using software like the Sequencer software V4.7 (Gene 
Codes Corporation, Ann Arbor USA) to obtain a complete sequence of the region of 
interest.  
1.14 Validation of methods 
Validation is the evaluation of a process to determine the fitness of the process for a 
particular use. There are different types and levels of validation. A full validation is 
performed when the method is developed and implemented for the first time. A partial 
validation is performed when the method was already validated and modifications are 
made to it. This validation can range from intra-assay accuracy and precision 
determination to a nearly full validation. A cross-validation is where the original 
validated method serves as a reference and the revised method is compared to it. In 
this study partial and cross validation methods will be applied (US Department of 
Health and Human Services, 2001). 
To validate a method, quality control (QC) samples are used to evaluate the 
performance of the method and comparison between methods is done using the same 
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samples. Acceptability of the performance of a method is determined by the accuracy, 
precision, specificity, sensitivity, reproducibility and stability of the method. 
Accuracy describes the closeness of the method result to the true result of the assay. 
Precision describes the closeness of individual results to one another if repeat 
measurements are made. Specificity determines the ability of the method to detect the 
correct analyte and sensitivity determines the ability of the method to detect the 
analyte. Reproducibility determines the ability of the assay to obtain the same result 
after repeated testing of the same sample. Stability determines the stability of the 
analyte in the sample for testing. For the method to be valid, specific acceptance 
criteria should be set in advance and achieved for accuracy and precision (Jacobson 
and Romatowski, 1996, US Department of Health and Human Services, 2001). 
1.15 Aim of the study 
The first aim of this study is to validate an in-house drug resistance assay, adapted 
from Jacobs et al (2008) as a diagnostic and research tool. The following parameters 
will be changed (a) input RNA volume into the PCR reaction, (b) the denaturing of 
RNA and (c) primer and magnesium concentrations. The output will be compared 
withexternal quality control samples. A second aim is to study the development of 
antiretroviral resistance in patients on the Western Cape MTCT regimen. This is done 
by testing patient samples with the newly optimised and validated genotyping assay. 
A third objective is to improve the optimised assay to be more cost effective and less 
technical and to validate it as a routine diagnostic assay. This is done by investigating 
the primer selection for both the PCR and sequencing reactions, adding an additive to 
the PCR reaction mix, comparing annealing temperature of the primers, volume 
reduction of the second round PCR reaction mix, and using sequencing buffer to 
reduced cost of the sequencing reaction.  
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Chapter 2 
2. The optimization and validation of a Two Fragment In-House HIV-1 
antiretroviral resistance assay  
2.1 Introduction 
The aim was to optimise and validate an in-house genotypic drug resistance assay 
published by Jacobs et al (2008) for a research study. The method by Jacobs et al 
(2008) was adapted from a method by Plantier et al (2005). The same primers were 
used in the PCR reaction for both assays with different sequencing primers. The 
optimized assay is referred to as “Two Fragment In-house assay (TFIH)”. To optimize 
the assay by Jacobs et al (2008) the following parameters were investigated: the input 
volume of RNA into the PCR reaction, the inclusion of a RNA denaturing step prior 
to reverse transcription and optimal primer and magnesium concentrations. Following 
optimisation, the assay was validated by comparison with the ViroSeq™ HIV-1 
Genotyping Assay, using external quality control (QC) samples. After optimization 
and validation, the TFIH assay was used to study the prevalence of genotypic-
antiretroviral resistance in patients treated according to the Western Cape Provincial 
PMTCT protocol.  
2.2 Methods 
Table 2.1 is a comparison between the Jacobs et al (2008) assay, described in 
Appendix A, and the TFIH assay.  
2.2.1 Samples  
Six isolates were received from Lynn Morris (National Institute Communicable 
Diseases (NICD) AIDS Virus Research Unit). The sequences for 3 of the samples 
DR10, DR19, and DR28 were published in Pillay et al (2008). Genebank accession 
number AY043173, AY589880, and AY589885. These samples were used for 
sensitivity determination of the TFIH assay. Samples NVP8b, NVP64 and NVP186 
were not published before. The expected resistance mutations as supplied by Lynn 
Morris, are listed in Appendix B. Six samples were received from the Round Robin 
HIV-1 genotyping assessment system, numbered WQ1 to WQ6, from the University 
of Würzburg, Department of Virology (Bodem, 2007). The expected resistance 
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mutations are in listed in Appendix C. These samples were used in the validation of 
the TFIH assay. 
Table 2.1: A comparison of the method used in Jacobs et al 2008 and the TFIH assay 
Steps in genotyping assay Jacobs et al (2008) TFIH 
Plasma used for extraction  1ml 1ml 
RNA extraction QIAamp UltraSens Kit QIAamp UltraSens Kit 
First round PCR   
*Denature of RNA No RNA denaturing RNA denatured 
*Input volume 5µl 10µl 
Additives  None None 
Number of primers used 4 4 
Second round PCR   
*Input volume  5µl 2µl 
Reaction volume 50µl 50µl 
Number of primers used 4 4 
Annealing temperature 55ºC 55ºC 
Sequencing reactions    
Volume of BigDye 
Terminator v3.1 ready 
reaction mix 
4µl  4µl 
Sequencing primers  8 8 
Annealing temperatures 45ºC and 50ºC 45ºC and 50ºC 
* Differences between assays 
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2.2.2 Materials and Methods 
2.2.2.1 Sample preparation 
Frozen isolates were received from the NICD AIDS Virus Research Unit and frozen 
plasma samples were received from the Round Robin HIV-1 genotyping assessment 
system and stored at -70ºC until use. RNA was extracted and the HIV-1 RNA loads of 
the extracted isolates were determined, in order to make appropriate serial dilutions of 
the viral isolates for the assay validation. The extracted RNA of these isolates and the 
Round Robin samples were subsequently used to optimise the PCR and sequencing 
reactions and to validate the TFIH assay.  
2.2.2.2 RNA Extraction  
The QIAamp UltraSens Kit (QIAGEN GmbH, Germany) was used for RNA 
extraction from 1ml plasma. This method utilises spin column technology with the 
selective binding properties of a silica-gel-membrane that was first described by 
Vogelstein and Gillespie (1979). Samples were added to a lyses buffer and placed in a 
spin column. The silica adsorbs the RNA at specific salt and pH concentrations while 
contaminants are washed from the membrane. The pure RNA was then eluted from 
the membrane with Tris buffer or water. The manufacturer’s instructions were 
followed and the RNA was eluted in two elution steps with 30 µl of AVE buffer 
added each time to obtain a total elution volume of 60 µl. 
2.2.2.3 HIV-1 viral load assay 
The NucliSens EasQ system V1.2 (bioMérieux, Boxtel, Netherlands) with 1ml 
plasma sample input was used according to the manufacturer’s instructions to 
determine the viral load.  
2.2.2.4 ViroSeq™ HIV-1 Genotyping assay 
The ViroSeq™ Genotyping system V2.0. (Celera Diagnostics, CA, USA) was used as 
a reference assay and performed according to the manufactures instructions, 
excluding the extraction method supplied by the manufacture.  
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2.2.2.5 Enrolment in the Quality Control of Molecular Diagnostic (QCMD) 
assessment system  
Quality Control for Molecular Diagnostics (QCMD) is a European quality assurance 
program established to advancing the quality of molecular diagnostics through 
External Quality Assessment (EQA), Proficiency Testing (PT) and other quality 
initiatives (Pandit et al, 2008). 
2.2.2.6 Polymerase Chain Reaction (PCR) 
This method described below was used for all PCR reactions performed, unless 
otherwise stated. The Access RT-PCR System (Promega, Madison, USA) was used 
for the first round reverse transcriptase-PCR (RT-PCR) reactions in a one step 
protocol. The PCR system that was used employs the Avian myeloblastosis virus 
Reverse transcriptase (AMV RT) and Thermus Flavus (Tfl) DNA polymerase to 
transcribe RNA to cDNA and amplify cDNA (Abramovici, 2001). The PCR primers 
are listed in Table 2.2 (Plantier et al, 2005). The first round reaction mix that 
consisted of AMV/Tfl 5X reaction buffer at a 1X concentration, a dNTP-mix at 
0.2mM each, primers at 40pmol, 2mM MgSO2, AMV RT 0.1U/µl, Tfl DNA 
Polymerase 0.1U/µl and nuclease-free water up to a final volume of 50µl. PCR 
cycling was done using 9700 PCR thermocyclers (Applied Biosystems, Foster City, 
USA) at 9600 ramp speed. The reaction mixtures were prepared in 0.2ml PCR tubes 
(QSP, Porex BioProducts Inc, California, USA). The following cycling conditions 
applied: First round PCR: For complementary DNA (cDNA) synthesis reaction tubes 
were incubated at 48°C for 45 minutes to allow for reverse transcription yielding 
double stranded-DNA (ds-DNA) and then at 94°C for 2 minutes to inactivate AMV 
Reverse transcriptase and to denature ds-DNA. For exponential amplification of DNA 
the cycling conditions were: 40 cycles of 94°C for 20 seconds to denature DNA, 55°C 
for 30 seconds for primer annealing and 68°C for 90 seconds for primer extension. 
This is followed by a final 5 minutes at 68°C to complete primer extension. The 
product was then stored at 4°C until the second round reactions could be done. The 
Taq DNA Polymerase in storage buffer B system (Promega, Madison, USA) was used 
for the second round PCR reaction mixture using the first round RT-PCR product as 
template input. The thermostable Thermus aquaticus (Taq) DNA polymerase was 
used to amplify the PCR product from the first round PCR. The PCR primers used 
were listed in Table 2.2 (Plantier et al, 2005). Five µl of the first round RT-PCR 
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reaction product was added to the second round reaction mix which consisted of 5X 
storage buffer B at a 1X concentration, PCR Nucleotide mix (Promega, Madison, 
USA) at 0.2mM each, primers at 40pmol each, 1.5mM MgCl2, Taq DNA Polymerase 
at 2.5U/µl, and nuclease-free water up to a final volume of 50µl. The cycling 
conditions for the second round PCR were: One cycle at 94°C for 2 minutes for DNA 
denaturing followed by 40 cycles of 94°C for 20 seconds for DNA denaturing, 55°C 
for 30 seconds for primers annealing and 68°C for 90 seconds for primer extension. 
This was followed by a final extension for 5 minutes at 68°C. The product was then 
stored at 4°C until it could be visualized.  
Table 2.2: Primers used for first and second round PCR of the TFIH assay 
Protease 
Primer 
HBX2 
number 
Primer 
Tm 
Primer 
direction 
Primer Sequence 
outer 3’prot1 2703-2734 57.6°C Reverse 5’- GCA AAT ACT GGA GTA TTG TAT GGA TTT TCA GG –3’ 
outer 5’prot1 2082-2109 57.0°C Forward 5’- TAA TTT TTT AGG GAA GAT CTG GCC TTC C -3’ 
inner 3’prot2 2621-2650 55.8°C Reverse 5’ AAT GCT TTT ATT TTT TCT TCT GTC AAT GGC –3’ 
inner 5’prot2 2136-2163 68.2°C Forward 5’- TCA GAG CAG ACC AGA GCC AAC AGC CCC A –3’ 
Reverse 
transcriptase 
Primer 
    
outer Mj4 3399-3420 54.8°C Reverse 5’- CTG TTA GTG CTT TGG TTC CTC T –3’ 
outer Mj3 2480-2499 54.3°C Forward 5- AGT AGG ACC TAC ACC TGT CA –3’ 
inner NE13 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 
inner  A35  2530-2564 58.4°C Forward  5’- TTG GTT GCA CTT TAA TTC CCA TTA GTC CTA TT –3’ 
2.2.2.7 Visualization of the PCR product with agarose gel electrophoresis  
The PCR product was identified according to product size (514bp for the protease 
gene and 804bp for the reverse transcriptase gene) with gel electrophoresis on a 0.8% 
agarose gel prepared with LE analytical grade agarose (Whitehead Scientific, Cape 
Town, RSA) in 1 x TAE Buffer (0.04M Tris acetate, 0.001M EDTA). Five µl of 5mg 
ethidium bromide (Promega, Madison, USA) was added to the gel to intercalate ds-
DNA. Two µl loading buffer (Promega, Madison, USA) was mixed with 5µl PCR 
product. Each specimen was sequentially loaded in a slot on the gel, including the non 
template control (a PCR reaction performed with nuclease free water instead of 
specimen input), positive controls and 1 kilobasepair marker (Promega, Madison, 
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USA). The electrical current was set at 50 mAmperes for a 50ml gel apparatus. When 
the products have migrated from the negative to the positive anode sufficiently, as 
indicated by the migration of the three coloured dyes in the loading buffer, the current 
was removed and the gel was visualised under ultra violet light at a wavelength of 
302nm. At this wavelength ethidium bromide intercalated DNA (PCR products) 
fluoresces brightly. The gel was photographed using the Syngene GeneGenius, 
version 4.00, program (Synoptics Ldt, Cambridge, United Kingdom). 
2.2.2.8 PCR product purification. 
The QIAquick Spin Kit (QIAGEN GmbH, Germany) was used to purify the PCR 
product from the second round PCR for sequencing reactions according to the 
manufacturer’s instructions. The purified PCR product was stored at -20ºC until use.   
2.2.2.9 Quantification of DNA with the NanoDrop  
The DNA product was quantified with the NanoDrop ND-1000. The NanoDrop ND-
1000 is a full-spectrum (220-750nm) spectrophotometer that measures the DNA 
concentration in 1µl samples with high accuracy and reproducibility. The patented 
sample retention technology uses surface tension alone to hold the sample in place. 
The ND-1000 can measure highly concentrated samples without dilution. One µl of 
sample was measured at wavelengths of 260nm and 280nm. The absorbance at 260nm 
measures the DNA concentration and the ratio of the sample absorbance at 260nm to 
280nm measures the purity of the sample. A ratio of 1.8 to 1.9 indicates highly 
purified preparations of DNA. The concentration of DNA obtained was used to work 
out a dilution factor to obtain 10ng-40ng of DNA to use in the sequencing reactions 
(Ausubel et al, 200, Sambrook et al, 1989). 
2.2.2.10 Sequence of PCR product  
Fluorescence-based cycle sequencing reactions was used to sequence DNA templates 
from PCR products. The ABI Prism BigDye Terminator v3.1 ready reaction cycle 
sequencing kit (Applied Biosystems, Warrington, UK) was used for the sequencing 
reactions. This kit is based on the dideoxy method developed by Sanger et al (1977, 
1980). A DNA polymerase is used to synthesise a complementary strand of DNA by 
elongation of DNA at the 3’ end of a primer. The dNTPs are the substrates for DNA 
polymerisation catalysed by the DNA polymerase enzyme. New bases complimentary 
to the template strand are incorporated at the 3’ end of the elongating primer chain. 
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The reaction mix contains a mixture of normal dNTPs and substituting 2’,3’-
dideoxynucleoside triphosphates (ddNTP) which lead to chain termination and are 
labelled with fluorescent markers (different fluorescent labels are used for each base 
(A, C, T, G) ). A single primer is used for each PCR reaction. Primer extension is 
terminated at different sequence lengths with the size of the extended primer 
corresponding to the sequence length and the particular fluorescent label 
corresponding to the terminal base. Gel-electrophoresis takes place in a long capillary 
tube that allowing discrimination of products that differ by one base pair. The 
sequence is determined by detecting the different terminal nucleotides at different 
wavelengths with laser excitation at the end of a gel. A template quantity of less than 
40ng was used to sequence the product. The primers used in the sequencing reactions 
are listed in Table 2.3.  
Table 2.3: Primers used for sequencing of the PR and RT regions with the TFIH 
assay 
PR Primers HBX2 
number 
Primer 
Tm 
Primer 
direction 
Primer Sequence References  
R2051 2486-2504 49.5°C Reverse 5'- TAT RTT GAC AGG TGT AGG T -3' Personal Communication, John Hackett 
pol1D 2251-2271 56.3°C Forward 5'- TCC CTC AAA TCA CTC TTT GGC -3' Loxton, 2004 
JA217 2622-2646 49.5°C Reverse 5'- CTT TTA TTT TTT CTT CTG TCA ATG G -3' Lindström and Albert, 2003 
RT Primers      
pol3D 2869-2884 48.7°C Forward 5' - CAG TAC TGG ATG TGG G - 3' Loxton, 2004 
pol3rev 2882-2901 51.1°C Reverse 5' - CTG AAA AAT ATG CAT CCC CC - 3' Personal Communication, Susan 
Engelbrecht 
ABB20-3F 2980-2999 51.6°C Forward 5' - ATC AGT ACA ATG TGC TTC CA - 3' Personal Communication, John Hackett 
AK12 2947-2969 50.6°C Reverse 5' - TGG TGT YTC ATT RTT TRY ACT AG - 3' Lindström and Albert, 2003 
AK11 2571-2592 48.4°C Forward 5' - GTA CCA GTA AAA TTA AAR CCA G - 3' Lindström and Albert, 2003 
Cycle sequencing reactions were prepared in a 96 well plate by adding 4µl of 
BigDye Terminator v3.1 ready reaction mix to 1µl of template, 1µl of 5pmol primer 
and 4µl nuclease free water to obtain a final volume of 10µl. The reaction mix was 
then exposed to thermocycling conditions repeated 25 times with DNA denaturing at 
96°C for 10 seconds and primer annealing for 5 seconds at the sequence primer 
specific annealing temperature (45°C or 50°C). This was followed by a final product 
extension at 60°C for 4 minutes. After completion of the cycling, the reactions were 
sent to the DNA sequencing facility of Stellenbosch University for sequencing on the 
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ABI 3100 Sequencer (Applied Biosystems, Foster City, USA). The sequencing data 
from the analyzer was converted to electopherograms by the DNA sequencing facility 
using the DNA Sequencing Analysis software™, version 3.3 (Applied Biosystems, 
Foster City, USA).  
2.2.2.11 Assembly and analysis of sequences  
2.2.2.11.1 Sequence assembly  
Sequence electropherograms was analysed, assembled, and edited using the 
Sequencer software V4.7 (Gene Codes Corporation, Ann Arbor USA). Primers for 
both the negative and the positive strand are used in the sequencing reaction. This 
ensures the quality of the sequence being analyzed (Murphy et al, 2005).  
2.2.2.11.2 Analysis for drug resistance mutations 
The fasta format of the sequence was exported and analyzed for resistance mutations 
with the Stanford HIVdb program for Genotyping resistance interpretation program 
http://hivdb.stanford.edu/index.html, Updated January 2007 (November 2010). The 
sample sequence was compared to a consensus sequence of HIV-1 subtype B pol 
sequences for notification and identification of resistance mutations.  
2.2.2.11.3 HIV-1 subtyping  
The Rega HIV-1 subtyping tool Version 2.0, was used to determine the HIV-1 
subtype (http://dbpartners.stanford.edu/RegaSubtyping/) (November 2010) with the 
jpHMM (jumping profile Hidden Markov Model) (http://jphmm.gobics.de/) 
(November 2010). The Rega HIV-1 subtyping tool Version 2.0, is designed to use 
phylogenetic methods to identify the subtype of a specific sequence. The sequence is 
analysed for recombination using bootscanning methods. The jpHMM compare 
nucleic acid sequences to multiple alignments of a sequence family for which a 
classification in subclasses is available (Zhang et al, 2006).  
2.2.3 Specificity determination 
The sequences were analysed by the Basic local alignment search tool (BLAST) of 
the National Centre of Biotechnology information (http://www.ncbi.nlm.nih.gov) 
(November 2010) to determine the specificity of the primers (Altschul et al, 1990). 
BLAST finds regions of local similarity between sequences. It compares nucleotide 
sequences to sequence databases and calculates the statistical significance of matches.  
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2.2.4 Statistical analysis 
A probit regression model in R (version 1.11.1), was used for statistical analysis of 
the sensitivity of the TFIH assay. It is a freely available environment for statistical 
analysis and graphics (www.r-project.org) (November 2010). 
2.2.5 Optimization  
2.2.5.1 Template input volume changes in PCR reactions.  
The amount of template was increased to raise the sensitivity of the PCR reaction. 
Too low a template input in the first round PCR will lead to low amplification rate of 
RNA. On the other hand it must also be taken into consideration that template 
overload could lead to inhibition of the PCR, which is especially relevant in the 
second-round (nested) PCR (Promega, Protocol and Applications guide 
http://www.promega.com/paguide/chap1.htm, November 2010, Ausubel et al, 2006). 
The input volume of the RNA template was increased from 5 µl to 10µl of RNA, as 
described in other studies (Duran et al, 2007, Plantier et al, 2005) for the first round 
reaction mix. This would increase the amount of template available for the first round 
cDNA. The input of PCR product into the second round reaction mix was decreased 
to 2µl from 5 µl of first round PCR product to prevent inhibition of the PCR reaction 
through a too high an input of PCR product. The procedure as described in section 
2.2.2.4 was followed for amplification. Samples from the NICD AIDS Virus Research 
Unit were used for this evaluation.  
2.2.5.2 Denaturing of RNA before starting the PCR reaction 
To eliminate termination sites that may be caused by secondary structures within the 
RNA, we investigated the effect of RNA denaturing prior to RT-PCR amplification. 
Ten µl of RNA was placed in 0.2ml thin wall PCR tubes (QSP, Porex BioProducts 
Inc., California, USA) and incubated for 30 seconds at 65°C and cooled to 48°C for 5 
minutes. Alternatively 10µl of RNA was placed in 0.2ml thin wall PCR tubes and 
incubated for 5 minutes at 70°C and then placed on ice for 5 minutes to snap freeze it. 
Forty µl of prepared first round PCR reaction mix was added and the procedure 
described in section 2.2.2.4 was followed for amplification. As a comparison, control 
specimens, compaired non-denatured RNA were amplified in parallel using the same 
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protocol (described in section 2.2.2.4 with changes made as in section 2.2.5.1). The 
same RNA specimens and input volumes were used for all 3 methods compared. 
2.2.5.3 Titration of magnesium and primer for the first and second round PCR 
concentrations 
A checkerboard titration was performed to determine optimal primer and Mg+ 
concentrations. Checkerboard titrations using 40pmol, 80pmol and 120pmol of the 
primers per reaction and concentrations of 1.5mM, 2mM and 2.5mM of magnesium 
sulphate were prepared for second round PCR reactions. The same procedure as 
described in section 2.2.2.4 was followed with noted in sections 2.2.5.1 and 2.2.5.2. 
2.2.6 Validation 
The final protocol for the TFIH assay as described in Appendix D was used for 
validation. The TFIH as was validated to evaluate the fitness of the assay for use. 
2.2.6.1 Validation criteria for this study  
2.2.6.1.1 Method of validation 
The partial and cross validation methods will be applied in this study since the method 
being validated will be compared to a previously validated method.  
2.2.6.1.2 Samples used for validation 
The validation of the TFIH assay was done using samples received from the NICD 
AIDS Virus Research Unit, for sensitivity testing to determine the limit of detection 
of the assay, and the Round Robin HIV-1 genotyping assessment system for 
comparison with the ViroSeq™ HIV-1 Genotyping assay as a reference assay. The 
TFIH assay was also enrolled in the QCMD assessment system. These samples are 
discussed in section 2.2.1. 
2.2.6.1.3 Reference method 
The ViroSeq™ HIV-1 Genotyping system V2.0 (Celera Diagnostics, CA, USA) will 
be used as a reference assay.  
2.2.6.1.4 Acceptance criteria for the method 
The same results must be obtained for the QC samples with both methods. The 
sensitivity and specificity of the investigated assay must not be inferior to the 
reference (that is at least within the same range as the reference assay). 
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2.2.6.2 Sensitivity  
The 6 viral isolate samples obtained from the NICD AIDS Virus Research Unit were 
used to determine the analytical sensitivity (limit of detection) of the TFIH assay. The 
viral load of the isolates were determined with the NucliSense Easy Q HIV-1 system 
V1.2 (Biomérieux bv, Boxtel). Ten fold dilutions form 100 000 to 1 copies/ml were 
prepared. In order to determine the limit of detection we used a probit regression 
model in R (version 1.11.1).  
2.2.6.3 Specificity 
To verify the specificity of this in-house reaction, the pol gene sequences, obtained, 
were submitted to blastn algoritm of the National Centre of Biotechnology 
information (http://www.ncbi.nlm.nih.gov).  
2.2.6.4 Comparison of samples from the NICD AIDS Virus Research Unit 
To determine if the TFIH assay could detect the resistance mutations in the samples 
received from the NICD AIDS Virus Research Unit, these samples were tested and 
analysed for resistance mutations with the Stanford HIVdb program for Genotyping 
resistance interpretation program http://hivdb.stanford.edu/index.html, Updated 
January 2007 (November 2010). 
2.2.6.5 Comparison of TFIH assay with the ViroSeq™ HIV-1 Genotyping assay  
To test if the TFIH assay performs as well as the ViroSeq™ HIV-1 Genotyping assay, 
6 QC samples received from the Round Robin HIV-1 genotyping assessment system, 
described in section 2.2.1, were tested in parallel with the ViroSeq™ HIV-1 
Genotyping assay. 
2.2.6.6 Quality Control of Molecular Diagnostic system (QCMD)  
The TFIH assay was enrolled in the QCMD external quality assessment system for 
evaluation in 2007.  
2.3 Results 
This section describes the results obtained from optimisation and validation of the 
TFIH assay.  
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2.3.1 Template input volume changes in PCR reactions. 
A PCR was performed with a 10µl input volume in the first round PCR and a 2µl 
input volume in the second round PCR and compared with a PCR with the input 
volumes in section 2.2.2.4. Figure 2.1 show the results obtained on a 0.8% agarose gel 
after electrophoresis. Two samples (DR10 and DR19) from the NICD AIDS Virus 
Research Unit and an HIV-1 negative plasma sample used as a negative control (Neg) 
were co-amplified. The best amplification was seen with the increased input in the 
first round PCR and the decreased input volume in the second round.  
 
Figure 2.1: DNA agarose gel electrophoresis of the RT fragment comparing a 10µl 
vs. 5µl input in first round PCR and a decrease to 2µl vs. 5µl input in second round 
PCR. Lanes 1 and 2 are samples from the NICD AIDS Virus Research Unit. Lane 3 is 
the Negative Control (Neg). The best amplification was seen with the 10µl input. 
2.3.2 Denaturing of RNA before starting the reaction.  
The RNA was denatured by incubation at 65°C and 70°C. Figure 2.2 show the results 
obtained after electrophoresis on a 0.8% agarose gel. A sample from the NICD AIDS 
Virus Research Unit was amplified with negative HIV-1 plasma used as a Neg. A 
reaction with water used as template substitute was used for a negative template 
control (NTC). The best amplification was seen with the 65°C and 70°C denaturing 
step than with the experimental setup without a prior denaturing step. This suggests 
higher yields of PCR product with denaturing of RNA than without.  
1         2      3 1         2          3 
10 µl input 
First round  
2 µl input  
Second round 
5 µl input 
First round  
5 µl input  
Second round 
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Figure 2.2: Denaturing of RNA before performing PCR reaction. Lane 1-Negative 
control (NEG), Lane 2-Sample, and Lane 3- No template control (NTC). The same 
samples were used for all 3 the PCR amplifications. Better amplification was seen, 
when RNA was denatured at 65°C and 70°C than without denaturing. 
2.3.3 Titration of magnesium and primer for the first and second round PCR 
concentrations  
A primer and magnesium checkerboard titration was performed to determine the 
optimal concentrations for amplification. For the optimisation reaction sample DR10 
from the NICD AIDS Virus Research Unit was amplified. HIV-1 plasma was used as 
a Neg. Figure 2.3 shows the second round titration result after electrophoresis on a 
0.8% agarose gel. The PCR products of the optimisation by checkerboard titration 
could only be visualized on an ethidium bromide containing 0.8% agarose gel after 
the second round PCR due to no visible bands on the agarose gel from the first round 
PCR reaction. The conditions as described in section 2.2.2.4 were used for the first 
round PCR.  
A 40pmol concentration for primers and a 2mM concentration for magnesium were 
selected as the best amplification could be seen at these concentrations for the second 
round PCR of the RT fragment. The PR fragment had the best amplification results at 
40pmol concentration for primers and a 2.5mM concentration for magnesium with 
good amplification seen at 2mM.  
 
No  
Incubation 
 
 
 
 
1       2      3       M 
65°C 
 
 
 
 
 
1        2      3        M 
 
70°C 
 
 
 
 
1        2      3 
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Figure 2.3: Titration of Mg+ and primer concentration for first round PCR.  
Lane 1 = primer 40pmoles and Mg+ 1.5mM, Lane 2 = primer 80pmoles and Mg+ 
1.5mM, Lane 3 = primer 120pmoles and Mg+ 1.5mM, Lane 4 = primer 40pmoles and 
Mg+ 2mM, Lane 5 = primer 80pmoles and Mg+ 2mM, Lane 5 = primer 120pmoles 
and Mg+ 2mM, Lane 7 = primer 40pmoles and Mg+ 2.5mM, Lane 8 = primer 
80pmoles and Mg+ 2.5mM, Lane 9 = primer 120pmoles and Mg+ 2.5mM, Lane 10 = 
Negative control and Lane 11 = Non template control. 
2.3.4 Validation 
2.3.4.1 Sensitivity and specificity testing  
2.3.4.1.1 Analytical sensitivity  
To ensure that the assay could detect low copy numbers, the 6 samples from the 
NICD AIDS Virus Research Unit were used in the sensitivity testing. The number of 
isolates detected for the RT gene at each copy number input was 6/6 at 1000 
copies/ml, 5/6 at 100 copies per ml and 3/6 at 10 copies per ml. Using a probit 
regression model the limit of detection for the RT gene PCR was estimated to be 112  
(37-881; 95%CI) copies/ml. The number of isolates detected for the PR gene at each 
copy number input was 6/6 at 1000 copies/ml, 4/6 at 100 copies per ml and 3/6 at 10 
copies per ml. Using a probit regression model the limit of detection for the in-house 
assay was estimated to be 190 (67-1524; 95%CI) copies/ml. 
2.3.4.1.2 Specificity of the assay 
All resultant sequences corresponded 100% to the HIV-1 pol gene according to the 
NCBI Blast algorithm which indicated the high specificity of the primers used.  
2.3.4.2 Comparison of samples from the NICD AIDS Virus Research Unit 
All six the isolates from the NICD AIDS Virus Research Unit could be amplified and 
sequenced using the TFIH assay.  
M M 
Protease gene Reverse transcriptase gene 
1   2   3    4   5   6   7   8    9 10 11 1    2   3   4   5   6   7   8   9  10 11 
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There was a 100% concordance between RT gene mutations that we detected and the 
sequences of the three samples, which were published by Pillay et al (2008). These 
samples were all HIV-1 subtype C. Only the RT gene was sequenced by the NICD 
AIDS Virus Research Unit and no results were made available for the PR gene. No 
resistance mutations were detected with the TFIH assay for the PR gene. No NRTI 
resistance mutations were detected in samples NVP8b, NVP64 and NVP186. The 
results for NVP8b were the same as supplied by the NICD AIDS Virus Research 
Unit. The results from the other 2 samples did not agree. The mutations found in 
sample NVP64 differed from the expected results and had the same mutations and 
subtype than sample NVP8b. The results also differed for NVP186 with no mutations 
detected by the TFIH assay. These samples were retested to exclude human errors. 
The same results were obtained with the repeat test. The results obtained for samples 
NVP8b, NVP64 and NVP186 are summarised in Table 2.4. 
Table 2.4: Resistance mutation detected in samples NVP8b, NVP64 and NVP186 
from the NICD AIDS Virus Research Unit that did not correlate with TFIH 
Sample 
*Expected Resistance 
mutations for NNRTI 
Resistance mutations obtained 
for NNRTI with the TFIH assay: 
Subtype  
NVP8b K103N K103N A1C 
NVP64 
V106A 
G190A 
K103N A1C 
NVP186 
K103N 
V179I 
G190A 
None A(A1) 
*The expected results were supplied by Lynn Morris from the NICD AIDS Research Unit 
The Rega HIV-1 subtyping tool Version 2.0 (http://dbpartners.stanford.edu/Rega Subtyping/) with 
jpHMM (jumping profile Hidden Markov Model) http://jphmm. gobics.de/ was used for determining 
the HIV-1 subtype  
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2.3.4.3 Comparison of Round Robin HIV-1 genotyping assessment system from 
the University of Würzburg. 
All the samples could be amplified and sequenced by both the TFIH assay and the 
ViroSeq™ HIV-1 genotyping system. In Table 2.5 a summary of the results obtained 
for both assays is shown. The expected results for the Round Robin HIV-1 genotyping 
assessment system are listed in Appendix C. Although all the samples received from 
the Round Robin HIV-1 genotyping assessment system could be amplified with both 
TFIH assay and the ViroSeq™ HIV-1 genotyping system, the quality of the 
sequences obtained for WQC1 was bad and the T69i insertion was missed by both 
assays. The V108IV mutation in WQC5 was missed by the TFIH assay and the 
E44DE mutation in WQC6 was missed by the ViroSeq™ HIV-1 genotyping system. 
Although a few mutations were missed, both assays performed the same with the 
Round Robin HIV-1 genotyping assessment system and the performance of the TFIH 
assay was acceptable.   
Table 2.5: Summary of results obtained from the Round Robin HIV-1 genotyping 
assessment system from the University of Würzburg. Samples are numbered WQC1 
to WQC6.  
Assays  WQC1 WQC2 WQC3 WQC4 WQC5 WQC6 
ViroSeq 
Missed 1 mutation  
Missed insertion 
T69i 
100% 100% 
Missed 1 
mutation 
N88D 
100% 
Missed 1 
mutation 
E44DE 
Two 
fragment 
In-House 
Missed 2 
mutations Missed 
insertion T69i and 
polymorphism 
S68N 
100% 100% 
Missed 1 
mutation 
N88D 
Missed 1 
mutation  
V108IV 
100% 
2.3.4.4 Testing with the Quality Control of Molecular Diagnostic system 
All samples from the QCMD system could be amplified and sequenced with a score 
of 329 out of 332. The mutations detected are shown in Table 2.6. 
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Table 2.6: Resistance mutation detected by the TFIH assay in 5 samples received 
from the 2007 QCMD program  
Sample PI Major 
Mutations: 
PI Minor 
Mutations: 
NRTI 
Mutations: 
NNRTI 
Mutations: 
Insertions *Subtype 
QCMD 1 D30N 
N88D 
L10F M41L 
E44D 
D67N 
T69D 
M184V 
L210W 
T215Y 
A98G  C 
QCMD 2 None None D67N 
T69i 
L210W 
T215Y 
K101E 
V106M 
G190A 
RT AA 
Insertion: 
codon 69 
AA: ES  
NA: 
GAGTCT 
C 
QCMD 3 M46I 
I54V 
V82A 
L90M 
L10IV 
A71T 
None None  B 
QCMD 4 M46I 
I54V 
V82A 
L90M 
L10IV 
A71T 
None None  B 
QCMD 5 None None None None  F 
*The Rega HIV-1 subtyping tool Version 2.0 (http://dbpartners.stanford.edu/Rega Subtyping/) with 
jpHMM (jumping profile Hidden Markov Model) http://jphmm. gobics.de/ was used for determining 
the HIV-1 subtype 
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Chapter 3 
3. Detection of resistance mutations in mothers from the Western Cape, who 
received a regimen of single dose nevirapine (sd NVP) combined with a short 
course zidovudine (AZT) as part of prevention of mother to child transmission 
(PMTCT).  
3.1 Introduction 
The prevelance of NVP resistance after an sd-NVP in PMTCT programs was found to 
be in 19%-69% with a significant difference in different HIV-1 subtypes as the 
highest percentages are seen in subtype D (36%) and C (46-69%) (Eshleman et al, 
2005 and Kurle et al, 2007). The aim of this study in part was to detect if dual 
therapy, a short course of AZT with sd-NVP, will be associated with a lower 
prevalence of resistance mutations in maternal patients included in the Western Cape 
PMTCT program. 
3.2 Materials and methods 
In this section a short overview of the materials and methods used not described in 
Chapter 2, Section 2.2 will be described. 
3.2.1 Sample cohort 
Approval for the project was obtained from the Ethics Committee of the University of 
Stellenbosch (Committee of Human Research) on 17 January 2005. The project 
number is N04/09/146. The letter of approval is attached in Appendix E. Samples 
were collected from pregnant women who took part in the Western Cape PMTCT 
program and visited the Tygerberg Obstetrics Clinic and Delft Community Hospital. 
These woman all received AZT during pregnancy from 34 weeks and NVP at 
delivery. Sample collection started from February 2005 and continued until 116 
samples have been obtained. Informed consent for drawing 10 ml of EDTA blood was 
obtained to measure CD4-cell count, viral load, and to do genotyping for viral subtype 
and the presence of resistance mutations. Information on prior exposure to 
antiretroviral therapy was also collected. At the follow-up visit EDTA blood was 
drawn from the mother to determine the presence of resistance mutations and 2ml of 
EDTA blood was drawn from the baby for a HIV-1 PCR. 
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3.2.2 Sample preparation  
Patient whole blood samples were used in this study for determining viral load, CD4 
cell count and to do genotyping. Approximately 3ml plasma from the mother and 1ml 
plasma from the baby was stored, in 1 ml aliquots, from the EDTA blood received for 
this study. Plasma was separating from the red blood cells with centrifugation at 3000 
revolutions per minute (rpm) for 10 minutes. The samples were stored at –70°C until 
analysis. RNA extraction was performed as described in 2.2.2.2.2.   
3.2.3 Determination the CD4 cell count 
The Pan Leucogating (Beckman Coulter Inc., USA) was used to determine the CD4 
cell count assay, as part of routine testing in the Tygerberg NHLS Immunology 
laboratory. 
3.2.4 Statistical Analysis  
The Mann-Whitney U Test was used for statistical analysis to compare CD4 counts 
and log10 HIV-1 viral loads in patients with or without resistance.  
3.3. Results  
The results of this study were published in Van Zyl et al (2008) Appendix F.  
3.3.1 Samples 
The maternal patients characteristics are set out in Appendix G. Patients were 
included for analysis on the basis that a baseline on the first visit to the clinic and a 
post partum follow-up specimen were collected. Follow-up visits were scheduled for 
six weeks post partum but due to logistical difficulties this could not always be 
achieved and let to variation in the follow-up intervals. The median follow-up time 
was 7 weeks (3 to 19 weeks). Follow-up samples were collected from 107 mothers. 
Using the TFIH assay, both samples from 97 of the 107 mothers could be amplified 
with PCR and complete sequences for the reverse transcriptase gene could be 
obtained for them. Due to the variation in follow-up times only 76 mothers were 
included in the study. The mothers that were included had follow-up samples 
collected within 60 days postpartum and administration of NVP. From the 76 
mothers, 62 (82%) had samples collected between 4 and 8 weeks postpartum. 
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3.3.2 Viral load (VL) and CD4 cell count 
A summary of the results can be seen in Table 3.1. VL results were available at 
baseline for 74 of the 76 patients. The VL were performed on the Nuclisens EasQ® 
assay (bioMérieux, Boxtel, Netherlands), which has a 95% hit rate at the lower limit 
of detection of 357 copies/ml for 1 ml input (Yao et al, 2005). The CD4 were 
performed on The Pan Leucogating (Beckman Coulter Inc., USA) assay. CD4 cell 
counts were available for all 76 patients include in the study. 
Table 3.1: VL and CD4 cell count results obtained for 76 samples included in the 
study  
Sample 
Code 
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4 
(Cells/µl) 
Sample 
Code 
Date of 
Samplin
g 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4 
(Cells/µl) 
RP 1.1 02/28/05 *LDL 353 RP 105.1 05/03/06 5600 365 
RP 1.2 08/04/05   RP 105.2 07/18/06   
RP 7.1 03/02/05 14000 286 RP 106.1 05/03/06 1500 252 
RP 7.2 06/30/05   RP 106.2 07/18/06   
RP 8.1 03/04/05 7900 365 RP 107.1 05/03/06 11000 289 
RP 8.2 08/31/05   RP 107.2 07/20/06   
RP 9.1 03/07/05 1200 624 RP 111.1 05/15/06 34000 181 
RP 9.2 06/30/05   RP 111.2 07/18/06   
RP 10.2 03/10/05 5700 717 RP 113.1 05/15/06 510 697 
RP 10.2 06/08/05   RP 113.2 08/25/06   
RP 12.1 03/14/05 3200 625 RP 116.1 05/22/06 5100 603 
RP 12.2 11/04/05   RP 116.2 08/15/06   
RP 13.1 03/14/05 5800 329 RP 121.1 05/29/06 17000 226 
RP 13.2 07/08/06   RP 121.2 08/01/06   
RP 17.1 03/22/05 5200 344 RP 122.1 06/05/06 14000 261 
RP 17.2 07/28/05   RP 122.2 08/22/06   
RP 19.1 03/24/05 12000 404 RP 124.1 06/05/06 46000 655 
RP 19.2 08/18/05   RP 124.2 08/22/06   
RP 25.1 04/04/05 6800 357 RP 126.1 06/07/06 5400 518 
RP 25.2 08/31/05   RP 126.2 08/29/06   
RP 28.1 04/04/05 9300 405 RP 128.1 06/12/06 29000 316 
RP 28.2 06/08/05   RP 128.2 09/12/06   
RP 29.1 04/06/05 17000 201 RP 129.1 06/12/06 25000 300 
RP 29.2 07/08/05   RP 129.2 08/29/06   
RP 35.1 04/23/05 20000 733 RP 131.1 06/19/06 510 658 
RP 35.2 08/01/05   RP 131.2 08/22/06   
RP 37.1 05/10/05 2000 417 RP 133.1 06/14/06 1400 738 
RP 37.2 10/05/05   RP 133.2 09/14/06   
RP 40.1 06/08/05 59000 317 RP 134.1 06/19/06 14000 188 
RP 40.2 10/05/05   RP 134.2 08/25/06   
RP 41.1 06/28/05  365 RP 135.1 06/19/06 6300 209 
RP 41.2 12/05/05   RP 135.2 08/29/06   
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Table 3.1 continue: VL and CD4 cell count results obtained for 76 samples included 
in this study  
Sample 
Code 
Date of 
Samplin
g 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4 
(Cells/µl) 
Sample 
Code 
Date of 
Samplin
g 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4 
(Cells/µl) 
RP 46.1 09/07/05 210000 255 RP 138.1 06/26/06 13000 384 
RP 46.2 12/05/05   RP 138.2A 06/26/07   
RP 47.1 09/08/05 29000 297 RP 138.2B 10/31/06   
RP 47.2 12/05/05   RP 139.1 06/26/06 4000 335 
RP 48.1 09/08/05 3200 651 RP 139.2 08/29/06   
RP 48.2 02/20/06   RP 140.1 06/28/06 1400 625 
RP 49.1 09/08/05 8600 737 RP 140.2 08/24/06   
RP 49.2 12/05/05   RP 143.1 06/28/06 29000 248 
RP 70.1 03/08/06 290000 168 RP 143.2 09/28/06   
RP 70.2 04/20/06   RP 144.1 07/10/06 2600 597 
RP 71.1 03/13/06 LDL 502 RP 144.2 09/14/06   
RP 71.2 06/06/06   RP 145.1 07/10/06 63000 342 
RP 72.1 03/13/06 630 595 RP 145.2 09/14/06   
RP 72.2 07/06/06   RP 149.1 07/19/06 12000 613 
RP 73.1 03/13/06 330000  RP 149.2 09/28/06   
RP 73.2 05/30/06   RP 150.1 07/09/06 1400 564 
RP 74.1 03/15/06 LDL 239 RP 150.2 10/26/06   
RP 74.2 05/12/06   RP 151.1 07/19/06 1700 428 
RP 75.1 03/22/06 9000 341 RP 151.2 09/28/06   
RP 75.2 06/01/06   RP 152.1 07/19/06 14000 206 
RP 76.1 03/22/06 LDL 789 RP 152.2 09/28/06   
RP 76.2 05/30/06   RP 156.1 07/26/06 1000 587 
RP 77.1 03/22/06 740 233 RP 156.2 09/27/06   
RP 77.2 06/09/06   RP 157.1 07/26/06 2600 498 
RP 79.1 03/22/06 940 654 RP 157.2 10/05/06   
RP 79.2 06/08/06   RP 159.1 08/16/06 9700 380 
RP 83.1 03/29/06 1700 443 RP 159.2 10/26/06   
RP 83.2 07/04/06   RP 162.1 08/30/06 2000 204 
RP 86.1 04/03/06 8600 345 RP 162.2 11/07/06   
RP 86.2 06/15/06   RP 165.1 09/11/06 65000 878 
RP 87.1 04/03/06 59000 587 RP 165.2 11/21/06   
RP 87.2 06/07/06   RP 166.1 09/13/06 3600 261 
RP 88.1 04/03/06 1100 390 RP 166.2 11/23/06   
RP 88.2 07/06/06   RP 167.1 09/13/06 3300 334 
RP 91.1 04/05/06 54000 510 RP 167.2 11/09/06   
RP 91.2 06/15/06   RP 169.1 09/13/06 6900 526 
RP 96.1 04/19/06 710 1018 RP 169.2 01/19/07   
RP 96.2 07/11/06   RP 172.1 18/09/06  295 
RP 99.1 04/19/06 29000 243 RP 172.2 17/11/06   
RP 99.2 07/04/06   RP 173.1 06/20/06 12000 372 
RP 100.1 04/19/06 36000 553 RP 173.2 11/09/06   
RP 100.2 07/06/06   RP 178.1 10/18/06 3400 364 
RP 101.1 04/24/06 57000  RP 178.2 01/10/07   
RP 101.2 07/04/06       
*LDL: Viral load that was lower than detection limit  
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A summary of the mean CD4 count and VL analysis is shown in Table 3.2. The mean 
CD4 count, given in cells per microliter (cells/µl), in the NVP resistant group was 353 
versus 458 in the NVP sensitive group; a difference which is not statistically 
significant (p=0.07, Mann-Whitney U Test). Geometric means of VL for the resistant 
and sensitive groups respectively were 4 652 (range LDL to 290 000) and 5 250 
(range LDL to 330 000) copies/ml. This difference was not statistically significant (p= 
0.94; Mann-Whitney U Test for log VL).  
Table 3.2: A summary of the CD4 count and VL results of mothers testing sensitive 
and resistant to NVP on follow-up 
Parameter Resistant (n=13) Sensitive (n=63) p value 
Mean CD4 count 
(range) 
353 (168-651) cells per 
microliter 
458 (181-1018) cells 
per microliter 
0.07 
Geometric mean of 
Viral load (range) 
4 652 (LDL -290 000) 5 250 (LDL -330 000) 0.94 
3.3.3 Genotyping assay 
Since commercial genotypic testing is expensive, the TFIH assay optimized from 
Jacobs et al (2008) was used for genotyping. Readable sequences could be obtained 
for 97 of 107 (90.7%) patients with the TFIH assay. Figure 3.1 show a representation 
of the PCR product for the RT fragment on a 0.8% agerose gel after electrophoresis.  
  
Figure 3.1: A representation of the PCR for sequencing of the RT fragment. The 
fragments obtained were purified using the QIAquick Spin Kit (QIAGEN GmbH, 
Germany) and sequenced using the ABI Prism BigDye Terminator v3.1 ready 
reaction cycle sequencing kit (Applied Biosystems, Warrington, UK).  Lanes: Lane M 
= 1kb DNA Marker, Lanes 1-26 = Patient samples, Lane 27=PC, Lane 28-29 = Neg 
and NTC. In 2 of the samples two amplification bands are visible. The RT band is 804 
bp of length while other unknown amplified fragments and are present at ±500 bp and 
±250 bp.  
  1    2    3    4   5    6    7   8    9   10  11 12 13 14 15  M 16  17 18  19  20  21  22  23  24 25  26  27 28 29 
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3.3.4  Sequencing analysis for resistance mutations  
Of the 76 sequences 75 were HIV-1 subtype C and 1 was HIV-1 subtype B by using 
the Rega Subtyping Tool Version 2.0 from the Stanford HIVdb website 
(http://dbpartners.stanford.edu/RegaSubtyping/ ). The mutations detected per patient 
are shown in Table 3.3. None of the baseline specimens showed NRTI resistance. One 
patient showed the K70R mutation at follow-up, which confers low-level AZT 
resistance.  
Table 3.3: Resistance mutations detected 
Patient Baseline 
mutations 
(n=1) 
Mutations on 
follow-up 
(n=16) 
*Resistance Follow-up 
interval 
(Days after 
delivery) 
Viral load 
Baseline 
sample tested 
CD4  
Baseline 
sample 
tested 
1 none G190E High-level 22 3200 625 
2 none V108I Potential low-
level 
55 5200 344 
3 none K103N High-level 49 17000 201 
4 none K103N; 
Y181C 
High-level 44 210000 255 
5 none K103N High-level 30 3200 651 
6 none K103N High-level 20 290000 168 
7 none K101E Low-level 52 LDL 502 
8 none V108I Potential low-
level 
35 LDL 239 
9 none K103N High-level 34 1100 390 
10 none K103N; 
V106A 
High-level 28 29000 243 
11 none K103N High-level 44 14000 261 
12 A98G A98G; Y181C High-level 22 4000 335 
13 none K70R; K101E Low-level 32 9700 204 
*According to the Stanford HIV Resistance Database Algorithm 
LDL = Below the lower detection limit 
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One of the 76 patients tested at baseline, the A98G mutation, confers low level 
resistance to NVP. The patient acquired the mutation Y181C after NVP exposure. In 
total, 13 out of the 76 (17.1%; 95% confidence interval (CI) 8.64- 25.5) patients had 
resistance mutations against NVP on the follow-up specimen, including the patient 
with a mutation at baseline. A total of 17 mutations were detected. The frequencies of 
mutations detected in the 76 patients are shown in Figure 3.2. The mutation most 
commonly detected was K103N in 7 patients with other NNRTI-associated mutations 
that included K101E, Y181C, V106A, V108I, and G190E. High-level NVP resistance 
were detected in 9 of the 13 patients with resistance mutations. The mutations present 
were K103N, Y181C, G190E or V106A, alone or in combination with other 
mutations. Low-level resistance was detected in 2 of the 13 patients with the K101E 
mutation present and potential low-level resistance was detected in 2 of the 13 
patients with the V108I mutation present. The Stanford HIV Resistance database 
Algorithm was used to interpret resistance (Update 2007). One of the patients that 
developed resistance mutations received NVP previously while 4 patients that 
previously received NVP did not develop any resistance mutations. The Genbank 
accession numbers for 149 sequences produced by the TFIH assay are EU283624-
EU283773. 
 
Figure 3.2: Resistance mutations detected in follow-up specimens  
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Chapter 4 
4. The further optimisation, validation and quality assurance of the in-house 
HIV-1 antiretroviral resistance tests to be more applicable and practical for 
routine resistance testing in a diagnostic setting 
4.1 Introduction 
Genotypic antiretroviral resistance testing, which is based on PCR and automated 
sequencing, has been used widely as a tool to monitor antiretroviral treatment of HIV-
1 positive patients in industrialised countries. (EuroGuidelines for HIV resistance, 
2001, Hirsch et al, 2000). Public funded therapy programmes in resource limited 
countries cannot afford resistance testing using commercial genotyping assays such as 
the ViroSeq™ Genotyping system V2.0. (Celera Diagnostics, CA, USA) and the 
Trugene™ HIV-1 genotyping System (Visible Genetics, Inc., Toronto, Canada). 
Nevertheless, there is a need for affordable and reliable genotyping testing in the 
developing world as resistance testing is valuable for patient management in choosing 
the best initial regimen or regimen after antiretroviral failure and for antiretroviral 
resistance surveillance, which can inform therapy programs. 
The aim of this part of the study was to further adapt, validate and implement the 
TFIH assay for use in a diagnostic setting: The National Health Laboratory Services 
(NHLS). The following aspects of the TFIH assay (Appendix D) were investigated to 
obtain a less technical and more cost effective assay: extraction method, primer 
selection for first and second round PCR, addition of dithiothreitol (DTT), increased 
annealing temperature and decreased reagent volume in second round PCR and 
improved primer selection for sequencing. A validation of the Improved In-House 
(IIH) assay was completed using QC samples comparing them with the TFIH and the 
ViroSeq™ Genotyping system V2.0. The assays were accredited by South African 
National Accreditation System (SANAS) and implemented as a diagnostic assay in 
2008.  
4.2 Material and Methods  
In this section a short overview of the materials and methods not detailed in Chapter 
2, Section 2.2 and Chapter 3, Section 3.2, are described. The TFIH assay optimised 
and validated in Chapter 2 was initially used for subsequenet optimitaion. Unless
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stated the same protocol was follow for the IIH assay. A comparison of the methods 
used in the TFIH assay and the IIH assay are listed in Table 4.1. 
Table 4.1: A comparison of the methods used in the TFIH assay and the IIH assay. 
Steps in genotyping assay TFIH IIH 
Plasma used for extraction  1ml 1ml 
RNA Extraction QIAamp UltraSens Kit QIAamp UltraSens Kit  
First round PCR   
Denature of RNA RNA denatured RNA denatured 
Input volume 10µl 10µl 
*Additives  None DTT 
*Number of primers used 4 2 
Second round PCR   
Input volume  2µl 2µl 
*Reaction volume 50µl 25µl 
*Number of primers used 4 2 
*Annealing temperature 55ºC 60ºC 
Sequencing reactions    
*Volume of BigDye 
Terminator v3.1 ready 
reaction mix 
4µl 1µl 
Sequencing primers  8 8 
*Annealing temperatures 45ºC and 50ºC 50ºC 
* Differences between assays 
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4.2.1 Sample  
4.2.1.1 ViroSeq™ HIV-1 genotyping assay  
Twenty nine samples received for routine diagnostic resistance testing at the NHLS, 
Department of Virology, Tygerberg Hospital were used for comparison of the IIH 
assay and the ViroSeq™ HIV-1 genotyping assay. 
4.2.1.2 Two Fragment In-House assay 
Sixty seven samples received for routine diagnostic resistance testing at the NHLS, 
Department of Virology, Tygerberg Hospital were used for comparison of the IIH 
assay and the TFIH assay. 
4.2.3 RNA extraction  
The QIAamp® UltraSens virus kit (QIAGEN GmbH, Germany), the QIAamp® viral 
RNA mini kit (QIAGEN GmbH, Germany) and the NucliSense EasyMag automated 
extraction systems (bioMérieux, Boxtel, Netherlands) were investigated for RNA 
extraction using different input and elution volumes. With the QIAamp UltraSens Kit 
(QIAGEN GmbH, Germany) RNA was extracted from 1ml sample and eluted in 
60µl. With the QIAamp® viral RNA mini kit (QIAGEN GmbH, Germany) RNA was 
extracted from 140µl of sample and a final elution volume of 60µl was obtained. With 
the NucliSense EasyMag automated extraction systems RNA was extracted from 1ml 
sample and eluted in 60µl. For viral load detection RNA was extracted from a 1ml 
sample and eluted in 25µl. Sample DR10 from the NICD AIDS Virus Research Unit 
was used. Ten-fold dilutions of the sample were made in plasma to a 1 in 1000 
dilution. One ml of each of the dilutions was used to extract RNA on each of the 
extraction systems evaluated. The viral loads of the dilutions were determined. A 
TFIH PCR was performed on RNA from each of the extraction systems as well as the 
RNA that was extracted for viral load quantification. The PCR product was visualized 
with gel electrophoresis on a 0.8% agarose gel. 
4.2.4 Dithiothreitol (DTT) 
DTT is a reducing agent that reduces disulfides quantitatively (Ausubel et al, 2006). It 
was found that DTT affects enzyme activity with reduction and is used in RNA 
amplification methods (Jeon et al, and Snoeck et al, 2006). Dithiothreitol (DDT) was 
added as an enhancer. 
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4.2.5 gag PCR  
A nested PCR was performed to obtain a PCR product from the gag gene to 
determine if the samples for comparison studies were amplifiable. The Access RT-
PCR System (Promega, Madison, USA) was used for the first round PCR reactions in 
a one step PCR protocol. The PCR primers used (Swanson et al, 2003) are listed in 
Table 4.2. Five microliter of RNA was added to the first round reaction mix 
consisting of AMV/Tfl 5X reaction buffer at a 1X concentration, dNTPs mix at 
0.2mM each, primers at 40pmol, 2.5mM MgSO2, AMV RT 0.1U/µl, Tfl DNA 
Polymerase 0.1U/µl, and nuclease-free water up to a final volume of 50µl. The 
reaction was preformed using a 9700 PCR system ((Applied Biosystems, Foster City, 
USA) using the 9600 ramp speed. The reaction mixtures were prepared in 0.2ml PCR 
tube (QSP, Porex BioProducts Inc, California, USA). The following cycles were used 
for first round PCRs. Incubation for one cycle at 48°C for 45 minutes to enable 
reverse transcription and then a cycle at 94°C for 2 minutes to inactivate AMV 
Reverse transcriptase and allowing denaturing of the DNA. For second strand cDNA 
and amplification the reaction was cycled 40 times at 94°C for 30 seconds to 
denature, at to 53°C for 30 seconds to anneal the primers and at 72°C for 60 seconds 
to extend the product. A last extension for at 72°C for 10 minutes was done. The 
reaction was then stored at 4°C until the second round reactions could be done. The 
Taq Go-Taq® Flexi DNA polymerase (Promega, Madison, USA) was used for the 
second round PCR reaction mixture using the first round PCR product. The PCR 
primers (Swanson et al, 2003) are listed in Table 4.2. A volume of 3µl of the first 
round PCR reaction was added two the second round reaction mix that consisted of 
5X buffer at a 1X concentration, PCR Nucleotide mix (Promega, Madison, USA) at 
0.2mM each, primers at 40pmol each, 1.5mM MgCl2, Taq DNA Polymerase 0.5U/µl, 
and nuclease-free water up to a final volume of 50µl. The following cycles were used 
for second round PCR reaction mixtures: 40 cycles of 94°C for 30 seconds to 
denature DNA, 56°C for 30 seconds for primer annealing and 68°C for 30 seconds for 
primer extension. This is followed by a final 7 minutes at 68°C to complete primer 
extension. The product was then stored at 4°C until the second round reactions could 
be done. 
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Table 4.2: Primers for gag PCR 
First round 
primers 
HBX2  Primer 
Tm 
Primer 
Direction 
Primer Sequence  
P24-1 1177-1193 47.1°C Forward 5’ - AGY CAA AAT TAY CCY ATA GT - 3’ 
P24-7 1826-1841 56.3°C Reverse 5’ – CCC TGR CAT GCT GTC ATC A – 3’ 
Second round 
primers 
    
M/O p24-2 1240-1256 54.2°C Forward 5’ – AGR ACY TTR AAY GCA TGG GT – 3’ 
M/O p24-6 1703-1718 55.2°C Reverse 5’ - TGT GWA GCT TGY TCR GCT C – 3’ 
4.2.4 ViroSeq™ HIV-1 genotyping assay  
The ViroSeq™ HIV-1 Genotyping system V2.0. (Celera Diagnostics, CA, USA) was 
used as a reference assay and performed according to the manufacturer’s instructions 
(including the extraction method).  
4.2.5 Assembly and analysis of sequencing results  
Sequencing alignment was done using the Sequencer software V4.7 (Gene Codes 
Corporation, Ann Arbor USA). The Stanford HIVdb program for Genotyping 
resistance interpretation was used to detect drug resistance mutations.  
http://hivdb.stanford.edu/ index.html, Updated January 2007. 
4.3 Optimization of the Improved In-House assay 
RNA extraction methods were evaluated, different primers for both the PCR and the 
sequencing reactions were selected, DTT was used as an additive to enhance the RT-
PCR, the reaction volume of the second round PCR was decreased, and the BigDye 
Terminator v3.1 ready reaction cycle sequencing reactions were adapted for better 
cost effectiveness.  
4.3.1 Primer selection  
4.3.1.1 Primer selection for PCR to obtain complete fragment 
A schematic representation shows the primer selection in Figure 4.1. The TFIH assay 
used four primers to amplify the PR and the RT gene separately to obtain two PCR 
products that have to be sequence with separate primer sets. For practical reasons a 
primer set were selected to amplify one fragment for sequencing. Four of the same 
primers used in the TFIH assay were selected for the IIH assay. The first and second 
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round forward primers of the PR PCR fragment with the reverse primers of the RT 
PCR fragment from the TFIH assay was selected to obtain one fragment of the pol 
gene for sequencing. The PCR primers are listed in Table 4.3. The samples from the 
NICD AIDS Virus Research Unit were used to perform a first and second round PCR 
according to protocol in Appendix D using the primers selected.  
 
Figure 4.1: Schematic representation of the Primer selection for IIH assay. The figure 
is not drawn to scale.  
Table 4.3: Primers used for IIH assays genotyping PCR 
First round 
Primers 
HBX2 
number  
Primer 
Tm 
Primer 
direction 
Primer Sequence 
outer 5’prot1 2082-2109 57.0°C Forward 5’- TAA TTT TTT AGG GAA GAT CTG GCC TTC C -3’ 
outer Mj4 3399-3420 54.8°C Reverse 5’- CTG TTA GTG CTT TGG TTC CTC T –3’ 
Second Round 
Primers 
    
inner 5'prot2 2136-2163 68.2°C Forward 5’- TCA GAG CAG ACC AGA GCC AAC AGC CCC A –3’ 
inner NE135 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 
 
 
 
outer 3’prot1  
inner 3’prot2 
pol 
gag 
inner 5’prot2 
outer 5’prot1 
inner 5’prot2 
outer MJ3 
outer 5’prot1 
inner A35 
outer Mj4  
inner NE135  
outer Mj4  
inner NE135  
IIH assay 
TFIH assay 
RT fragment 
TFIH assay 
PR fragment 
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4.3.1.2  Selection of primers for sequencing to anneal at same temperature  
The primers used for sequencing of the TFIH assay had two different annealing 
temperatures, 50°C and 45°C. This complicated the practical performance of the 
sequencing, since sequencing reactions could not be performed on one thermocycler 
at the same time. The reactions had to be prepared at separate times or two separate 
thermocyclers were required to accommodate the difference in primer annealing 
temperature. Different primers, as seen in Table 4.4, were selected and tested to find 
those that annealed at the same temperature with the same effectiveness. 
Table 4.4: Primer tested for use in sequencing reaction in the IIH assay. 
Primer HBX2 
number  
Primer 
Tm 
Primer 
Direction 
Primer Sequence References 
JA204 2138-2159 67.9°c Forward 5’ – TTC AGA GCA GAC CAG AGC CAA CAG C – 3’ Lindström and Albert, 2003 
inner 5’prot2 2139-2163 68.2°C Forward 5’- TCA GAG CAG ACC AGA GCC AAC AGC CCC A –3’ Plantier et al, 2005 
pol1D 2254-2271 56.3°C Forward  5'- TCC CTC AAA TCA CTC TTT GGC -3' Loxton, 2004 
outer Mj3 2483-2499 54.3°C Forward   5- AGT AGG ACC TAC ACC TGT CA –3’ Plantier et al, 2005 
ABB20F2 2470-2486 49.7°C Forward 5’ – TAG GTA CAG TGT TAG TAG GA – 3’ Personal Communication, 
John Hackett 
F2054 2511-2528 53.4°C Forward  5’ – GGR CGA AAT ATG TTG ACT CAG – 3’ Personal Communication, 
John Hackett 
inner A35 2533-2564 58.4°C Forward  5’- TTG GTT GCA CTT TAA TTC CCA TTA GTC CTA TT –3’ Plantier et al, 2005 
AK11 2574-2592 48.4°C Forward 5' - GTA CCA GTA AAA TTA AAR CCA G - 3' Lindström and Albert, 2003 
pol rev 2D 2588-2599 49.0°C Reverse  5’ – CCA TCC ATT CCT GGC – 3’ Loxton, 2004 
JA217 2622-2643 49.5°C Reverse  5'- CTT TTA TTT TTT CTT CTG TCA ATG G -3' Lindström and Albert, 2003 
outer 3’prot1 2703-2731 57.6°C Reverse  5’- GCA AAT ACT GGA GTA TTG TAT GGA TTT TCA GG –3’ Plantier et al, 2005 
pol 3D rev 2869-2881 48.5°C Reverse 5’- CCC ACA TCC AGT ACT G – 3’ Loxton, 2004 
pol 3 2885-2901 63.4°C Forward  5’ - GGG GGA TGC ATA TTT TTC AG –3’ Personel communication, 
Susan Engelbrecht 
AK12 2947-2944 50.6°C Reverse 5' - TGG TGT YTC ATT RTT TRY ACT AG – 3' Lindström and Albert, 2003 
ABB20-3F 2983-2999 51.6°C Forward 5' – ATC AGT ACA ATG TGC TTC CA - 3' Personal Communication, 
John Hackett 
inner NE135 3300-3331  61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 Plantier et al, 2005 
JA205 3311-3335 61.7°C Reverse 5’ – TTT TCC CAC TAA CTT CTG TAT GTC ARR G – 3’ Lindström and Albert, 2003 
AK10 3316-3333 50.5°C Reverse  5’ - TYC CCA CTA AYT TCT GTA TRT C –3’ Lindström and Albert, 2003 
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4.3.2 Addition of Dithiothreitol (DTT) to obtain a more sensitive PCR 
To investigate if the addition of DTT enhances the performance of the PCR, reaction 
mixes was prepared as described in Appendix D with the primers used described in 
Table 4.3. DTT was added to the first round reaction mix at a concentration of 0.8mM 
as described in the reference assay. 
Sample DR10 received from the NICD AIDS Virus Research Unit was used to 
prepare six 10 fold dilutions to determine if the addition of DTT would influence the 
amplification of RNA. These dilutions were amplified in parallel reactions mixtures 
with and without DTT.  
4.3.3 Changes made to the second round PCR 
Production of Taq DNA Polymerase in storage buffer B system (Promega, Madison, 
USA), which was used to optimise The TFIH assay, was discontinued by the 
manufacture and replaced with Go-Taq® Flexi DNA polymerase (Promega, Madison, 
USA). This improved polymerase system was implemented in the IIH assay. 
4.3.3.1 Increased annealing temperature of the second round PCR 
The melting temperatures of the primers for the IIH assay in the second round PCR 
are listed in Table 4.3. In the TFIH assay, the annealing temperature for the second 
round PCR was 55° due to the lower melting temperatures of 2 primers (see Table 
D.1 in Appendix D). The possibility of increasing the melting temperature of the 
second round PCR to 60°C was investigated by performing the PCR with an 
annealing temperature of 60°C in parallel with 55°C using 10 fold dilutions of sample 
DR10 from the NICD AIDS Virus Research Unit. 
4.3.3.2 Decreased reaction mix volume and an increased cDNA input volume in 
the second round PCR 
A combination of DTT and Go-Taq® Flexi DNA polymerase improved the PCR 
reaction. Subsequently a good quality PCR product was obtained in a 50µl reaction. 
To save on costs and to increase sensitivity of the second round PCR reaction, the 
possibility of a smaller reaction mix volume was investigated. The PCR reaction mix 
described in the TFIH assay was reduced to a final volume of 25µl with a 2 µl input 
of first round PCR product. This was compared to the PCR reaction mix of TFIH 
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assay at 50µl with a 2µl input using 10 fold dilutions of sample DR10 from the NICD 
AIDS Virus Research Unit.  
4.3.4 Sequencing buffer to reduce cost of sequencing reaction 
The sequencing buffer supplied by Applied Biosystems, Warrington, UK was used to 
reduce the cost of sequencing by reducing the amount of ABI Prism BigDye 
Terminator v3.1 ready reaction mix needed in a reaction. Sequencing reactions were 
performed using the terminator ready reaction mix diluted with sequencing buffer in a 
1 to 3 dilution.  
4.4  Validation  
Validation of the IIH assay was performed according to the protocol described in 
Appendix H using six HIV-1 samples obtained from the NICD AIDS Virus Research 
Unit, the six samples obtained from the Round Robin HIV-1 genotyping assessment 
system as well as the samples obtained from the Quality Control of Molecular 
Diagnostic system. 
4.4.1 Sensitivity and specificity testing  
4.4.1.1 Analytical sensitivity 
Six samples obtained from the NICD AIDS Virus Research Unit were used to 
determine the analytical sensitivity. The viral loads of the isolates were determined 
with the NucliSense Easy Q HIV-1 system V1.2 (Biomérieux bv, Boxtel). Ten fold 
dilutions form 100 000 to 1 copies/ml was prepared. Viral RNA was extracted with 
the QIAamp® UltraSens™ Virus Kit (QIAGEN GmbH, Germany) and amplified 
with IIH assay to obtain a 1200 bp region of the pol gene coding for the protease (PR) 
and approximately 260 amino acids of the reverse transcriptase (RT) enzymes. In 
order to determine the limit of detection we used a probit regression model in R 
(version 1.11.1).  
4.4.1.2 Specificity 
To verify the specificity of this IIH assay, the pol gene sequences obtained, were 
submitted to BLAST (as described in section 2.2.3) of the National Center of 
Biotechnology information (http://www.ncbi.nlm.nih.gov).  
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4.4.1.3  Comparison with the NICD AIDS Virus Research Unit Samples 
The six HIV-1 isolates obtained from the NICD AIDS Research Unit were amplified 
and sequenced with the IIH assay. 
4.4.1.4 Comparison with the Round Robin HIV-1 genotyping assessment system  
The six QC samples obtained from the Round Robin HIV-1 genotyping assessment 
system were analysed in parallel with the IIH assay, the TFIH assay as described in 
Appendix D and the ViroSeq™ HIV-1 Genotyping system. 
4.4.1.5 Quality Control of Molecular Diagnostic system (QCMD)  
The TFIH assay as described in Appendix D was enrolled in the QCMD external 
quality assessment system for evaluation. The samples were also tested with the IIH 
assay as describe in Appendix H, for comparison with the TFIH assay. The IIH assay 
was enrolled in the QCMD external quality assessment system for evaluation in 2008.  
4.4.1.5 Comparison of methods 
EDTA whole blood samples received for routine drug resistance testing at the NHLS 
Tygerberg Hospital, Department of Virology, were separated from the red blood cells 
with centrifugation at 3000 revolutions per minute (rpm) for 10 minutes and plasma 
was stored in 1ml aliquots at -70°C.  
4.4.1.5.1 gag PCR to determine if the samples are amplifiable 
A nested PCR was performed to obtain a PCR product from the gag gene to 
determine if the samples for comparison studies were amplifiable.  
4.4.1.5.2 ViroSeq™ HIV-1 genotyping assay  
Twenty nine samples were tested in parallel on the IIH assay and the ViroSeq™ HIV-
1 genotyping system. 
4.4.1.5.3 Two Fragment In-House assay 
Sixty seven samples were tested in parallel on the IIH assay and the TFIH assay 
described in Appendix D.  
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4.5 Results 
4.5.1 Optimisation of IIH assay for use in routine diagnostic HIV-1 drug 
resistance testing  
The following section describes the results obtained after investigating different 
aspects of the genotyping assay to improve cost effectiveness and technical efficiency. 
4.5.1.1 Extraction of viral RNA for genotyping 
A summary of the detection of RNA after extraction with the QIAamp® UltraSens 
virus kit (QIAGEN GmbH, Germany), the QIAamp® viral RNA mini kit (QIAGEN 
GmbH, Germany) and the NucliSense EasyMag automated extraction systems 
(bioMérieux, Boxtel, Netherlands) are shown in Table 4.5. 
Table 4.5: Detection of RNA with different extraction methods 
 
Elution 
Volume 
10000 
copies/ml 
1000 
copies/ml 
100 
copies/ml 
QIAamp® UltraSens virus kit 60 µl + + + 
QIAamp® viral RNA mini kit 60 µl + + - 
NucliSense EasyMag automated 
extraction systems 
60 µl + + - 
NucliSense EasyMag automated 
extraction systems RNA from 
Viral load extraction 
25 µl + + + 
Sample DR10 from the NICD AIDS Virus Research Unit was used for extraction and 
an HIV-1 negative plasma sample was included as a Neg. A non template control 
(NTC) was included. The QIAamp® UltraSens virus kit performed the best of all the 
assays with a final elution of 60µl. The NucliSense EasyMag automated extraction 
systems with a 60µl elution did not perform well, as it could not amplify the sample 
with 100 copies/ml. Weak amplification bands were visible with the naked eye in 
samples with higher copy numbers (Figure 4.2). The NucliSense EasyMag automated 
extraction systems with a 25µl elution performed as well as the QIAamp® UltraSens 
virus kit. A disadvantage of the method was the small volume of RNA available for 
further use. The QIAamp® viral RNA mini kit (QIAGEN GmbH, Germany) with a 
60µl elution did not perform well as it could only detect 1000 copies/ml. The best 
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assayfor optimization will be the QIAamp® UltraSens virus kit as it has the best 
results with a larger elution volume of 60µl.  
 
 
Figure 4.2: Agarose gel of PCR product obtained from RNA extracted with different 
extraction methods. U=QIAamp® UltraSens virus kit, N25=NucliSense EasyMag with 
25µl elution, N60=NucliSense EasyMag with 60µl elution, R=QIAamp® viral RNA 
mini kit. Lane 1=10000 copies/ml, Lane 2=1000 copies/ml, Lane 3=100 copies/ml, 
N=Negative control, NT=Non template control. 
4.5.1.2 Primer selection 
4.5.1.2.1 Primer selection for PCR to obtain a complete fragment 
For practical reasons, one set of primers that can amplify one PCR product for 
sequencing was selected. The first and second round forward primers of the PR PCR 
with the reverse primers of the RT PCR from the TFIH assay were selected to obtain 
one PCR fragment. Figure 4.3 shows a representation of the complete fragment 
amplification visualised on 0.8% agarose gel by electrophoresis. This fragment 
amplified the same region as the PR and RT assay and obtains a sequence of 
approximately 1200 base pairs for analysis of resistance mutations in the PR and RT 
genes. An HIV-1 negative plasma sample was included as a Neg along with a NTC. 
 
   U                 N25             R            N60   
 1    2    3   1    2    3    1    2   3   1    2    3    N NT 
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Figure 4.3: A complete fragment of 1200 base pairs was obtained by using the first 
and second round forward primers of the PR PCR with the reverse primers of the RT 
PCR from the TFIH assay. Lane 1-3 = Known HIV-1 positive patient samples, N = 
Negative Control and NTC = Non Template Control. 
4.5.1.2.2 Selection of primers to anneal at the same temperature  
Primers were selected for sequencing of PCR product to obtain a set of sequencing 
primers that can be annealed at 50°C to produce a high quality sequence for 
genotyping analysis. The primers are in Table 4.6. With the TFIH assay the two PCR 
products were sequenced with three and five primers respectively (see Figure 4.1). 
One of the sequencing primers for the PR assay had an annealing temperature of 45°C 
and the other two annealed at 50°C. One of the sequencing primers of the RT assay 
anneal at 45°C and the other four annealed at 50°C. There were two annealing 
temperatures for sequencing and two separate PCR reactions had to be performed, 
necessitating two instruments or a longer time to completion on one instrument. This 
caused a delay in sequencing. Primers with an annealing temperature of 50°C were 
selected for sequencing. A list of the primers selected is shown in Table 4.6. By 
selecting primers at the same annealing temperature one sequence amplification cycle 
could be performed leading to more efficient time management and fewer errors.  
 
 
 
 
 M           1          2          3         4          5  
             Complete pol fragment   
                  4      
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Table 4.6: Primer selected for use in sequencing reaction of the IIH assay. 
Primer HBX2 
number  
Primer 
Tm 
Primer 
Direction 
Primer Sequence References 
pol1D 2254-2271 56.3°C Forward  5'- TCC CTC AAA TCA CTC TTT GGC -3' Loxton, 2004 
F2054 2511-2528 53.4°C Forward  5’ – GGR CGA AAT ATG TTG ACT CAG – 3’ Personal Communication, 
John Hackett 
AK11 2574-2592 48.4°C Forward 5' - GTA CCA GTA AAA TTA AAR CCA G - 3' Lindström and Albert, 2003 
JA217 2622-2643 49.5°C Reverse  5'- CTT TTA TTT TTT CTT CTG TCA ATG G -3' Lindström and Albert, 2003 
pol 3 2885-2901 63.4°C Forward  5’ - GGG GGA TGC ATA TTT TTC AG –3’ Personal Communication, 
Susan Engelbrecht 
inner NE135 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 Plantier et al, 2005 
ABB20-3F 2983-2999 51.6°C Forward 5' – ATC AGT ACA ATG TGC TTC CA - 3' Personal Communication, 
John Hackett 
AK10 3316-3333 50.5°C Reverse  5’ - TYC CCA CTA AYT TCT GTA TRT C –3’ Lindström and Albert, 2003 
4.5.1.3 Addition of Dithiothreitol (DTT) to obtain a more sensitive PCR 
DTT was added to reaction mixtures to enhance the sensitivity of the PCR reaction. 
Tenfold dilutions of RNA from NVP8b sample of the NICD AIDS Virus Research 
Unit were prepared and amplified with the protocol form Appendix G. With addition 
of DTT, RNA could be detected down to a concentration of 100 copies/ml (Figure 
4.4). The PCR reaction without the DTT could only detect RNA down to 1000 
copies/ml. An HIV-1 negative plasma sample was included as a Neg. 
 
Figure 4.4: Tenfold dilutions of sample amplified with PCR reaction mixes without 
DTT and with DTT. M=Marker, 1=100 000 copies/ml, 2=1000 copies/ml, 3=100 
copies/ml, 4=10 copies/ml, 5=1 copies/ml, 6=0 copies/ml, 7=Negatice Control. 
 
Without DTT  With DTT  
  1    2    3    4    5    6    7  M  1    2    3    4    5    6    7  
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4.5.1.4 Changes to second round PCR 
4.5.1.4.1 Increased annealing temperature of the second round PCR 
The primer annealing temperature for the second round PCR of the IIH assay was 
increased because the newly selected primers had a higher melting temperature than 
the primers used in the TFIH. A second round PCR was performed with an annealing 
temperature of 60°C to increase the specificity and sensitivity of the second round 
PCR reaction. RNA could be detected down to a concentration of 100 copies/ml with 
the annealing temperature of 60°C. With the annealing temperature of 55°C, RNA 
could be detected down to 1000 copies/ml with no amplification visible at 100 
copies/ml. Figure 4.5 shows PCR products, for different inputs and annealing 
temperatures after gel electrophoresis on a 0.8% agarose gel. An HIV-1 negative 
plasma sample was included as a Neg along with a NTC. 
 
Figure 4.5: Agarose gel of PCR reaction with a 60°C and 55°C annealing 
temperature. M=Marker, 1=1000 copies/ml, 2=100 copies/ml, 3=10 copies/ml, 4=1 
copies/ml, 5=0 copies/ml, 6=0 copies/ml, 7=Negative Control, 8=Non Template 
Control. RNA could be detected up to a 1000 copies/ml with a 60°C annealing 
temperature and only 1000 copies/ml with a 55°C annealing temperature. 
4.5.1.4.2 Decrease of reaction mix volume with increased cDNA input in 
second round PCR 
To decrease the cost of the PCR and to increase the sensitivity of the assay the 
reaction volume of the second round PCR was decreased to 25µl with an input of 2 µl 
of first round PCR product. Keeping the input volume at 2µl increased the 
concentration of cDNA input and thus possibly the sensitivity of the assay. RNA 
could be detected up to a 100 copies/ml dilution of the sample with both PCR reaction 
mixes and the amplification bands expressed on 0.8% agarose gels are more 
prominent with the lower reaction volume and higher input as shown in Figure 4.6.  
60°C 
  1   2    3   4   5   6   7    8 
55°C 
   1   2   3   4   5   6   7   8 
  M 
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Figure 4.6: Tenfold dilutions of sample amplified in 50µl and 25µl PCR reaction 
with a 2µl input visualized on a agarose gel.  M=Marker, 1=1 000 000 copies/ml, 
2=100 000 copies/ml, 3=10 000 copies/ml, 4=1000 copies/ml, 5=100 copies/ml, 6=10 
copies/ml, 7=1 copies/ml, 8=0 copies/ml, 9=0 copies/ml 10=Negative Control. 
4.5.1.5 Sequencing buffer to reduce cost of sequencing reaction 
To reduce the cost of the sequencing reactions a 3 fold dilution of the ABI Prism 
BigDye Terminator v3.1 ready reaction mix with sequencing buffer, supplied free 
of cost by Applied Biosystems, Warrington, UK, were used to obtain sequences. 
These were analysed with the Sequencer software V4.7. By using sequencing buffer 
the amount of sequencing reaction that could be performed with the in-house assay 
increased 3 fold and this lead to lower assay cost. 
4.5.2 Sensitivity and specificity testing  
4.5.2.1 Analytical sensitivity  
The number of isolates detected at each copy number input was 6/6 at 1000 copies/ml, 
5/6 at 100 copies per ml, 2/6 at 10 copies per ml and 1/6 at 1 copy per ml. Using a 
probit regression model the limit of detection for the in-house assay was estimated to 
be 137 (87-794; 95%CI) copies/ml.  
4.5.2.2 Specificity of the assay 
All PCR products as sequenced corresponded to the HIV-1 pol gene. 
4.5.3 Validation 
4.5.3.1 Testing with samples from the NICD AIDS Virus Research Unit 
All the samples from the NICD AIDS virus Research Unit could be amplified and 
sequenced. The results obtained correlated a 100% with that of the TFIH assay 
described in section 2.3.4.4. 
50µl 
 25µl 
     1    2   3   4    5  6   7   8    9  10  
      1    2   3   4    5  6   7    8    9  10 
M 
 M 
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4.5.3.2 Round Robin HIV-1 genotyping assessment system from the University 
of Würzburg 
All the samples could be amplified and complete sequences were obtained with the 
IIH assay. The assay could detect all except one the resistance associated mutations, 
insertion T69i, and polymorphism S68N as seen in Table 4.7. The performance of the 
assay was better than the VirSeq™ HIV-1 genotyping system and the TFIH assay. 
Table 4.7: Summary results for the Round Robin HIV-1 genotyping assessment 
system for the VirSeq™ HIV-1 genotyping system, the TFIH assay and the IIH assay  
 WQC1 WQC2 WQC3 WQC4 WQC5 WQC6 
*Subtype B B G B B B 
ViroSeq™ 
1 mutation 
missed 
100% 
Correlation 
100% 
Correlation 
1 mutation 
missed 
100% 
Correlation 
1 mutation 
missed 
TFIH 
1 mutation 
missed 
100% 
Correlation 
100% 
Correlation 
1 mutation 
missed 
1 mutation 
missed 
100% 
Correlation 
IIH  
1 mutation 
missed 
100%100% 
Correlation 
100% 
Correlation 
100% 
Correlation 
100% 
Correlation 
100% 
Correlation 
Comment 
WQC 1 sequence was of poor quality for all assays. Only fragments could be 
analysed. All missed insertion T69i and polymorphism S68N 
*The Rega HIV-1 subtyping tool Version 2.0 (http://dbpartners.stanford.edu/Rega Subtyping/) with 
jpHMM (jumping profile Hidden Markov Model) http://jphmm. gobics.de/ was used for determining 
the HIV-1 subtype 
4.5.3.3 Quality Control of Molecular Diagnostic system (QCMD)  
All samples received from the 2007 QCMD program could be amplified and 
sequenced. The resistance mutations detected corresponds to the ones obtained with 
the TFIH assay as discussed in section 2.3.4.4 and shown in Table 2.7, Chapter 2. All 
but one of the samples could be amplified by the IIH for the 2008 QCMD program 
with a score of 266 out of 266. The resistance mutation detected by the IIH assay in 5 
samples is listed in Table 4.8.  
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Table 4.8: Resistance mutation detected by the IIH assay in 5 samples received with 
the 2008 QCMD program 
Sample PI Major 
Mutations: 
PI Minor 
Mutations: 
NRTI 
Mutations: 
NNRTI 
Mutations: 
Insertions *Subtype 
QCMD 1 None None None None  G 
QCMD 2 D30N 
N88D 
L10F 
T74S 
M41L 
E44D 
D67N 
T69D 
M184V 
L210W 
T215Y 
A98G  C 
QCMD 3 M46I 
I54V 
V82A 
L90M 
L10IV 
A71T 
None None  B 
QCMD 5 None None D67N 
T69i 
L210W 
T215Y 
K101E 
V106M 
G190A 
RT AA 
Insertion: 
codon 69 
AA: ES  
NA: 
GAGTCT 
C 
*The Rega HIV-1 subtyping tool Version 2.0 (http://dbpartners.stanford.edu/Rega Subtyping/) with 
jpHMM (jumping profile Hidden Markov Model) http://jphmm. gobics.de/ was used for determining 
the HIV-1 subtype   
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4.5.3.4 Comparison between assays 
4.5.3.4.1 gag PCR to determine if comparison samples are amplifiable 
4.5.3.4.1.1 gag PCR amplification of samples for comparison between IIH assay 
with the ViroSeq™ HIV-1 genotyping assay 
The 29 samples selected for the comparison between the IIH assay and the ViroSeq™ 
HIV-1 genotyping assay were tested with the gag PCR to determine if they are 
amplifiable. All the samples could be amplified with the gag PCR. The results are 
shown in Table 4.9. 
Table 4.9: The results of the gag PCR amplification. All samples could be amplified  
Sample gag PCR 
result 
Sample gag PCR 
result 
330314 Pos 333676 Pos 
330315 Pos 333679 Pos 
330316 Pos 333983 Pos 
330318 Pos 333985 Pos 
330818 Pos 334791 Pos 
330819 Pos 335286 Pos 
330820 Pos 335287 Pos 
330822 Pos 335291 Pos 
330823 Pos 335294 Pos 
331101 Pos 335299 Pos 
331502 Pos 335301 Pos 
332071 Pos 336514 Pos 
332885 Pos 336517 Pos 
333599 Pos 336844 Pos 
333601 Pos   
*Pos=Positive for amplification 
Neg=Negative for amplification 
4.5.3.4.1.2 gag PCR amplification of samples for comparison between IIH assay 
with the TFIH assay 
The 67 samples, selected for the comparison between the IIH assay and the TFIH 
assay, were tested with the gag PCR to determine if they are amplifiable. Five of the 
samples could not be amplified with the gag PCR. The results are set out in Table 
4.10. 
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Table 4.10: The results of the gag PCR amplification. Five samples could not be 
amplified, highlighted in grey 
Sample no. gag PCR 
result Sampleno. 
gag PCR 
result Sample no. 
gag PCR 
result 
144745 *Pos 149518 Pos Aretas 22 Pos 
144771 Pos 150142 Pos Aretas 23 Pos 
144831 Pos 150143 Neg Aretas 25 Pos 
145426 Neg 151267 Pos Aretas 24 Pos 
145427 Pos 151450 Pos Aretas 29 Pos 
145881 Neg 151679 Pos Aretas 30 Pos 
145882 Pos 151680 Pos Aretas 32 Pos 
146142 Neg 151924 Pos Aretas 43 Pos 
146143 Neg 151925 Pos Aretas 84 Pos 
146593 Pos 152122 Pos Aretas 88 Pos 
147028 Pos 152529 Pos Aretas 89 Pos 
147642 Pos 152869 Pos Aretas 90 Pos 
147643 Pos 153545 Pos Aretas 91 Pos 
148090 Pos 153547 Pos Aretas 92 Pos 
148091 Pos 153549 Pos Aretas 93 Pos 
148092 Pos 153550 Pos Aretas 94 Pos 
148093 Pos 153551 Pos Aretas 95 Pos 
148221 Pos 153792 Pos Aretas 96 Pos 
148222 Pos 153793 Pos Aretas 100 Pos 
148824 Pos Aretas 12 Pos Aretas 101 Pos 
148825 Pos Aretas 19 Pos Aretas 102 Pos 
149004 Pos Aretas 20 Pos   
149517 Pos Aretas 21 Pos   
*Pos=Positive for amplification 
Neg=Negative for amplification 
4.5.3.4.2 Comparison between IIH assay and the ViroSeq™ HIV-1 genotyping 
assay 
The Improved in-house assay was compared with the ViroSeq™ HIV-1 genotyping 
assay by testing 29 samples in parallel. The patient’s characteristics are in Appendix 
J. The ViroSeq™ HIV-1 Genotyping assay could amplify 25 out of 29 samples with 3 
incomplete sequences obtained from the 25 samples amplified. One sample could not 
be sequence with the ViroSeq™ HIV-1 Genotyping assay. The IIH assay could 
amplify and sequence all 29 samples with one incomplete sequence obtained. All of 
the samples were found to be HIV-1 subtype C except for one sample that was HIV-1 
Subtype D. 
Primer failures for the IIH assay were as follows: JA217 (n=5), AK10 (n=2), HIV-
AK11 (n=3), outer 3’prot1 (n=2) and Pol3 (n=1). Obtaining a consensus sequence 
with the IIH assay by assembly of sequences from both strands was not possible for 
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10% of the samples due to primer failure with only 1 incomplete sequence obtained. 
Primer failures for the ViroSeq™ HIV-1 Genotyping assay were as follows: Primer A 
(n=9), Primer B (n=2), Primer C (n=1), Primer D (n=25), Primer F (n=3), Primer G 
(n=4), and Primer H (n=9). With the ViroSeq™ HIV-1 Genotyping assay consensus 
sequence from both strands was not possible for 48% of the samples due to primer 
failure with 3 incomplete sequences obtained. Primers for the IIH assay failed in 31% 
of the samples compared to an 80% (excluding primer D) failure rate in the 
ViroSeq™ HIV-1 Genotyping assay. 
4.5.3.4.2.1 Antiretroviral drug resistance associated mutations detected by the 
IIH assay with the TFIH assay 
 
 
Figure 4.7: Schematic comparison of samples sequences with ViroSeq™ HIV-1 
Genotyping assay and the IIH assays 
 
A schematic comparison of the sequencing results are shown in Figure 4.7. Twenty 
five samples were sequenced with both the ViroSeq™ HIV-1 Genotyping assay and 
the IIH assays and a total of 94 and 105 mutation listed in the Stanford database were 
identified respectively by the ViroSeq™ HIV-1 Genotyping assay and the IIH assays. 
Identical resistance associated mutations were detected in 15 samples. A summary of 
the resistance mutations detected are shown in Figure 4.8.  
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Figure 4.8: Comparison of mutations in 15 samples sequenced on both the In-house 
and the ViroSeq™ HIV-1 Genotyping assays.  
Of the 6 samples with discrepant results, the ViroSeq™ HIV-1 Genotyping assay 
system detected 2 mutations not detected by the IIH assay. A summary of the 
mutations detected in each assay is given in Appendix I. The IIH assay detected 9 
mutations that the ViroSeq™ HIV-1 Genotyping assay did not detect. A summary of 
the discrepant results are listed in Appendix K. The ViroSeq™ HIV-1 Genotyping 
assay and the IIH assay could each detect one mutation, in one case, that the other 
could not detect. Of the 11 discordant results, 8 were associated with drug resistance. 
No sequence could be obtained with the ViroSeq™ HIV-1 Genotyping assay for 1 
sample, however a sequence could be obtained by the IIH assay and 10 mutations 
were detected of which 7 were associated with drug resistance (Table 4.11).  
Table 4.11: Mutations in one sample sequenced with In-house assay only 
PI NRTI 
L24I L74V 
L33F Y115F 
L10F M184V 
A71V   
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The IIH assay could detect 15 mutations in the 4 samples that could not be amplified 
by the Viroseq, all these 4 samples harboured drug resistance mutations (Table 4.12). 
Incomplete sequences were obtained for 3 samples with the Viroseq assay and 1 
sample with the IIH assay (Table 4.13). Most of the samples that could be sequenced 
were HIV-1 subtype C except for two HIV-1 subtype B sample.  
 
Table 4.12: Mutations detected in 4 samples amplified with IIH assay only   
 PI NRTI NNRTI 
Sample 1  M184V  
Sample 2 T74S A62AV V106M 
 
 M184V E138A 
 
  V179D 
 
    F227FL 
Sample 3   M184MV K101E 
 
  V106M 
 
  V108I 
 
    G190A 
Sample 4   M184V K103N 
 
Table 4.13: Mutations detected in 4 samples with incomplete sequences 
 ViroSeq   In House  
 NRTI NNRTI PI NRTI NNRTI 
K70EK A98G T74S K70EK A98G 
M184V K103N  M184V K103N Viroseq Protease gene not sequenced 
 P225H   P225H 
M184V V106M  M184V V106M Viroseq 
82 AA Short on the Reverse 
Transcriptase gene  F227L   F227L 
M184V K101E  M184V K101E 
 V106M   V106M 
Viroseq 
62 AA Short on the Reverse 
Transcriptase gene  G190A   G190A 
M184V K101P  M184V K101P 
 K103N   K103N 
IIH assay 
24 AA Short on Protease gene 
    E138EK 
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4.5.3.4.3 Comparison between IIH assay and the TFIH assay 
The IIH assay was compared to the TFIH assay by testing 67 samples in parallel. The 
characteristics of these patients are in Appendix L. A summary of the amplification of 
samples compared with the TFIH and IIH assay are shown in Table 4.14. 
Table 4.14: A summary of the amplification of samples compared with the TFIH 
assay and the IIH assay  
 TFIH assay IIH assay Total  
Amplified 63 (94%) 57 (85%) 67 
Complete sequence obtained 39 (62%) 53 (93%) 67 
Incomplete sequences 24 (38%) 4 (7%) - 
Only PR sequence obtained 4 (1.5%) NA - 
Only RT sequence obtained 8 (12%) NA - 
The TFIH assay could amplify 63(94%) of 67 samples with 39 (62%) complete 
sequences and 24 (38%) incomplete sequences obtained from the amplified samples.  
The IIH assay could amplify 57 samples and complete sequences were obtained for 
53 (93%) of samples with incomplete sequence obtained in only 4 (7%) samples. All 
the samples that could be sequenced were HIV-1 subtype C except for two HIV-1 
Subtype B sample. A summary of the amplification and sequences obtained is shown 
in Table 4.15. 
Table 4.15: A summary of amplification and sequence comparison between the TFIH 
assay and the IIH assay  
Sample 
gag PCR 
result TFIH assay 
Sequence 
obtained  IIH assay 
Sequence 
obtained 
144745 Positive A Complete  A Complete  
144771 Positive A Complete  A Complete  
144831 Positive A Fragments  A Complete 
145426 Negative A  PR gene No A  
145427 Positive A Complete  A Fragments  
145881 Negative A  PR gene No A  
145882 Positive A Fragments  A Complete  
146142 Negative A  PR gene No A  
146143 Negative No A  No A  
146593 Positive A Complete  A Complete  
147028 Positive A Complete  A Fragments  
147642 Positive A Complete  A Complete  
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Table 4.15 continue: A summary of amplification and sequence comparison between 
the TFIH assay and the IIH assay  
Sample 
gag PCR 
result TFIH assay 
Sequence 
obtained  IIH assay 
Sequence 
obtained 
147643 Positive A Complete  A Complete  
148090 Positive A Complete  A Complete  
148091 Positive A Complete  No A  
148092 Positive A Complete  A Complete  
148093 Positive A RT gene A Complete  
148221 Positive A RT gene A Complete  
148222 Positive A Complete  *No A No Sequence 
148824 Positive A Complete  A Fragments  
148825 Positive A Complete  A Complete  
149004 Positive A Fragments  A Complete  
149517 Positive A Complete  A Complete  
149518 Positive A Complete  A Complete  
150142 Positive A Complete  A Complete  
150143 Negative No A No Sequence No A No Sequence 
151267 Positive A RT gene A Complete  
151450 Positive A Complete  A Complete  
151679 Positive A Complete  A Complete  
151680 Positive A Complete  A Complete  
151924 Positive A RT gene A Complete  
151925 Positive A Fragments  A Complete  
152122 Positive A Complete  A Complete  
152529 Positive A RT gene A Complete  
152869 Positive A RT gene A Complete  
153545 Positive A Complete  A Complete  
153547 Positive A PR gene A Complete  
153549 Positive A Fragments  A Complete  
153550 Positive A Complete  A Complete  
153551 Positive A Complete  No A No Sequence 
153792 Positive A Complete  A Complete  
153793 Positive A Complete  A Complete  
Aretas 12 Positive A Complete  A Complete  
Aretas 19 Positive A Fragments  A Complete  
Aeretas 20 Positive A Complete  A Complete  
Aeretas 21 Positive A Complete  A Complete  
Aeretas 22 Positive A Fragments  A Complete  
Aeretas 23 Positive A Complete  A Complete  
Aretas 25 Positive A Complete  A Complete  
Aeretas 24 Positive A Complete  A Complete  
Aeretas 29 Positive A Complete e A Fragments  
Aeretas 30 Positive A Fragments  A Complete  
Aretas 32 Positive No A No Sequence A Complete  
Aretas 43 Positive A RT gene A Complete  
Aretas 84 Positive A Fragments  A Fragments  
Aretas 88 Positive A Complete  A Complete  
Aretas 89 Positive A Complete  A Complete  
Aretas 90 Positive A Fragments  A Complete  
Aretas 91 Positive A Complete  A Complete 
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Table 4.15 continue: A summary of amplification and sequence comparison between 
the TFIH assay and the IIH assay  
Sample 
gag PCR 
result TFIH assay 
Sequence 
obtained  IIH assay 
Sequence 
obtained 
Aretas 92 Positive A Fragments  A Complete  
Aretas 93 Positive A Fragments  A Complete  
Aretas 94 Positive A Complete  A Complete  
Aretas 95 Positive A Complete  A Complete  
Aretas 96 Positive No A No Sequence No A No Sequence 
Aretas 100 Positive A RT gene A Complete  
Aretas 101 Positive A Complete  A Complete  
Aretas 102 Positive A Complete  A Complete  
*No A = No Amplification  
A = Amplification 
The TFIH assay could amplify only the PR fragment in 4 samples. These samples 
could not be amplified with the gag PCR. The IIH assay could amplify 1 of these 
samples to obtain a PCR product for sequencing. The TFIH assay could amplify only 
the RT fragment in 8 samples and the IIH assay could amplify all of these samples to 
obtain product for sequencing. In one of these samples 2 major PI mutations were 
detected by the IIH assay.  
Four samples could not be amplified by the TFIH assay, of which one sample could 
be amplified by the IIH assay. Two of these samples could not be amplified with the 
gag PCR. No amplification could be achieved in 10 samples with the IIH assay. Five 
of these samples could not be amplified by the gag PCR. In 4 of the 10 samples the 
TFIH assay could only amplify the PR fragment. In 4 samples that could not be 
amplified a complete fragment could be detected with the TFIH assay and 2 of the 
samples could not be detected by either assay. One sample could not be amplified by 
the TFIH assay but a complete fragment could be detected by the IIH assay.  
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4.5.3.4.3.1 Antiretroviral drug resistance associated mutations detected by the 
IIH assay with the TFIH assay 
 
Figure 4.9: Schematic comparison of samples sequences with the IIH assay and the 
TFIH assays. 
A schematic comparison of the sequencing results are shown in Figure 4.9. Complete 
sequences could be obtained with both the TFIH assay and the IIH assay in 38 
samples and a total of 104 and 109 mutations listed in the Stanford database were 
identified respectively by the two assays. The resistance mutations detected are listed 
in Appendix M. Identical resistance associated mutations were detected in 31 
samples. Eighteen samples had discrepant results. A summary of the samples with 
discordant resistance mutations are listed in Appendix N. Of the 18 samples with 
discrepant results the TFIH assay could detect 7 mutations not detected by the IIH 
assay. The IIH assay could detect 11 mutations that the TFIH assay did not detect. In 
2 samples the TFIH assay and the IIH assay could both detect a mutation that the 
other could not detect. Of the 20 discordant mutations 14 were associated with drug 
resistance.  
Incomplete sequences were obtained in 16 samples. Incomplete sequences were 
obtained with the TFIH assay in 12 samples, all of which could be sequenced 
completely with the IIH assay. In 4 samples incomplete sequences were obtained with 
the IIH assay that could be sequenced completely with the TFIH assay.  
Primer failures for the TFIH assay were as follows R2051 (n=6), pol1D (n=7), JA217 
7, pol3D (n=8), pol3rev 3, ABB20-3F (n=13), AK12 (n=7), AK11 (n=7) in 27 
samples. Obtaining a consensus sequence with the assay from both strands was not 
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possible for 16 samples due to primer failure with 10 incomplete sequences obtained. 
Primer failures for the IIH assay were as follows: pol1D (n=0), AK11 (n=2), JA217 
(n=2), outer 3’prot1 (n=2), pol 3 (n=5), AK10 (n=3), inner NE135 (n=4) and F2054 
(n=15). Obtaining a consensus sequence with the assay from both strands was not 
possible for 4 samples due to primer failure with incomplete sequences obtained. 
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Chapter 5 
5.1 Discussion and Conclusion 
5.1 Discussion 
5.1.1 Introduction 
This study has 3 objectives (1) to optimize a in-house assay for genotyping, published 
in Jacobs et al (2008), for a research and diagnostic tool, (2) to determine the 
resistance mutation from patient treated according to the provincial PMTCT protocol 
in the Western Cape, a sd-NVP, combined with a short course AZT and (3) to do 
further optimization and validation of the in-house assay to obtain a less technically 
difficult and more cost effect assay for the diagnostic setting.  
5.1.2 The optimization and validation of a Two Fragment In-House HIV-1 
antiretroviral resistance assay  
The first aim of this study was to optimize and validate the TFIH assay for use in a 
diagnostic testing and research setting. The assay uses four primes to amplify the PR 
and the RT gene separately to obtain PCR products, of 487 and 804 base pairs 
respectively for sequencing. The two PCR products were sequenced with three and 
five primers respectively to sequence the complete PR and approximately 250 amino 
acids of the RT gene. The sequences generated are analysed and assembled with the 
Sequencer V4.7 software to obtain a consensus sequence of approximately 1200 base 
pairs for analysis of resistance mutations in two genes.  
PCR is a tool with many different applications and no single PCR protocol is 
appropriate for all applications, therefore optimisation is always necessary when a 
new protocol is implemented. In the attempt to optimise the PCR, the following 
factors were investigated: the RNA and cDNA input volumes, the denaturing RNA 
before amplification and magnesium and primer concentrations. We investigated 
increasing the amount of input RNA as the amount of template influences the 
performance of the PCR. The input volume of the RNA template was increased from 
5 µl to 10µl of RNA to increase the amplification rate in the first round PCR. To 
prevent inhibition of the second round PCR template, overload the input volume was 
reduced to 2µl. (Ausubel et al, 2006, Promega, Protocol and Applications guide 
http://www.promega.com/paguide/chap1.htm, November 2010). There was better 
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amplification in the reactions with increased input, probably due to a higher yield of 
PCR product. The 10µl input in the first round probably contribute to the raised 
sensitivity of the TFIH assay with a high yield of PCR product for sequencing. 
One of the problems encountered with RNA amplification is that during primer 
extension areas in the RNA are encountered that cause the reverse transcriptase to 
pause or terminate. The termination sites may be caused by secondary structures 
within the RNA. A high incubation temperature minimizes the effect of secondary 
structures (Ausubel et al, 2006). To eliminate termination sites that may be caused by 
secondary structures within the RNA, it should be denatured before amplification is 
performed. The ViroSeq™ HIV-1 Genotyping assay commercial system (Abbott 
Diagnostic Laboratories, Chicago, USA) suggest incubation at 65°C as the first step 
in the PCR and the Promega Impromp II (Promega, Madison, USA) assay also uses a 
incubation at 70°C as first step in RNA amplification. Both these methods were 
investigated for the TFIH assay. Better amplification was observed with denaturing of 
RNA than without. The two different methods of denaturing investigated at 65°C and 
70°C. Both performed well. In this study the method of denaturing at 65°C was 
selected as the most simple to perform with no extra incubation on ice before 
amplification reactions could be performed.  
A primer and magnesium titration was performed to optimise the concentrations for 
amplification. The concentration of the magnesium affects primer annealing, strand 
dissociation temperatures, product specificity, formation of primer-dimer artefacts and 
enzyme activity and also fidelity. The optimal magnesium concentration is dependent 
on the concentration of the dNTP’s, primers and template. It is recommended that a 
PCR should contain 0.5-2.5 mM magnesium per reaction and that a titration must be 
done to determine the optimum concentration of magnesium for use (Innis et al, 
1990).  
An incorrect primer concentration may lead to mispriming and non-specific product 
formation. It also can increase the formation of primer-dimer artefacts. The formation 
of the aforementioned, compete with the selected target for enzyme, dNTPs and 
primers resulting in lower yields of product. A primer concentration between 0.1 and 
0.5µM is the optimum for a PCR (Innis et al, 1990).   
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A problem encountered in this study was that the first round PCR, a one step reverse 
transcriptase PCR, did not deliver enough DNA for visualization on agarose gel. The 
titration was therefore performed on the second round PCRs. Both the RT and the PR 
PCR performed best at a 40pmol concentration of primer. The RT fragment had the 
best amplification results at 2mM concentration for magnesium will the PR fragment 
had the best amplification results at 2.5mM concentration with good amplification 
seen at 2mM. The original concentrations for the Jacobs et al (2008) assay used 2mM 
for both fragments. To keep the TFIH assay simple as possible the same conditions 
were used for both fragments. 
The analytical sensitivity of the TFIH assay was determined to be 112 (37-881; 
95%CI) copies/ml for the RT gene and 190 (67-1524; 95%CI) copies/ml for the PR 
gene. DNA blast of sequences showed that PCR products were specific for HIV-1. 
The sensitivity of the ViroSeq™ HIV-1 genotyping system is 1000 copies/ml 
(Manufacturers instructions).  
Validation of the TFIH assay was done by testing samples received from the NICD 
AIDS Research Unit, comparing the TFIH assay with the ViroSeq™ HIV-1 
genotyping system in the Round Robin HIV-1 genotyping assessment system and 
rolling the TFIH assay in the QCMD external quality assessment system. The results 
from the TFIH assay for the samples from the NICD AIDS Virus Research Unit 
published in Pillay et al (2008) correlated. The same resistance mutation could be 
detected. However the unpublished samples had discrepant results. NV8b and NV64 
appear to be the same sample. Sample NV186 did not have any mutations present. 
The samples received and tested in this study were viral cultures while the sequence 
results supplied by the NICD AIDS Virus Research Unit were from plasma. There is a 
possibility that the cultured virus could have lost its mutations as it was under no 
antiretroviral drug pressure.  Although all the samples received from the Round Robin 
HIV-1 genotyping assessment system could be amplified with both the TFIH assay 
and the ViroSeq™ HIV-1 genotyping system the quality of the sequences obtained for 
WQC1 was bad and the T69i insertion was missed by both assays. This sample was a 
recombinant virus and that could have contributed to the poor amplification (Bodem, 
2007). The V108IV mutation in sample WQC5 was missed by the TFIH assay and the 
E44DE mutation in sample WQC6 was missed by the ViroSeq™ HIV-1 genotyping 
system. Although mutations were missed, both assays performed the same with the 
 119 
Würzburg Quality Assessment system and the performance of the TFIH assay was 
considered acceptable. 
The assay performed well with the QCMD system and scored 329 out of 332. All the 
mutations were detected with no mutations detected that were not included in the 
samples. The 3 points loss was due to base pair mixtures that were detected by the 
TFIH assay.  
The TFIH assay showed good performance on the international assessment panels and 
the performance in the Round Robin HIV-1 genotyping assessment system was the 
same as the ViroSeq™ HIV genotyping assay. Satisfactory results were also obtained 
with the QCMD evaluations as all mutation present could be detected. 
The cost off the commertial assay per sample is R4571.89. The TFIH assay can be 
completed for R 1636.88, with a total saving of R2935.01. The assay could be 
performed over a period of 4 days from extraction to the release of the final results. .  
This assay can be used as a research and diagnostic resistance testing. An advantage 
of the TFIH assay is the use of the two fragments as separate assays for investigation 
of the PR and the RT gene, which could decrease the cost of a study.  
5.1.3 Detection of resistance mutations in mothers from the Western Cape, who 
received a regimen of single dose nevirapine (sd NVP) combined with a short 
course zidovudine (AZT) as part of prevention of mother to child transmission 
(PMTCT).  
The TFIH assay was used to determine the development of genotypic-antiretroviral 
resistance in patients treated according to the provincial PMTCT protocol in the 
Western Cape (sd-NVP, combined with a short course AZT). The resistance rate of 
17.1% in a population that is predominant HIV-1 subtype C, was lower than seen in 
other studies done where sd-NVP alone was administered in HIV-1 subtype C 
positive patients in the PMTCT programs (Eshleman et al, 2005 and Kurle et al, 
2007) which indicated that the dual therapy could reduce the risk of resistance to 
NVP. This might have been due to the fact the short course of AZT combined with 
NVP reduced the viral load to lower levels than sd-NVP alone with less viral 
replication and therefore a decreased likelihood of mutations (Chaix et al, 2007).  
A potential bias towards under detection of resistance in this study is the relative 
lower baseline viral load and higher CD4 count in patients qualifing for PMTCT. 
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Patients with CD4 counts below 200 cells/µl qualified for HAART instead of this 
intervention. It was found that a higher viral load and low CD4 count are associated 
with the development of resistance (Eshleman et al, 2001 and Chaix et al, 2007).  
Resistance mutations were found in 13 of the 76 samples included in this study and all 
patients with resistance mutations were infected with HIV-1 subtype C. Only one 
patient had a resistance mutation at baseline, this being the A98G mutation giving 
potential low level resistance to NVP. The A98G mutation is seen in 1% of drug naïve 
patients and in higher frequencies in HIV-1subtype C than in subtype B (Grossman et 
al, 2004). This patient acquired the Y181C mutation, causing high-level resistance to 
NVP, after receiving the PMTCT treatment. The K103N mutation that results in high-
level resistance to NVP was found in 7 of the 13 patients. This has been reported as 
the most common mutation in sd NVP treatment in PMTCT by other studies as well 
(Flys et al, 2005, Eshelman (a) et al, 2004 and Eshelman (b) et al, 2004). The K103N 
mutations persist for a long period of time after sd-NVP (Flys et al, 2007, Palmer et 
al, 2006). The Y181C mutation that results in high-level resistance to NVP and 
increased susceptibility to AZT was present in 2 of 13 patients. In both patients the 
mutation occurred with the K103N and A98G mutations. The K101E mutation, which 
is associated with low-level resistance and the V108I mutation, which on its own is 
associated with potential low-level resistance, was found in two patients. The clinical 
impact of this potential low-level resistance is unknown but will probably decrease 
the threshold for further resistance-associated mutations in the presence of NVP 
treatment. One of each of the A98G mutation giving low-level resistance to NVP, the 
V106A mutation giving high-level resistance against NVP, and the G190E mutation 
also giving high-level resistance to NVP, were found. One patient had the K70R 
mutation, which results in low-level resistance to AZT. The K70R mutation a 
thymidine analogue mutations (TAMs) which is the most common mutation occurring 
in patients receiving AZT for long periods (Chaix et al, 2005). These mutations 
accumulate over time and 4 or more cause high-level resistance to AZT (Ross et al, 
2001). The patient acquiring this mutation also had a K101E mutation that results in 
low-level resistance to NVP. The risk of AZT resistance appears to be low since only 
one patient had a low-level resistance mutation. 
The use of a short course of AZT and sd-NVP is effective in lowering the MTCT rate 
and this study shows that it decreases mutations in woman and increases the 
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likelihood of successful response to NNRTI containing ART. The Western Cape 
Province programme has shown that it is feasible to maintain the short course AZT 
and sd-NVP with 81% of woman being enrolled in the program and a transmission 
rate of lower than 10% (Coetzee et al, 2005).   
Like in most studies of sd-NVP, sequencing was used to detect resistance-associated 
mutations. Since commercial genotypic testing is expensive, the TFIH assay was 
used. This assay gave a high yield of readable sequences and could be used to look for 
RT resistance in 97 of 107 (90.7%) patients.  
5.1.4 The further optimisation, validation and quality assurance of the in-house 
HIV-1 antiretroviral resistance tests to be more applicable and practical for 
routine resistance testing in a diagnostic setting.  
Since 2004, South African patients in the public sector have had access to 
antiretroviral therapy and CD4 and viral load monitoring to detect therapy failure. 
However as the cost is prohibitive, antiretroviral resistance testing is not part of the 
HIV management program. Resistance testing is valuable for management of 
individual patients failing antiretroviral therapy through guiding selection of optimal 
second line or salvage therapy. It is also necessary for resistance surveillance and as 
an outcome measure of program success in the South African antiretroviral roll-out. 
Apart from the high cost, commercial resistance assays are usually designed and 
validated for HIV-1 subtype B viruses. The sequencing primers do not always 
perform as well when HIV-1 subtype non-B virus is prevalent (Beddows et al, 2003, 
Fontaine et al, 2001). 
The manual QIAamp® UltraSens virus kit performed the best of all the extraction kits 
with a final elution of 60µl. Although the most effective, it is a long and labour 
intensive method. Therefore, we recommended that for a diagnostic setting the 
NucliSense EasyMag automated extraction systems with a 25µl elute should be used 
as this system performed as well as the QIAamp® UltraSens virus kit. Previous 
studies documented that the NucliSense EasyMag automated extraction systems is as 
sensitive as manual methods (Perandin et al, 2009, Pillet et al, 2009, Burgener et al, 
2003) with a inhibition range at the same level as the QIAamp® UltraSens virus kit 
(Burgener et al, 2003). The efficiency of the NucliSense EasyMag automated 
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extraction systems were 4 to 6 times higher than the QIAamp® UltraSens virus kit 
(Burgener et al, 2003) but at a lower elution volume.  
It was possible to optimise and validate a nested PCR assay, IIH assay, which uses 8 
primers for sequencing. A 1200 bp sequence that containing the protease and the 5’ of 
the reverse transcriptase genes where antiretroviral resistance associated mutations are 
found. The sequence obtained does not cover the integrase gene, but integrase 
inhibitors are not currently used in the South African public sector.  
Additives in the PCR reaction are used to enhance the yield and specificity of the 
reaction. DTT reduces disulfide bonds of proteins (Nagai et al, 1998, Ralser et al, 
2006). In this study the addition of DTT increased the yield cDNA ten-fold in the first 
round PCR.   
The primer annealing temperature is often within 5°C of the melting temperature of 
the primers. The increase of the annealing temperature closer to or higher than the 
annealing temperature will lead to increased annealing stringency and minimizes non-
specific primer annealing (Promega, Protocol and Applications guide 
http://www.promega.com/paguide/chap1.htm, November 2010). In this study, the rise 
of the annealing temperature closer to the melting temperature in the second round 
PCR increase the yield of PCR product tenfold.  
Too low a specimen input in a PCR reaction can lead to low yields of PCR product 
and a too high an input can lead to inhibition of the reaction or non specific 
amplification (Promega, Protocol and Applications guide http://www.promega. 
com/paguide/chap1.htm, November 2010). The increase of the PCR product input in 
the second round PCR increase the yield of cDNA product for sequencing. 
In this study, a partial and cross-validation of the IIH assay was done as quality 
control samples and an original validated assay, the ViroSeq™ HIV-1 genotyping 
assay, serves as a reference.  
The analytical sensitivity of the IIH assay was determined to be 137 (87-794; 95%CI) 
copies/ml. DNA blast of sequences showed that PCR products were specific. A 
drawback of the study is that we did not evaluate the assay with a full panel of 
different HIV-1 subtypes and recombinants to test its ability to detect these viruses, 
although a large number of different subtypes were detected with the assay during its 
evaluation. However, that should not detract from using the assay. 
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A second round (nested) PCR reaction allowed us to achieve high analytic sensitivity. 
As using two rounds of PCR could be more prone to contamination, phylogenetic 
trees are drawn for each specimen batch, using neighbour-joining phylogenetic trees 
to identify similar sequences. The pol sequences generated were aligned with Clustal 
X (Thompson et al, 1997) and compared with the Kimura two-parameter distance 
neighbour-joining method to estimate genetic distance (Saitou and Nei, 1987) with 
1000 bootstrap replicates in Mega 4.0 software (Kumar et al, 2004).The IIH assay 
also showed good performance on international assessment panels. The performance 
in the Round Robin HIV-1 genotyping assessment system was better than the 
ViroSeq™ HIV-1 genotyping assay and TFIH assay, with detection of all but one 
mutation. Satisfactory results were also obtained with the QCMD evaluations as all 
mutation present could be detected.  
We found the IIH assay more sensitive than a commercial reference assay for 
detectioning HIV-1 subtype C, producing complete sequencing results on most 
samples. All 29 samples could be amplified with the IIH assay and good results were 
obtained from sequencing of the samples with only one incomplete sequence was 
obtained. The ViroSeq™ HIV-1 genotyping assay could amplify 25 of 29 samples. 
Incomplete sequences were only obtained in 3 samples; despite the high primer failure 
rate in more than 80% of the samples. As in the other cases, a complete sequence 
could be assembled from the remaining sequenced fragments, due to sufficient read-
length. This is due to Primer A and D producing a similar sequence. When both failed 
ould one cnot obtain a complete sequence (Fontaine et al, 2001). However the 
integrity of these results obtained from the assay is compromised as (48%) consensus 
sequences requiered assembly from single stranded sequencing data. Primer D has 
previously been shown to perform poorly in non-subtype B samples and other studies 
previously described a high failure rate of primers A, D and H (Beddows et al, 2003, 
Mracna et al, 2001 and Fontaine et al, 2001). 
The TFIH and IIH assays could amplify 94% and 85% of samples respectively. 
Although the TFIH assays had a higher amplification rate, it also produced a high 
number of incomplete sequences (24), which could not be analysed properly for 
resistance mutations. This could be primer related. New primers were selected for the 
IIH assay with better results. The IIH assay only produced 4 incomplete sequences. 
Primer failures occurred in 40% and 32% of samples respectively. The integrity of the 
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sequences was compromised in only 6% of the samples from the IIH assay. In 79% of 
samples complete sequence could be detected with the IIH assay. Of the 10 samples 
failing to amplify with the IIH assay, 3 also did not amplify with the TFIH assay. In 3 
samples, only the protease fragment could be amplified. This could possibily be due 
to the decreased efficiency of the amplification reaction as a result of the larger 
product size in the IIH assay, which amplifies a 1200 bp target while the two TFIH 
assay fragments had sizes of 487 and 804 base pairs respectively.  
The cost of the IIH assay was R1518.11. There was a decrease in the price of the Ih-
house assay of R118.77. The assay could be performed over a 3 day period from 
sample extraction to the release of the final result.final result. 
5.2 Conclusion  
We have shown in Chapter 2 that an in-house assay was valuable in monitoring the 
effect of therapy options on resistance in patients failing therapy and in the 
monitoring of resistance in therapy naive patients. The extensive optimisation and 
validation of this assay allowed us to use it with confidence in either a diagnostic or 
research setting. We obtained SANAS accreditation for its diagnostic use. As the 
antiretroviral roll out matures, and more patients will have failed both the first and 
second line regimens there will be an increased need to have affordable resistance 
tests to select appropriate third-line or salvage regimens.  
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Appendix A: Protocol from Jacobs et al (2008)  
Extraction of viral RNA for genotyping 
The method used the QIAamp UltraSens Kit (QIAGEN GmbH, Germany) for RNA 
extraction from 1ml plasma. The manufactures instructions was followed and the 
RNA was eluted in two elution steps with 30 µl of AVE buffer added to each to 
obtain a total elution volume of 60 µl. 
First round RT-PCR reactions  
The Access RT-PCR System (Promega, Madison, USA) was used to do the first 
round RT-PCR reactions in a one step protocol. The PCR primers are listed in Table 
A.1 (Plantier et al, 2005). Five µl of RNA was added to the first round reaction mix 
that consisted of AMV/Tfl 5X reaction buffer at a 1X concentration, a dNTP-mix at 
0.2mM each, primers at 40pmol, 2mM MgSO2, AMV RT 0.1U/µl, Tfl DNA 
Polymerase 0.1U/µl and nuclease-free water up to a final volume of 50µl. PCR 
cycling was done using 9700 PCR system thermocyclers (Applied Biosystems, Foster 
City, USA) at 9600 ramp speed. The reaction mixtures were prepared in 0.2ml PCR 
tubes (QSP, Porex BioProducts Inc, California, USA).  
The following cycling conditions applied: First round PCR: For complementary DNA 
(cDNA) synthesis reaction tubes were incubated at 48°C for 45 minutes to allow for 
reverse transcription (yielding double stranded-DNA (ds-DNA)) and then at 94°C for 
2 minutes to inactivate AMV Reverse transcriptase and to denature ds-DNA. For 
exponential amplification of DNA the cycling conditions were: 40 cycles of 94°C for 
20 seconds to denature DNA, 55°C for 30 seconds for primer annealing and 68°C for 
90 seconds for primer extension. This is followed by a final 5 minutes at 68°C to 
complete primer extension. The product was then stored at 4°C until the second round 
reactions could be done.  
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Table A.1: Primers for genotyping PCR 
Protease 
Primer 
HBX2 
number 
Primer 
Tm 
Primer 
direction 
Primer Sequence 
outer 30prot1 2703-2734 57.6°C Reverse 5’- GCA AAT ACT GGA GTA TTG TAT GGA TTT TCA GG –3’ 
outer 50prot1 2082-2109 57.0°C Forward 5’- TAA TTT TTT AGG GAA GAT CTG GCC TTC C -3’ 
inner  30prot2 2621-2650 55.8°C Reverse 5’ AAT GCT TTT ATT TTT TCT TCT GTC AAT GGC –3’ 
inner 50prot2 2136-2163 68.2°C Forward 5’- TCA GAG CAG ACC AGA GCC AAC AGC CCC A –3’ 
Reverse 
transcriptase 
Primer 
    
outer Mj4 3399-3420 54.8°C Reverse 5’- CTG TTA GTG CTT TGG TTC CTC T –3’ 
outer Mj3 2480-2499 54.3°C Forward 5- AGT AGG ACC TAC ACC TGT CA –3’ 
inner NE13 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 
inner A35  2530-2564 58.4°C Forward  5’- TTG GTT GCA CTT TAA TTC CCA TTA GTC CTA TT –3’ 
 
Second round PCR reactions  
The Taq DNA Polymerase in storage buffer B system (Promega, Madison, USA) was 
used for the second round PCR reaction mixture using the first round RT-PCR 
product as template input. The PCR primers used are listed in Table A.1 (Plantier et 
al, 2005). Five µl of the first round RT-PCR reaction product was added to the second 
round reaction mix which consisted of 5X storage buffer B at a 1X concentration, 
PCR Nucleotide mix (Promega, Madison, USA) at 0.2mM each, primers at 40pmol 
each, 1.5mM MgCl2, Taq DNA Polymerase at 2.5U/µl, and nuclease-free water up to 
a final volume of 50µl.  
The cycling conditions that applied to the second round PCR were: One cycle at 94°C 
for 2 minutes for DNA denaturing followed by 40 cycles of 94°C for 20 seconds for 
DNA denaturing, 55°C for 30 seconds for primers annealing and 68°C for 90 seconds 
for primer extension to extend. This was followed by a final extension for 5 minutes 
at 68°C. The product was then stored at 4°C until it could be visualized.  
Visualization of the PCR product with agerose gel electrophoresis  
The PCR product was identified according to product size (514bp for the protease 
gene and 804bp for the reverse transcriptase gene) with gel electrophoresis on a 0.8% 
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agarose gel prepared with LE analytical grade agarose (Whitehead Scientific, Cape 
Town, RSA) in 1 x TAE Buffer (0.04M Tris acetate, 0.001M EDTA). Five µl of 
ethydium bromide (Promega, Madison, USA) was added to the gel to intercalate ds-
DNA.  
Two µl loading buffer (Promega, Madison, USA) was mixed with 5µl PCR product. 
Each specimen was sequentially loaded in a slot on the gel, including the blanks, 
positive controls and 1 kilobasepair marker (Promega, Madison, USA). The electrical 
current was set at 50 mAmperes for a 50ml gel apparatus.  
When the products have migrated from the negative to the positive anode sufficiently, 
as indicated by the migration of the two coloured dyes in the loading buffer, the 
current was removed and the gel was visualised under ultra violet light at a 
wavelength of 302nm, ethydium bromide intercalatede DNA (PCR products) 
fluoresces brightly. A photograph was taken by using the Syngene GeneGenius, 
version 4.00, program (Synoptics Ldt, Cambridge, United Kingdom). 
PCR product purification 
The QIAquick Spin Kit (QIAGEN GmbH, Germany) was used to clean the PCR 
products for use in sequencing reactions according to the manufactures instructions.  
Sequencing of PCR product  
The ABI Prism BigDye Terminator v3.1 ready reaction cycle sequencing kit 
(Applied Biosystems, Warrington, UK) was used for the sequencing reactions. Cycle 
sequencing reactions were prepared in a 96 well plate by adding 4µl of terminator 
ready reaction mix to 1µl of template, 1µl of 5pmol primer and 4µl nuclease free 
water to obtain a final volume of 10µl. The reaction mix was then exposed to 
thermocycling conditions repeated 25 times with DNA denaturing at 96°C for 10 
seconds and primer annealing for 5 seconds at the sequence primer specific annealing 
temperature. This was followed by a final product extension at 60°C for 4 minutes. 
After completion of the cycling the reactions were sent to the DNA sequencing 
facility of Stellenbosch University for sequencing on the ABI 3100 Sequencer 
(Applied Biosystems, Foster City, USA). The primers used in the sequencing 
reactions are listed in Table A.2.  
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Table A.2: Primers used for sequencing of the protease and reverse transcriptase 
regions with the TFIH assay 
PR 
Primers 
HBX2 
number 
Primer 
Tm 
Primer 
direction 
Primer Sequence References  
R2051 2486-2504 49.5°C Reverse 5'- TAT RTT GAC AGG TGT AGG T -3' Personal Communication, John Hackett 
pol1D 2251-2271 56.3°C Forward 5'- TCC CTC AAA TCA CTC TTT GGC -3' Loxton, 2004 
JA217 2622-2646 49.5°C Reverse 5'- CTT TTA TTT TTT CTT CTG TCA ATG G -3' Lindström and Albert, 2003 
RT 
Primers 
     
pol3D 2869-2884 48.7°C Forward 5' - CAG TAC TGG ATG TGG G - 3' Loxton, 2004 
pol3rev 2882-2901 51.1°C Reverse 5' - CTG AAA AAT ATG CAT CCC CC - 3' Personal Communication, Susan 
Engelbrecht 
ABB20-3F 2980-2999 51.6°C Forward 5' - ATC AGT ACA ATG TGC TTC CA - 3' Personal Communication, John Hackett 
AK12 2947-2969 50.6°C Reverse 5' - TGG TGT YTC ATT RTT TRY ACT AG - 3' Lindström and Albert, 2003 
AK11 2571-2592 48.4°C Forward 5' - GTA CCA GTA AAA TTA AAR CCA G - 3' Lindström and Albert, 2003 
Assembly and analysis of sequences 
Sequencing alignment was done using the Sequencer software V4.7 (Gene Codes 
Corporation, Ann Arbor USA). The Stanford HIVdb program for Genotyping 
resistance interpretation was used to detect drug resistance mutations.  
http://hivdb.stanford.edu/index.html .  
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Appendix B: Expected mutations as supplied by Lynn Morris from the NICD AIDS 
Virus Research Unit 
Sample 
PI Major 
Resistance 
Mutations: 
PI Minor 
Resistance 
Mutations: 
NRTI Resistance 
Mutations: 
NNRTI 
Resistance 
Mutations: 
Insertions 
DR10 None None M41L 
E44D 
D67N 
T69D 
V118I 
M184I 
L210W 
T215Y 
A98G 
Y188L 
G190A 
 
DR19 None None M41LM 
D67N 
L210W 
T215Y 
K101E 
V106M 
G190A 
 
RT AA Insertion: 
codon 69 
AA: ES  
NA: GAGTCT 
DR28 None None M184V 
T215Y 
A98G 
K103N 
M230L 
 
NVP8b   None K103N  
NVP64   None 
V106A 
G190A 
 
NVP186   None 
K103N 
V179I 
G190A 
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Appendix C: Expected mutations as supplied by Jochen Bodem (2007) from the 
Round Robin HIV-1 genotyping assessment system.  
Sample PI Major 
Resistance 
Mutations: 
PI Minor 
Resistance 
Mutations: 
NRTI Resistance 
Mutations: 
NNRTI 
Resistance 
Mutations: 
*Subtype 
1 L76V 
I84V 
L90M 
L33F 
A71V 
M41L 
D67K 
T69i 
K70R 
M184V 
T215F 
K219Q 
None Combined viruses 
2 V46I 
V82F 
None M41L 
L74I 
M184V 
L210W 
T215Y 
K103N B 
3 None None M41L 
T215Y 
None G 
4 G48GV 
I54IT 
V82VA 
N88NS 
L90LM 
L10LI 
L33F 
A71AV 
M41LM 
E44AE 
V118I 
L210LW 
T215NSTY 
K103KN 
Y188FY 
 
B 
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Appendix C continued: Expected mutations as supplied by Jochen Bodem (2007) 
from the Round Robin HIV-1 genotyping assessment system  
Sample PI Major 
Resistance 
Mutations: 
PI Minor 
Resistance 
Mutations: 
NRTI Resistance 
Mutations: 
NNRTI 
Resistance 
Mutations: 
*Subtype 
5 I54V 
V82VF 
L90M 
L10IV 
A71V 
A62V 
K65R 
D67N 
T69DN 
V75I 
F77L 
F116Y 
Q151M 
M184MV 
K219E 
K103KN 
V108IV 
B 
6 I54V 
V82C 
I84V 
L90M 
L10F 
V11I 
K43T 
A71T 
G73S 
L89V 
M41L 
E44DE 
D67N 
T69DN 
K70R 
V75M 
M184V 
L210W 
T215Y 
K219E 
K101E 
V108I 
G190A 
 
B 
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Appendix D: Final protocol of optimized and validated TFIH assay 
Extraction of viral RNA for genotyping 
The method used the QIAamp UltraSens Kit (QIAGEN GmbH, Germany) for RNA 
extraction from 1ml plasma. The manufacturer’s instructions supplied with the kit was 
followed and the RNA was eluted in two elution steps with 30µl of AVE buffer added 
in each step to obtain a total elution volume of 60µl.  
First round PCR reactions  
The Access RT-PCR System (Promega, Madison, USA) was used to do the first 
round PCR reactions in a one step PCR protocol. The PCR primers are listed in Table 
D.1. Ten µl of RNA was added to the first round reaction mix that consisted of 
AMV/Tfl 5X reaction buffer at a 1X concentration, dNTPs mix at 0.2mM each, 
primers at 40pmol, 2mM MgSO2, AMV RT 0.1U/µl, Tfl DNA Polymerase 0.1U/µl 
and nuclease-free water up to a final volume of 50µl. The reaction was done on a 
9700 PCR system (Applied Biosystems, Foster City, USA) using the 9600 ramp 
speed. The reaction mixtures were prepared in 0.2ml PCR tube (QSP, Porex 
BioProducts Inc, California, USA).  
The following cycling conditions were used for first round PCR: Incubation at 65°C 
for 30 seconds to straighten the RNA was done. The RNA was then cooled to 48°C. 
Forty µl of the reaction mix was added and for the first strand cDNA synthesis the 
reaction were incubate for one cycle at 48°C for 45 minutes so that reverse 
transcription could take place and then a cycle at 94°C for 2 minutes to inactivate 
AMV Reverse transcriptase and denaturing of the DNA to occur. For second strand 
cDNA and amplification the reaction was cycled 40 times at 94°C for 20 seconds to 
denature, at to 55°C for 30 seconds to anneal the primers and at 68°C for 90 seconds 
to extend the product. A last extension for at 68°C for 5 minutes was done. The 
reaction was then stored at 4°C until the second round reactions could be done.  
Second round PCR reactions  
The Taq DNA Polymerase in storage buffer B system (Promega, Madison, USA) was 
used to do the second round PCR reaction mixture using the first round PCR product. 
The PCR primers used is listed in Table D.1. Two µl of the first round PCR reaction 
was added two the second round reaction mix that consisted of 5X storage buffer B at 
a 1X concentration, PCR Nucleotide mix (Promega, Madison, USA) at 0.2 mM each, 
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primers at 40 pmol each, 1.5 mM MgCl2, Taq DNA Polymerase 2.5 U/µl, and 
nuclease-free water up to a final volume of 50µl.  
The following cycling conditions were used for second round PCR reaction mixtures. 
One cycle at 94°C for 2 minutes for denaturing of the DNA and then cycled for 40 
times at 94°C for 20 seconds to denature, at to 55°C for 30 seconds to anneal the 
primers and at 68°C for 90 seconds to extend the product. A last extension for at 68°C 
for 5 minutes was done. The reaction was then stored at 4°C until it could be 
visualized.  
Table D.1: Primers used for first and second round PCR 
Protease 
Primer 
HBX2 
number 
Primer 
Tm 
Primer 
direction 
Primer Sequence 
outer 3’prot1 2703-2734 57.6°C Reverse 5’- GCA AAT ACT GGA GTA TTG TAT GGA TTT TCA GG –3’ 
outer 5’prot1 2082-2109 57.0°C Forward 5’- TAA TTT TTT AGG GAA GAT CTG GCC TTC C -3’ 
inner 3’prot2 2621-2650 55.8°C Reverse 5’ AAT GCT TTT ATT TTT TCT TCT GTC AAT GGC –3’ 
inner 5’prot2 2136-2163 68.2°C Forward 5’- TCA GAG CAG ACC AGA GCC AAC AGC CCC A –3’ 
Reverse 
transcriptase 
Primer 
    
outer Mj4 3399-3420 54.8°C Reverse 5’- CTG TTA GTG CTT TGG TTC CTC T –3’ 
outer Mj3 2480-2499 54.3°C Forward 5- AGT AGG ACC TAC ACC TGT CA –3’ 
inner NE13 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 
inner  A35  2530-2564 58.4°C Forward  5’- TTG GTT GCA CTT TAA TTC CCA TTA GTC CTA TT –3’ 
Visualization of the PCR product with electrophoresis  
Gel electrophoresis was done to visualize the PCR product on a 1% agarose gel 
prepared with LE analytical grade agarose (Whitehead Scientific, Cape Town, RSA) 
in 1 x TAE Buffer (0.04M Tris acetate, 0.001 M EDTA). 50g of agarose were weight 
in a glass flask and 50ml of 1 x TAE Buffer was added. It was then heated in a 
microwave oven to boiling point and mixed by stirring on magnetic stirrer. Five µl of 
ethydium bromide (Promega, Madison, USA) was added to the gel to stain the DNA.  
Two µl loading buffer (Promega, Madison, USA) was mixed with 5µl PCR product. 
Each specimen was sequentially loaded in a slot on the gel, including the blanks, 
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positive controls and 1 kilobasepair marker (Promega, Madison, USA). A current of 
50 mAmperes per 50ml gel was then passed through the gel.  
When the products migrated from the negative to the positive anode sufficiently, as 
indicated by the migration of the two coloured dyes in the loading buffer, the current 
was removed and the gel was visualised under ultra violet light at a wavelength of 
302nm, ethydium bromide stained DNA (PCR products) appeared as bright band. A 
photograph was taken by using the Syngene GeneGenius, version 4.00, program 
(Synoptics Ldt, Cambridge, United Kingdom). 
PCR product purification 
The QIAquick Spin Kit (QIAGEN GmbH, Germany) was used to clean the PCR 
products for use in sequencing reactions according to the manufactures instructions.  
Quantification of DNA with the NanoDrop  
The DNA product was quantified with the NanoDrop ND-1000. The concentration of 
DNA obtained was used to work out a dilution factor to obtain 10ng-40ng of DNA to 
use in the sequencing reactions. 
Sequencing of PCR product  
The ABI Prism BigDye Terminator v3.1 ready reaction cycle sequencing kit 
(Applied Biosystems, Warrington, UK) was used for the sequencing reactions. Cycle 
sequencing reactions were prepared in a 96 well plate by adding 4µl of terminator 
ready reaction mix to 1µl of template, 1µl of 5pmol primer and 4µl nuclease free 
water to obtain a final volume of 10µl. The reaction mix was then exposed to 
thermocycling conditions repeated 25 times with DNA denaturing at 96°C for 10 
seconds and primer annealing for 5 seconds at the sequence primer specific annealing 
temperature. This was followed by a final product extension at 60°C for 4 minutes. 
After completion of the cycling the reactions were sent to the DNA sequencing 
facility of Stellenbosch University for sequencing on the ABI 3100 Sequencer 
(Applied Biosystems, Foster City, USA). The primers used in the sequencing 
reactions are listed in Table D.2.  
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Table D.2: Primers used for sequencing of the PR and RT region 
PR 
Primers 
HBX2 
number 
Primer 
Tm 
Primer 
direction 
Primer Sequence References  
R2051 2486-2504 49.5°C Reverse 5'- TAT RTT GAC AGG TGT AGG T -3' Personal Communication, John Hackett 
pol1D 2251-2271 56.3°C Forward 5'- TCC CTC AAA TCA CTC TTT GGC -3' Loxton, 2004 
JA217 2622-2646 49.5°C Reverse 5'- CTT TTA TTT TTT CTT CTG TCA ATG G -3' Lindström and Albert, 2003 
RT 
Primers 
     
pol3D 2869-2884 48.7°C Forward 5' - CAG TAC TGG ATG TGG G - 3' Loxton, 2004 
pol3rev 2882-2901 51.1°C Reverse 5' - CTG AAA AAT ATG CAT CCC CC - 3' Personal Communication, Susan 
Engelbrecht 
ABB20-3F 2980-2999 51.6°C Forward 5' - ATC AGT ACA ATG TGC TTC CA - 3' Personal Communication, John Hackett 
AK12 2947-2969 50.6°C Reverse 5' - TGG TGT YTC ATT RTT TRY ACT AG - 3' Lindström and Albert, 2003 
AK11 2571-2592 48.4°C Forward 5' - GTA CCA GTA AAA TTA AAR CCA G - 3' Lindström and Albert, 2003 
Analysis of sequencing results  
Sequencing alignment was done using the Sequencer software V4.7 (Gene Codes 
Corporation, Ann Arbor USA). The Stanford HIVdb program for Genotyping 
resistance interpretation was used to detect drug resistance mutations.  
http://hivdb.stanford.edu/index.html,  
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Appendix E: Letter of approval 
Approval for the project was obtained from the Ethics Committee of the University of 
Stellenbosch (Committee of Human Research) on 17 January 2005. The project 
number is N04/09/146 
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Appendix G: Patient characteristics of samples included in the MTCT study  
 
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 1.1 1980/10/15 2005/02/28 LDL 353 22/52 28/06/2005 N C 

S 
  N 
RP 1.2 1980/10/15 2005/08/04        C S     
RP 7.1 1964/01/09 2005/03/02 14000 286 21/52 26/05/2005 N C S   N 
RP 7.2 1964/01/09 2005/06/30        C S     
RP 8.1 1970/09/10 2005/03/04 7900 365 20.4/52 23/07/2006 N C S   N 
RP 8.2 1970/09/10 2005/08/31        C S     
RP 9.1 1978/11/07 2005/03/07 1200 624 30/52 31/05/2005 Y C S   N 
RP 9.2 1978/11/07 2005/06/30        C S     
RP 10.2 1978/01/04 2005/03/10 5700 717 34/52 19/04/2005 N C S   N 
RP 10.2 1978/01/04 2005/06/08        C S     
RP 12.1 1968/02/22 2005/03/14 3200 625 10/52 29/10/2005 N C S   N 
RP 12.2 1968/02/22 2005/11/04        C Resist G190E   
RP 13.1 1980/07/07 2005/03/14 5800 329 31/52 12/05/2005 N C S   N 
RP 13.2 1980/07/07 2006/07/08        C S     
RP 17.1 1978/04/12 2005/03/22 5200 344 29/52 03/06/2005 N C S   N 
RP 17.2 1978/04/12 2005/07/28        C Resist V108N   
RP 19.1 1975/01/25 2005/03/24 12000 404 24.5/52 20/07/2005 N C S   N 
RP 19.2 1975/01/25 2005/08/18        C S     
RP 25.1 1975/12/08 2005/04/04 6800 357 24/52 17/07/2005 N C S   N  
RP 25.2 1975/12/08 2005/08/31        C S     
RP 28.1 1980/11/29 2005/04/04 9300 405 34/52 24/04/2005 N C S   N 
RP 28.2 1980/11/29 2005/06/08        C S     
RP 29.1 1976/06/01 2005/04/06 17000 201 34/52 19/05/2005 N C S   N 
RP 29.2 1976/06/01 2005/07/08        C Resist K103KN   
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Appendix G continued: Patient characteristics of samples included in the MTCT study 
 
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 35.1 1984/10/10 2005/04/23 20000 733 34/52 06/06/2005 N C S   N  
RP 35.2 1984/10/10 2005/08/01        C S     
RP 37.1 1969/08/06 2005/05/10 2000 417 34/52 29/08/2005 N C S   N 
RP 37.2 1969/08/06 2005/10/05        C S     
RP 40.1 1973/09/26 2005/06/08 59000 317 29.5/52 12/08/2005 N C S   N 
RP 40.2 1973/09/26 2005/10/05        C S     
RP 41.1 1981/12/01 2005/06/28  365 21/52 18/11/2005 N C S   N 
RP 41.2 1981/12/01 2005/12/05        C S     
RP 46.1 1975/10/26 2005/09/07 210000 255 36/52 21/10/2006 N C S   
Yes - 
2002 
RP 46.2 1975/10/26 2005/12/05        C Resist 
K103KN 
Y181CY 
  
RP 47.1 1975/12/06 2005/09/08 29000 297 34/52 23/10/2005 N C S   N 
RP 47.2 1975/12/06 2005/12/05        C S     
RP 48.1 1968/09/13 2005/09/08 3200 651 20/52 20/01/2006 N C S   N 
RP 48.2 1968/09/13 2006/02/20        C Resist 
K103KN 
T215AT   
RP 49.1 1978/01/19 2005/09/08 8600 737 32/52 02/11/2005 N C S   N 
RP 49.2 1978/01/19 2005/12/05        C S     
RP 70.1 1984/12/29 2006/03/08 290000 168 38/52 30/03/2006 N C S   N 
RP 70.2 1984/12/29 2006/04/20        C Resist K103KN   
RP 71.1 1980/11/23 2006/03/13 LDL 502 34/52 14/04/2006 Y C S   N 
RP 71.2 1980/11/23 2006/06/06        C Resist K101EK   
RP 72.1 1985/08/07 2006/03/13 630 595 ?28/52 06/06/2006 N C S   N 
RP 72.2 1985/08/07 2006/07/06        C S     
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Appendix G continued: Patient characteristics of samples included in the MTCT study  
 
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 73.1 1971/02/27 2006/03/13 330000   34/52 17/04/2006 Both C S   N 
RP 73.2 1971/02/27 2006/05/30        C S     
RP 74.1 1973/10/28 2006/03/15 LDL 239 ?39/52 07/04/2006 N C S   N 
RP 74.2 1973/10/28 2006/05/12        C Resist V108IV   
RP 75.1 1986/02/14 2006/03/22 9000 341 35/52 06/04/2006 N C S   N 
RP 75.2 1986/02/14 2006/06/01        C S     
RP 76.1 1980/02/20 2006/03/22 LDL 789 35/52 28/04/2006 N C S   N 
RP 76.2 1980/02/20 2006/05/30        C S     
RP 77.1 1978/09/09 2006/03/22 740 233 34/52 11/04/2006 N C S   N 
RP 77.2 1978/09/09 2006/06/09        C S     
RP 79.1 1980/11/30 2006/03/22 940 654 34/52 09/04/2006 N C S   N 
RP 79.2 1980/11/30 2006/06/08        C S     
RP 83.1 1985/09/21 2006/03/29 1700 443 34/52 23/05/2006 N C S   N 
RP 83.2 1985/09/21 2006/07/04        C S     
RP 86.1 1972/05/08 2006/04/03 8600 345 34/52 28/04/2006 N C S   N 
RP 86.2 1972/05/08 2006/06/15        C S     
RP 87.1 1982/09/09 2006/04/03 59000 587 37/52 09/04/2006 N C S   N 
RP 87.2 1982/09/09 2006/06/07        C S     
RP 88.1 1981/01/21 2006/04/03 1100 390 34/52 02/06/2006 N C S   N 
RP 88.2 1981/01/21 2006/07/06        C Resist K103KN   
RP 91.1 1972/06/16 2006/04/05 54000 510 35/52 28/04/2006 N C S   N 
RP 91.2 1972/06/16 2006/06/15        C S     
RP 96.1 1975/10/26 2006/04/19 710 1018 34/52 11/06/2006 N C S   N 
RP 96.2 1975/10/26 2006/07/11        C S     
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Appendix G continued: Patient characteristics of samples included in the MTCT study 
 
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 99.1 1971/04/21 2006/04/19 29000 243 34/52 06/06/2006 N C S   N 
RP 99.2 1971/04/21 2006/07/04  
      
C Resist 
K103KN 
V1O6AV 
  
RP 100.1 1981/02/06 2006/04/19 36000 553 34/52 09/06/2006 N C S   N 
RP 100.2 1981/02/06 2006/07/06        C S     
RP 101.1 1989/02/06 2006/04/24 57000   34/52 03/06/2006  C S   N 
RP 101.2 1989/02/06 2006/07/04        C S     
RP 105.1 1975/09/28 2006/05/03 5600 365 34/52 21/05/2006 N C S   N 
RP 105.2 1975/09/28 2006/07/18        C S     
RP 106.1 1979/01/01 2006/05/03 1500 252 34/52 31/05/2006 N C S   N 
RP 106.2 1979/01/01 2006/07/18        C S     
RP 107.1 1977/06/03 2006/05/03 11000 289 34/52 25/05/2006 N C S   N 
RP 107.2 1977/06/03 2006/07/20        C S     
RP 111.1 1981/10/06 2006/05/15 34000 181 35/52 05/06/2006 N C S   N 
RP 111.2 1981/10/06 2006/07/18        C S     
RP 113.1 1981/09/21 2006/05/15 510 697 34/52 07/07/2006 N C S   N 
RP 113.2 1981/09/21 2006/08/25        C S     
RP 116.1 1984/10/22 2006/05/22 5100 603 34/52 30/06/2006 N C S   N 
RP 116.2 1984/10/22 2006/08/15        C S     
RP 121.1 1984/07/30 2006/05/29 17000 226 34/52 07/06/2006 N C S   N 
RP 121.2 1984/07/30 2006/08/01        C S     
RP 122.1 1974/05/01 2006/06/05 14000 261 34/52 08/07/2006 N C S   N 
RP 122.2 1974/05/01 2006/08/22        C Resist K103KN   
RP 124.1 1971/06/24 2006/06/05 46000 655 34/52 13/07/2006 N C S   N 
RP 124.2 1971/06/24 2006/08/22        C S     
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Appendix G continued: Patient characteristics of samples included in the MTCT study 
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 126.1 1978/05/16 2006/06/07 5400 518 34/52 18/07/2006 N C S   N 
RP 126.2 1978/05/16 2006/08/29        C S     
RP 128.1 1984/06/28 2006/06/12 29000 316 34/52 25/07/2006 N C S   N 
RP 128.2 1984/06/28 2006/09/12        C S     
RP 129.1 1979/06/15 2006/06/12 25000 300 34/52 17/07/2006 N C S   N 
RP 129.2 1979/06/15 2006/08/29        C S     
RP 131.1 1976/02/15 2006/06/19 510 658 34/52 21/07/2006 N C S   
Yes - 
2004 
RP 131.2 1976/02/15 2006/08/22        C S     
RP 133.1 1979/11/24 2006/06/14 1400 738 34/52 01/08/2006 N C S   
Yes - 
2004 
RP 133.2 1979/11/24 2006/09/14        C S     
RP 134.1 1978/02/21 2006/06/19 14000 188 34/52 13/07/2006 N C S   N 
RP 134.2 1978/02/21 2006/08/25        C S     
RP 135.1 1986/11/26 2006/06/19 6300 209 34/52 11/07/2006 N C S   N 
RP 135.2 1986/11/26 2006/08/29        C S     
RP 138.1 1980/02/24 2006/06/26 13000 384 34/52 27/09/2006 N C S   N 
RP 138.2A 1980/02/24 2007/06/26    34/53 27/09/2007 N C S   N 
RP 138.2B 1980/02/24 2006/10/31        C S IC      
RP 139.1 1988/02/14 2006/06/26 4000 335 34/52 07/08/2006 N C P R A98G N 
RP 139.2 1988/02/14 2006/08/29        C Resist 
A98G 
Y181CY 
  
RP 140.1 1973/05/15 2006/06/28 1400 625 34/52 28/06/2006 N C S   N 
RP 140.2 1973/05/15 2006/08/24        C S     
RP 143.1 1985/12/20 2006/06/28 29000 248 34/52 31/08/2006 N C S   N 
RP 143.2 1985/12/20 2006/09/28        C S     
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Appendix G continued: Patient characteristics of samples included in the MTCT study  
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 144.1 1982/09/16 2006/07/10 2600 597 34/52 05/08/2006 N C S   N 
RP 144.2 1982/09/16 2006/09/14        C S IC      
RP 145.1 1971/01/15 2006/07/10 63000 342 34/52 16/08/2006 N C S   N 
RP 145.2 1971/01/15 2006/09/14        C S     
RP 149.1 1984/01/25 2006/07/19 12000 613 34/52 30/08/2006  C S   N 
RP 149.2 1984/01/25 2006/09/28        C S     
RP 150.1 1983/10/29 2006/07/09 1400 564 34/52 22/09/2006 N C S   N 
RP 150.2 1983/10/29 2006/10/26        C S     
RP 151.1 1979/05/13 2006/07/19 1700 428 34/52 28/08/2006  C S   N 
RP 151.2 1979/05/13 2006/09/28        C S     
RP 152.1 1987/05/06 2006/07/19 14000 206 34/52 30/08/2006  C S   N 
RP 152.2 1987/05/06 2006/09/28        C S     
RP 156.1 1983/07/04 2006/07/26 1000 587 34/52 30/08/2006  C S   N 
RP 156.2 1983/07/04 2006/09/27        C S     
RP 157.1 1985/11/10 2006/07/26 2600 498 34/52 06/09/2006  C S   N 
RP 157.2 1985/11/10 2006/10/05        C S     
RP 159.1 1983/05/30 2006/08/16 9700 380 35/52 24/09/2006 N C S   N 
RP 159.2 1983/05/30 2006/10/26        C Resist 
K70KR 
K101EK 
  
RP 162.1 1991/08/14 2006/08/30 2000 204 34/52 04/10/2006 N C S IC   N 
RP 162.2 1991/08/14 2006/11/07        C S IC     
RP 165.1 1975/01/01 2006/09/11 65000 878 34/52 13/10/2006 N C S   N 
RP 165.2 1975/01/01 2006/11/21        C S     
RP 166.1 1982/05/27 2006/09/13 3600 261 34/52 19/10/2006 N C S   N 
RP 166.2 1982/05/27 2006/11/23        C S     
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Appendix G continued: Patient characteristics of samples included in the MTCT study.  
Sample 
Code 
Date of 
Birth  
Date of 
Sampling 
Viral load 
(RNA 
Copies/ml) 
Baseline 
CD4  
(Cells/µl) 
Week of 
pregnancy 
Date of 
Delivery 
Breast 
feeding 
Y/
 
   
 
N 
HIV-1 
Subtype *Resist Mutations 
Previous 
MTCT? 
Y/N 
RP 167.1 1984/03/09 2006/09/13 3300 334 34/52 08/10/2006 N C S IC   N 
RP 167.2 1984/03/09 2006/11/09        C S IC     
RP 169.1 1985/10/22 2006/09/13 6900 526 34/52 27/11/2006 N C S   N 
RP 169.2 1985/10/22 2007/01/19        C S     
RP 172.1 1975/10/11 2006/09/18  295 34/52 25/09/2006 N C S   
Yes - 
2005 
RP 172.2 1975/10/12 2006/11/17        C S     
RP 173.1 1969/08/11 2006/06/20 12000 372 34/52 14/10/2006 N C S   
Yes - 
2004 
RP 173.2 1969/08/11 2006/11/09        C S     
RP 178.1 1981/09/05 2006/10/18 3400 364 34/52 29/11/2006 N B S   No 
RP 178.2 1981/09/05 2007/01/10        B S     
Y = Yes 

N = No 
*Resist = Resistant 

S = Sensitivity 
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Appendix H: Final protocol for Improved In-house assay  
Extraction of viral RNA for genotyping 
The method used the QIAamp UltraSens Kit (QIAGEN GmbH, Germany) for RNA 
extraction from 1ml plasma. The manufactures instructions supplied was followed and 
the RNA was eluted in two elution steps with 30µl of AVE buffer added to each step 
to obtain a total elution volume of 60µl. 
First round PCR reactions  
The Access RT-PCR System (Promega, Madison, USA) was used to do the first 
round PCR reactions in a one step PCR protocol. The PCR primers used is listed in 
Table H.1. Ten microliters of RNA was added to the first round reaction mix that 
consisted of AMV/Tfl 5X reaction buffer at a 1X concentration, dNTPs mix at 0.2mM 
each, primers at 40pmol, 2mM MgSO2, AMV RT 0.1U/µl, Tfl DNA Polymerase 
0.1U/µl, DTT at 0.8mM and nuclease-free water up to a final volume of 50µl. The 
reaction was done on a 9700 PCR system ((Applied Biosystems, Foster City, USA) 
using the 9600 ramp speed. The reaction mixtures were prepared in 0.2ml PCR tube 
(QSP, Porex BioProducts Inc, California, USA).  
The following cycles was used for first round PCRs. Incubation at 65°C for 30 
seconds to denature the RNA was done. The RNA was then cooled to 48°C. Forty 
microliter of the reaction mix was added and for the first strand cDNA synthesis the 
reaction were incubate for one cycle at 48°C for 45 minutes so that reverse 
transcription could take place and then a cycle at 94°C for 2 minutes to inactivate 
AMV Reverse transcriptase and denaturation of the DNA to occur. For second strand 
cDNA and amplification the reaction was cycled 40 times at 94°C for 20 seconds to 
denature, at to 55°C for 30 seconds to anneal the primers and at 68°C for 90 seconds 
to extend the product. A last extension for at 68°C for 5 minutes was done. The 
reaction was then stored at 4°C until the second round reactions could be done.  
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Table H.1: Primers used for IIH assays genotyping PCR 
First round 
Primers 
HBX2 
number  
Primer 
Tm 
Primer 
direction 
Primer Sequence 
outer 5’prot1 2082-2109 57.0°C Forward 5’- TAA TTT TTT AGG GAA GAT CTG GCC TTC C -3’ 
outer Mj4 3399-3420 54.8°C Reverse 5’- CTG TTA GTG CTT TGG TTC CTC T –3’ 
Second Round 
Primers 
    
inner 5'prot2 2136-2163 68.2°C Forward 5’- TCA GAG CAG ACC AGA GCC AAC AGC CCC A –3’ 
inner NE135 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 
Second round PCR reactions  
The Taq Go-Taq® Flexi DNA polymerase (Promega, Madison, USA) was used to do 
the second round PCR reaction mixture using the first round PCR product. The PCR 
primers used is listed in Table H.1. Two µl of the first round PCR reaction was added 
two the second round reaction mix that consisted of 5X buffer at a 1X concentration, 
PCR Nucleotide mix (Promega, Madison, USA) at 0.2mM each, primers at 40pmol 
each, 2mM MgCl2, Taq DNA Polymerase 2.5U/µl, and nuclease-free water up to a 
final volume of 25µl.  
The following cycles was used for second round PCR reaction mixtures. One cycle at 
94°C for 2 minutes for denaturing of the DNA and then cycled for 40 times at 94°C 
for 20 seconds to denature, at to 60°C for 30 seconds to anneal the primers and at 
68°C for 90 seconds to extend the product. A last extension for at 68°C for 5 minutes 
was done. The reaction was then stored at 4°C until it could be visualized.  
Visualization of the PCR product with electrophoresis  
Gel electrophoresis was done to visualize the PCR product on a 1% agarose gel 
prepared with LE analytical grade agarose (Whitehead Scientific, Cape Town, RSA) 
in 1 x TAE Buffer (0.04M Tris acetate, 0.001M EDTA). 500mg of agarose were 
weight in a glass flask and 50ml of 1 x TAE Buffer was added. It was then microwave 
to boiling point and mixed by stirring on magnetic stirrer. Five µl of ethydium 
bromide (Promega, Madison, USA) was added to the gel to stain the DNA.  
Two µl loading buffer (Promega, Madison, USA) was mixed with 5µl PCR product. 
Each specimen was sequentially loaded in a slot on the gel, including the blanks, 
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positive controls and 1 kilobasepare marker (Promega, Madison, USA). A current of 
50 mAmperes per 50ml gel was then passed through the gel.  
When the products migrated from the negative to the positive anode sufficiently, as 
indicated by the migration of the two coloured dyes in the loading buffer, the current 
was removed and the gel was visualised under ultra violet light at a wavelength of 
302nm, ethydium bromide stained DNA/PCR products appeared as bright band. A 
photograph was taken by using the Syngene GeneGenius, version 4.00, program 
(Synoptics Ldt, Cambridge, United Kingdom). 
PCR product purification 
The QIAquick Spin Kit (QIAGEN GmbH, Germany) was used to clean the PCR 
products for use in sequencing reactions according to the manufactures instructions.  
Quantification of DNA with the NanoDrop  
The DNA product was quantified with the NanoDrop ND-1000. The concentration of 
DNA obtained was used to work out a dilution factor to obtain 10ng-40ng of DNA to 
use in the sequencing reactions. 
Sequencing of PCR product  
The ABI Prism BigDye Terminator v3.1 ready reaction cycle sequencing kit 
(Applied Biosystems, Warrington, UK) was used for the sequencing reactions. Cycle 
sequencing reactions were prepared in a 96 well plate by adding 1µl of terminator 
ready reaction mix to 3µl of sequencing buffer, 1µl of template, 1µl of 5pmol primer 
and 4µl nuclease free water to obtain a final volume of 10µl. The reaction mix was 
then exposed to thermocycling conditions repeated 25 times with DNA denaturing at 
96°C for 10 seconds and primer annealing for 5 seconds at the sequence primer 
specific annealing temperature. This was followed by a final product extension at 
60°C for 4 minutes. After completion of the cycling the reactions were sent to the 
DNA sequencing facility of Stellenbosch University for sequencing on the ABI 3100 
Sequencer (Applied Biosystems, Foster City, USA). The primers used in the 
sequencing reactions are listed in Table H.2.  
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Table H.2: Primers used for IIH assays sequencing 
Primer HBX2 
number  
Primer 
Tm 
Primer 
Direction 
Primer Sequence References 
pol1D 2254-2271 56.3°C Forward  5'- TCC CTC AAA TCA CTC TTT GGC -3' Loxton, 2004 
F2054 2511-2528 53.4°C Forward  5’ – GGR CGA AAT ATG TTG ACT CAG – 3’ Personal Communication, 
John Hackett 
AK11 2574-2592 48.4°C Forward 5' - GTA CCA GTA AAA TTA AAR CCA G - 3' Lindström and Albert, 2003 
JA217 2622-2643 49.5°C Reverse  5'- CTT TTA TTT TTT CTT CTG TCA ATG G -3' Lindström and Albert, 2003 
pol 3 2885-2901 63.4°C Forward  5’ - GGG GGA TGC ATA TTT TTC AG –3’ Personal Communication, 
Susan Engelbrecht 
inner NE135 3300-3334 61.4°C Reverse 5’- CCT ACT AAC TTC TGT ATG TCA TTG ACA GTC CAG CT –‘3 Plantier et al, 2005 
ABB20-3F 2983-2999 51.6°C Forward 5' – ATC AGT ACA ATG TGC TTC CA - 3' Personal Communication, 
John Hackett 
AK10 3316-3333 50.5°C Reverse  5’ - TYC CCA CTA AYT TCT GTA TRT C –3’ Lindström and Albert, 2003 
Alignment and analysis of sequencing results  
Sequencing alignment was done using the Sequencer software V4.7 (Gene Codes 
Corporation, Ann Arbor USA). The Stanford HIVdb program for Genotyping 
resistance interpretation was used to detect drug resistance mutations.  
http://hivdb.stanford.edu/index.html, Updated January 2007.  The pol sequences 
generated were aligned with Clustal X (Thompson et al., 1997) and compared with the 
Kimura two-parameter distance neighbour-joining method (Saitou and Nei, 1987) 
with 1000 bootstrap replicates in Mega 4.0 software (Kumar 2004). The subtype pol 
reference sequences provided by Los Alamos National Laboratory 
(http://www.hiv.lanl.gov/content/index ) were included in the phylogenetic tree. 
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Appendix J: Patient characteristics of samples used for comparison of the IIH assay 
with the Viroseq™ HIV-1 genotyping system 
Sample 
Age 
(years) Gender Specimen Date Treatment *Subtype 
330314 9 $M 14/12/09 Unknown C 
330315 1 M 14/12/09 Unknown C 
330316 12 M 11/12/09 3TC,D4T,EFV C 
330318 42 F 11/12/09 3TC,TDF,EFV C 
330818 33 F 17/12/09 Unknown C 
330819 15 F 17/12/09 Unknown C 
330820 15 F 17/12/09 3TC,D4T,KLT,ABC C 
330822 6 F 15/12/09 Unknown C 
330823 7 M 15/12/09 3TC,D4T,EFV C 
331101 9 F 18/12/09 Unknown C 
331502 42 F 18/12/09 3TC,AZT,EFV C 
332071 7 M 22/12/09 3TC,D4T,EFV C 
332885 62 F 31/12/09 3TC,D4T,EFV C 
333599 15 M 07/01/10 3TC,D4T,EFV C 
333601 4 F 05/01/10 3TC,D4T,EFV C 
333676 36 F 07/01/10 EFV,COMBIVIR C 
333679 46 F 07/01/10 3TC,EFV,TDF C 
333983 11 M 08/01/10 3TC,D4T,EFV C 
333985 4 M 08/01/10 3TC,AZT,EFV,DDI C 
334791 6 F 11/01/10 Unknown C 
335286 14 F 14/01/10 3TC,D4T,EFV C 
335287 36 F 14/01/10 Unknown C 
335291 15 F 14/01/10 3TC,ABC,EFV C 
335294 47 M 13/01/10 Unknown C 
335299 34 M 13/01/10 3TC,AZT,EFV C 
335301 14 F 14/01/10 3TC,D4T,EFV C 
336514 7 M 15/01/10 3TC,D4T,EFV D 
336517 33 F 13/01/10 3TC,D4T,NVP C 
336844 5 F 20/01/10 AZT,ABC,RTV, C 
*The Rega HIV-1 subtyping tool Version 2.0 (http://dbpartners.stanford.edu/Rega Subtyping/) was 
used for determining the HIV-1 subtype 
$M = Male 
F = Female 
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Appendix I: Resistance mutations detected with Viroseq™ HIV-1 genotyping system and IIH assay  
 
Viroseq™ HIV-1 genotyping system  IIH assay 
Sample Mutations Sample Mutations 
  PR Major PR Minor NRTI NNRTI Subtype   PR Major 
PR 
Minor NRTI NNRTI Subtype 
330314 None None M184V 
K103N 
H221HY 
M230L 
C 330314 None None M184V 
K103N 
H221HY 
M230L 
C 
330315      330315 
L24I 
L33F 
M46I 
I54V 
V82A 
L10F 
71V 
L74V 
Y115F 
M184V 
None C 
330316 None L10LV M184V 
K103R 
V106M 
V179D 
C 330316 None L10LV M184V 
K103R 
V106M 
V179D 
C 
330318   K70EK M184V 
A98G 
K103N 
P225H 
C 330318 None T74S K70EK M184V 
A98G 
K103N 
P225H 
C 
330818 None A71T 
A62AV 
D67DN 
M184V 
T215Y 
V106M 
E138EK 
F227L 
C 330818 None A71T 
A62AV 
D67DN 
V75IV 
M184V 
T215STY 
V106M 
E138EK 
F227L 
C 
330819 None None None None C 330819 None None None None C 
330820      330820 None None M184V None C 
330822 None None M184V 
K101E 
E138S 
G190A 
C 330822 None None M184V 
K101E 
E138S 
G190AG 
C 
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Appendix I continued: Resistance mutations detected with Viroseq™ HIV-1 genotyping system and IIH assay  
 
Viroseq™ HIV-1 genotyping system IIH assay 
Sample Mutations Sample Mutations 
  PR Major PR Minor NRTI NNRTI Subtype   PR Major 
PR 
Minor NRTI NNRTI Subtype 
330823      330823 None T74S A62AV M184V 
V106M 
E138A 
V179D 
F227FL 
C 
331101 None T74S M184V 
V106M 
V179DV 
F227L 
C 331101 None T74S M184V V106M F227L C 
331502 None T74S M184V 
K103N 
E138A 
P225H 
C 331502 None T74S M184V 
K103N 
E138A 
P225H 
C 
332071 None None T69ST M184V 
K101E 
V106M 
G190A 
C 332071 None None M184V L210IL 
K101E 
V106M 
G190A 
C 
332885 None None M184V K103N C 332885 None None M184V K103N C 
333599 None T74S D67N M184V K103N C 333599 None T74S 
D67N 
M184V K103N C 
333601 None None M184V V106M F227L C 333601 None None M184V 
V106M 
F227L C 
333676 None None 
M184V 
L210W 
T215Y 
A98G 
K103N 
P225H 
C 333676 None None 
M184V 
L210W 
T215Y 
A98G 
K103N 
P225H 
C 
333679 None None None K103KN V179S C 333679 None None None K103KN C 
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Appendix I continued: Resistance mutations detected with Viroseq™ HIV-1 genotyping system and IIH assay  
 
Viroseq™ HIV-1 genotyping system IIH assay 
Sample Mutations Sample Mutations 
  PR Major PR Minor NRTI NNRTI Subtype   PR Major 
PR 
Minor NRTI NNRTI Subtype 
333983 None T74S M184V 
K101Q 
V106M 
G190AG 
F227L 
C 333983 None T74S M184V 
K101Q 
V106M 
G190A 
F227L 
C 
333985 None T74S 
K70R 
M184 
K219E 
K101N 
V106M 
Y181C 
C 333985 None T74S 
D67DN 
K70R 
M184V 
K219E 
K101N 
V106M 
Y181C 
C 
334791 None None M184V K101P K103N C 334791 None None M184V 
K101P 
K103N 
E138EK 
C 
335286 None None M184V 
K101E 
V106M 
G190A 
C 335286 None None M184V 
K101E 
V106M 
G190A 
C 
335287 None T74S T69N M184V K103N C 335287 None T74V 
T69N 
K70R 
M184V 
K219KQ 
K101KPQT 
K103N C 
335291 None Q38E L41IL M184V 
V106M 
V179D C 335291 None Q38E 
L41IL 
M184V 
V106M 
V179DV 
G190AG 
C 
335294 None T74S None E138A C 335294 None T74V None E138A C 
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Appendix I continued: Resistance mutations detected with Viroseq™ HIV-1 genotyping system and IIH assay  
 
Viroseq™ HIV-1 genotyping system IIH assay 
Sample Mutations Sample Mutations 
  PR Major PR Minor NRTI NNRTI Subtype   PR Major 
PR 
Minor NRTI NNRTI Subtype 
335299 None None M184V K103N P225H C 335299 None None M184V 
K103N 
P225H C 
335301      335301 None None M184MV 
K101E 
V106M 
V108I 
G190A 
C 
336514 None None M184V 
K101Q 
K103N 
P225H 
D 336514 None A71AT M184V 
K101Q 
K103N 
P225H 
D 
336517      336517 None None M184V K103N C 
336844 None L10V None 
K101E 
Y181C 
G190A 
C 336844 None L10LV None 
K101E 
Y181C 
G190A 
C 
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Appendix K: Discrepant mutations between Viroseq™ HIV-1 genotyping system and IIH assay  
 
Viroseq™ HIV-1 genotyping system IIH assay  
Sample Mutations Mutations 
  PR Major PR Minor NRTI NNRTI Subtype PR Major PR Minor NRTI NNRTI Subtype 
330315      
L24I 
L33F 
M46I 
I54V 
V82A 
L10F 
A71V 
L74V 
Y115F 
M184V 
None C 
330818 None A71T 
A62AV 
D67DN 
M184V 
T215Y 
V106M 
E138EK 
F227L 
C None A71T 
A62AV 
D67DN 
V75IV 
M184V 
T215STY 
V106M 
E138EK 
F227L 
C 
330820      None None M184V None C 
330823      None T74S A62AV M184V 
V106M 
E138A 
V179D 
F227FL 
C 
331101 None T74S M184V 
V106M 
V179DV 
F227L 
C None T74S M184V V106M F227L C 
332071 None None T69ST M184V 
K101E 
V106M 
G190A 
C None None M184V L210IL 
K101E 
V106M 
G190A 
C 
333679 None None None K103KN V179S C None None None K103KN C 
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Appendix K continued: Discrepant mutations between Viroseq™ HIV-1 genotyping system and IIH assay  
 
Viroseq  IIH assay  
Sample Mutations Mutations 
  PR Major PR Minor NRTI NNRTI Subtype PR Major PR Minor NRTI NNRTI Subtype 
333985 None T74S 
K70R 
M184 
K219E 
K101N 
V106M 
Y181C 
C None T74S 
D67DN 
K70R 
M184V 
K219E 
K101N 
V106M 
Y181C 
C 
334791 None None M184V K101P K103N C None None M184V 
K101P 
K103N 
E138EK 
C 
335287 None T74S T69N M184V K103N C None T74V 
T69N 
K70R 
M184V 
K219KQ 
K101KPQT 
K103N C 
335291 None Q38E L41IL M184V 
V106M 
V179D C None Q38E 
L41IL 
M184V 
V106M 
V179DV 
G190AG 
C 
335301      None None M184MV 
K101E 
V106M 
V108I 
G190A 
C 
336514 None None M184V 
K101Q 
K103N 
P225H 
D None A71AT M184V 
K101Q 
K103N 
P225H 
D 
336517      None None M184V K103N C 
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Appendix L: Patient characteristics of samples used for TFIH assay and IIH assay comparison 
Sample Age in years Gender Specimen Date Treatment 
144745 6 F 2008/01/14 Unknown 
144771 38 F 2008/01/15 3TC,AZT,EFV 
145426 7 $M 2008/01/21 3TC, LPV/r,ABC 
145427 9 M 2008/01/21 3TC,d4T,EFV 
145831 41 M 2008/01/22 LPV/r,AZT,ddi 
145881 55 F 2008/01/17 LPV/r,AZT,ddi 
145882 34 F 2008/01/17 3TC,d4T,EFV 
146142 15 M 2008/01/24 3TC, LPV/r,ABC,AZT 
146143 54 F 2008/01/24 3TC,d4T,EFV 
146593 5 F 2008/01/28 3TC,d4T,KLT 
147028 27 F 2008/01/30 LPV/r,AZT,ddi 
147642 36 F 2008/01/31 3TC,d4T,NVP 
147643 41 F 2008/01/31 LPV/r,AZT,ddi 
148090 6 M 2008/02/05 3TC,d4T,EFV 
148091 7 M 2008/02/05 3TC,d4T,EFV 
148092 3 Unknown 2008/02/05 3TC,d4T,LPV/r 
148093 3 F 2008/02/05 3TC,d4T,LPV/r 
148221 8 Unknown 2008/02/06 3TC,d4T,LPV/r 
148222 33 F 2008/02/06 3TC,AZT,EFV 
148824 41 M 2008/02/08 3TC,AZT,EFV 
148825 12 M 2008/02/08 Unknown 
149004 12 M 2008/02/11 3TC,KLT,ABC 
149517 42 M 2008/02/13 LPV/r,AZT,ddi 
149518 18 F 2008/02/12 Unknown 
150142 34 F 2008/02/14 Unknown 
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Appendix L continued: Patient characteristics of samples used for TFIH assay and IIH assay comparison 
Sample Age in years Gender Specimen Date Treatment 
150143 41 M 2008/02/15 3TC,AZT,EFV 
151267 9 F 2008/02/20 3TC,AZT,ddi 
151450 37 F 2008/02/21 3TC,d4T,EFV 
151679 52 F 2008/02/19 Unknown 
151680 7 F 2008/02/19 Unknown 
151924 12 F 2008/02/22 3TC,d4T, LPV/r,ABC 
151925 8 F 2008/02/26 3TC,d4T,EFV 
152122 43 M 2008/02/27 3TC,d4T,EFV 
152529 51 M 2008/02/28 3TC,d4T.ddi 
152869 6 F 2008/02/13 3TC,d4T,EFV 
153545 45 M 2008/03/06 3TC,d4T,EFV 
153547 42 F 2008/03/06 3TC,AZT,EFV 
153549 49 M 2008/03/05 Unknown 
153550 45 F 2008/03/05 LPV/r,AZT,ddi 
153551 40 F 2008/03/05 3TC,AZT,EFV 
153792 37 M 2008/03/07 3TC,AZT,EFV 
153793 44 F 2008/03/07 3TC,d4T,EFV 
Aretas 12 3 M 2007/05/15 AZT,3TC,EFV 
Aretas 19 8 M 2007/05/15 ddI,ABC, LPV/r 
Aretas 20 6 M 2007/05/08 d4T,3TC,EFV 
Aretas 21 57 F 2007/07/18 d4T, 3TC, EFV 
Aretas 22 1 F 2007/06/07 d4T, 3TC, RTV 
Aretas 23 13 F 2007/06/20 AZT,3TC,NVP 
Aretas 24 2 M 2007/06/06 d4T,3TC, NVP 
Aretas 25 7 F 2007/07/12 AZT,3TC, NVP 
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Appendix L continued: Patient characteristics of samples used for TFIH assay and IIH assay comparison 
Sample Age in years Gender Specimen Date Treatment 
Aretas 29 2 F 2007/07/26 AZT,3TC, LPV/r 
Aretas 30 2 M 2007/08/07 d4T, 3TC, KLT, RTV 
Aretas 32 2 F 2007/07/16 d4T,3TC, LPV/r 
Aretas 43 13 M 2007/08/20 d4T,3TC, ddi 
Aretas 84 5 M 2008/01/21 AZT,3TC,EFV 
Aretas 88 6 months F 2008/01/30 None 
Aretas 89 35 F 2008/01/31 d4T, 3TC, NVP 
Aretas 90 4 months M 2008/01/15 None 
Aretas 91 1 M 2008/02/01 None 
Aretas 92 4 months M 2008/02/05 None 
Aretas 93 11 months M 2008/01/15 None 
Aretas 94 4 M 2008/02/06 d4T, 3TC, LPV/r 
Aretas 95 7 F 2007/11/28 d4T, 3TC, EFV 
Aretas 100 26 M 2008/01/14 d4T, 3TC, EFV 
Aretas101 32 M 2008/02/07 d4T, 3TC, NVP 
Aretas 102 1 F 2008/03/06 None 
$M = Male 
F = Female 
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Appendix M: Comparison of mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
144745 M184V K103N Y188H None None C M184V 
K103N 
Y188H None None C 
144771 
M41L 
D67N 
K70N 
V75T 
T215Y 
K219KN 
V106M 
Y188CFL None None C 
M41L 
D67N 
K70N 
V75T 
T215Y 
K219KN 
V106M 
Y188CFL None None C 
144831 None K103N None None C None K103N None None C 
145426 No Amp No Amp None None C No Amp No Amp No Amp No Amp  
145427 None None None T74S C None None None T74S C 
145881 No Amp No Amp None None C No Amp No Amp No Amp No Amp  
145882 None 
K103N 
P225HP 
L234IL  
None None B None 
K103N 
P225HP 
L234IL 
None None B 
146142 No Amp No Amp None L10I C No Amp No Amp No Amp No Amp 
 
146143 No Amp No Amp No Amp No Amp 
 
No Amp No Amp No Amp No Amp 
 
146593 M184V None None None C V75L M184V None None None C 
147028 
D67G 
K70KR 
M184V 
K219EK 
L100I 
K103N L76LIV None C D67G 
L100I 
K103N L76LIV None C 
147642 M184V 
K103N 
V179L 
Y181C 
None None C M184V 
K101E 
Y181C 
G190A 
None None C 
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Appendix M continued: Comparison of mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
147643 None None None T74TS C None None None None C 
148090 M184V K103 P225H None None C M184V 
K103 
P225H None None C 
148091 M184V K103N V108I None None C No Amp  No Amp No Amp No Amp  
148092 M184V None None L10I C M184V None None L10I C 
148093 T69S Y181C None None C T69S Y181C None None C 
148221 M184V None No Amp No Amp C M184V None None None C 
148222 None None None None C No Amp No Amp No Amp No Amp  
148824 
K65KR 
D67N 
M184IMV 
K101E 
M46MI 
V82L 
L90LM 
None C 
K65KR 
D67N 
M184IMV 
None 
M46MI 
V82L 
L90LM 
None C 
148825 M184V T215Y K103N None None C 
M184V 
T215Y K103N None None C 
149004 M41L M184V 
V106M 
V179T 
G190A 
F227L 
None None C M41L M184V 
V106M 
V179T 
G190A 
F227L 
None None C 
149517 None K103KN None None C None None None None C 
149518 
M41L 
D67N 
K70N 
V75T 
T215Y 
K219N 
V106M 
Y188*L 
F227L 
None None C 
M41L 
E44DE 
D67N 
K70N 
V75T 
T215Y 
K219N 
V106M 
Y188L 
F227L 
None None C 
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Appendix M continued: Comparison of mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
150142 M184V None None None C M184V None None None C 
150143 No Amp No Amp No Amp No Amp  No Amp No Amp No Amp No Amp  
151267 D67N T215F 
K101P 
K103N No Amp No Amp C 
D67N 
T215F 
K101P 
K103N 
I54V 
V82A L10LI C 
151450 M184V Y188L None None C M184V A98AG Y188L None None C 
151679 M184V 
K101E 
V106M 
G190AG 
F227FL 
None None C           
151680 D67G Y106M Y188C None T74TS C D67G 
Y106M 
Y188C None None C 
151924 Q151KLMQ M184V K103N No Amp No Amp C 
F116FY 
Q151KLM
Q 
M184V 
K103N E35G None C 
151925 A62V M184V 
K101H 
V106M 
F227FL 
None None C M184V 
K101H 
V106M 
G190A 
None None C 
152122 M184V V106M G190A None None C M184V 
V106M 
G190A None None C 
152529 None K103N No Amp No Amp C None K103KN None None C 
152869 M184V 
K101E 
V106M 
F227L 
No Amp No Amp C M184V 
K101E 
V106M 
F227L 
None None C 
153545 V118I None None None C E44EV V118I None None None C 
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Appendix M continued: Comparison of mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
153547 No Amp No Amp None None C M184V K103N V106M None None C 
153549 None None None None B None None None None B 
153550 None K103N None None C None K103N None None C 
153551 None None None None C           
153792 
D67N 
T69N 
K70N 
M184V 
T215NSTY 
K219E 
K101P 
K103N None None C 
D67N 
T69N 
K70N 
M184V 
T215Y 
K219E 
K101P 
K103N None None C 
153793 M184V T215IT 
K103N 
F227FL 
M230L 
M46V None C M184V T215IT 
K103N 
M230L M46V None C 
Aretas 12 M184V K103N P225H None None C M184V 
K103N 
P225H None None C 
Aretas 19 M41L A98AG K101E No Amp No Amp C 
M41L 
M184V 
T215Y 
A28G 
K101E 
G190A 
None None C 
Aretas 20 M184V 
K103N 
E138K 
Y188L 
None None C M184V 
K103N 
E138K 
Y188L 
None None C 
Aretas 21 M184V 
K103N 
V108I 
P225H 
None None C M184V 
K101KN 
K103N 
V108I 
P225H 
None None C 
Aretas 22 M184V None None T74S C M184V None None T74S C 
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Appendix M continued: Comparison of mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
Aretas 23 
M41L 
M184V 
L210W 
T215Y 
A28G 
K101E 
G190A 
None None C 
M41L 
M184V 
L210W 
T215Y 
A28G 
K101E 
G190A 
N88NK None C 
Aretas 25 T69N M184V 
V108IV 
Y181C None None C 
T69N 
M184V 
V108IV 
Y181C None None C 
Aeretas 24 M184V Y181C None T74S C T69S M184V 
V108IV 
Y181C None T74S C 
Aeretas 29 M184V None None None C M184V None I54IV None C 
Aeretas 30 V75L M184V None None None C 
V75L 
M184V None None None C 
Aretas 32 No Amp No Amp No Amp No Amp   M184V None I54V V82A 
L10I 
T74S C 
Aretas 43 
D67N 
M184I 
T215F 
L100I 
K100E 
K103N 
None None C 
D67N 
M184I 
T215F 
L100I 
K100E 
K103N 
None None C 
Aretas 84 
D67N 
T69NT 
K70R 
M184V 
K219Q 
A98G 
K101E 
K103R 
G190A 
None None C 
D67N 
T69N 
K70R 
M184V 
T215NST
Y 
K219Q 
A98G 
K101E 
K103R 
G190A 
None None C 
Aretas 88 None None None None C None None None None C 
Aretas 89 M184V G190A None None C V75I M184V G190A None None C 
Aretas 90 T69S None None None C T69S None None None C 
Aretas 91 None None None None C V75I None None None C 
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Appendix M continued: Comparison of mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
Aretas 92 None None None None C None None None None C 
Aretas 93 None None None None C None None None None C 
Aretas 94 M184V None 
M46I 
I54V 
V82A 
L10LF 
L24I C M184V None 
M46I 
I54V 
V82A 
L10F 
L24I C 
Aretas 95 V118I None None None C V118I None None None C 
Aretas 96 No Amp No Amp No Amp No Amp 
 
No Amp No Amp No Amp No Amp 
 
Aretas 100 None K103KN No Amp No Amp C None K103KN None None C 
Aretas 101 V118FV M184V 
V108IV 
Y181C None None C M184V 
V106MV 
Y181C None None C 
Aretas 102 None None None None C None None None None C 
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Appendix N: Comparison of discrepant mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
146593 M184V None None None C V75L M184V None None None C 
147028 
D67G 
K70KR 
M184V 
K219EK 
L100I 
K103N L76LIV None C D67G 
L100I 
K103N L76LIV None C 
147643 None None None T74TS C None None None None C 
149517 None K103KN None None C None None None None C 
149518 
M41L 
D67N 
K70N 
V75T 
T215Y 
K219N 
V106M 
Y188L 
F227L 
None None C 
M41L 
E44DE 
D67N 
K70N 
V75T 
T215Y 
K219N 
V106M 
Y188L 
F227L 
None None C 
151450 M184V Y188L None None C M184V A98AG Y188L None None C 
151680 D67G Y106M Y188C None T74TS C D67G 
Y106M 
Y188C None None C 
151925 A62V M184V 
K101H 
V106M 
F227FL 
None None C M184V 
K101H 
V106M 
G190A 
None None C 
153545 V118I None None None C E44EV V118I None None None C 
153793 M184V T215IT 
K103N 
F227FL 
M230L 
M46V None C M184V T215IT 
K103N 
M230L M46V None C 
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Appendix N continued: Comparison of discrepant mutations between TFIH assay and the IIH assay  
 TFIH assay IIH assay  
Sample NRTI NNRTI Major PI Minor PI Subtype NRTI NNRTI Major PI Minor PI Subtype 
Aretas 21 M184V 
K103N 
V108I 
P225H 
None None C M184V 
K101KN 
K103N 
V108I 
P225H 
None None C 
Aretas 23 
M41L 
M184V 
L210W 
T215Y 
A28G 
K101E 
G190A 
None None C 
M41L 
M184V 
L210W 
T215Y 
A28G 
K101E 
G190A 
N88NK None C 
Aeretas 24 M184V Y181C None T74S C T69S M184V 
V108IV 
Y181C None T74S C 
Aeretas 29 M184V None None None C M184V None I54IV None C 
Aretas 84 
D67N 
T69NT 
K70R 
M184V 
K219Q 
A98G 
K101E 
K103R 
G190A 
None None C 
D67N 
T69N 
K70R 
M184V 
T215NST
Y 
K219Q 
A98G 
K101E 
K103R 
G190A 
None None C 
Aretas 89 M184V G190A None None C V75I M184V G190A None None C 
Aretas 91 None None None None C V75I None None None C 
Aretas 101 V118FV M184V 
V108IV 
Y181C None None C M184V 
V106MV 
Y181C None None C 
 
 
